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ABSTRACT
Persistent local activation of the coagulation cascade typifies fibroproliferative lung 
disorders such as idiopathic pulmonary fibrosis and the acute respiratory distress 
syndrome. In addition to its role in coagulation, thrombin exerts potent pro- 
inflammatory and pro-fbrotic effects via activation of its major cellular receptor 
proteinase-activated receptor-1 (PARi). In this thesis, the relevance of PARi 
activation to inflammation and fibrosis in a model of lung injury and fibrosis based on 
the intra-tracheal instillation of bleomycin was examined. Lung inflammation and 
fibrosis were substantially attenuated in PARi-deficient mice. The attenuated 
inflammatory response was manifest by substantial reductions in bronchoalveolar 
lavage protein content, total leukocyte numbers, and lung levels of the chemokine 
CCL2. The attenuated fibrotic response was manifest by a reduction in lung collagen 
accumulation of around 60%, and reduced mRNA and/or protein levels of the pro- 
fibrotic mediators connective tissue growth factor (CTGF) and transforming growth 
factor-beta-1 (TGF-pi). These data suggest that PAR] may promote inflammation and 
fibrosis, at least in part, via the expression of CCL2, CTGF, and TGFpi. Further 
studies demonstrated prominent immunostaining for PAR] on lung epithelial cells 
following bleomycin injury, consistent with these cells being a potential source of 
PARi-dependent secondary mediators in the injured lung. Widespread epithelial 
injury is a prominent feature of fibroproliferative lung disorders, in which 
hyperplastic activated epithelial cells represent a major source of pro-inflammatory 
and pro-fibrotic mediators. The effect of PARi activation on lung epithelial 
expression of CCL2, CTGF and TGFPi was therefore examined in vitro. Exposure to 
both thrombin and the PARi agonist peptide TFLLR-NH2 substantially increased 
mRNA levels of CCL2 and CTGF, but not TGFpi in A549 and BEAS-2B human lung 
epithelial cells. Increases in CCL2 and CTGF mRNA levels in response to thrombin 
were attenuated with the PARi antagonist RWJ-58259. PARi-dependent increases in 
CCL2 and CTGF mRNA are apparently protein kinase C-dependent since increases in 
response to TFLLR-NH2 were inhibited by the protein kinase C inhibitor Ro-31-8425. 
Increases in CCL2 and CTGF mRNA in response to PARi activation were mirrorred 
by comparable increases at the protein level. Taken together, these data suggest that 
epithelial cells may represent a source of PARi-dependent pro-inflammatory and pro- 
fibrotic mediators following lung injury.
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1. INTRODUCTION
1.1. Pulmonary fibrosis
Pulmonary fibrosis is a pathological process characterized by excessive and 
disorganised deposition of extracellular matrix proteins, such as collagen within the 
pulmonary interstitium. This has a profound detrimental impact on gas exchange, and 
is responsible for considerable morbidity and mortality in patients. Pulmonary fibrosis 
is common to a number of interstitial lung disorders which may have distinct 
aetiologies and pathophysiology. Such conditions include those resulting from 
exposure to radiation, dust, infectious agents, allergens, or chemicals. In addition, 
pulmonary fibrosis may be a feature of diseases which progressively affect the lungs 
as one part of systemic involvement. Examples of this are systemic sclerosis, 
rheumatoid arthritis and sarcoidosis. Conversely, pulmonary fibrosis may occur 
rapidly following acute severe insults to the lung. Examples of this are the acute 
respiratory distress syndrome (ARDS) which can occur in response to septicaemia or 
various other insults, and bronchopulmonary dysplasia which can occur in premature 
infants. This latter probably results in part from the effect of high oxygen 
concentrations and shear stresses associated with mechanical ventilation on 
underdeveloped lungs. Pulmonary fibrosis is also a hallmark feature of the idiopathic 
interstitial pneumonias. There are seven separate clinicopathological categories of 
interstitial pneumonia. Diagnosis of these is based on clinical, radiological, and 
histological findings. The categories of interstitial pneumonia are as shown in table
1.1.
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Histological pattera Diagnosis based on clinical, radiological, and 
histological findmgs
Usual interstitial pneumonia 
(UIP)
Idiopathic pulmonary fibrosis 
(IPF)
Nonspecific interstitial pneumonia 
(NSIP)
Nonspecific interstitial pneumonia 
(NSIP)
Organizing pneumonia Cryptogenic organizing pneumonia 
(COP)
Diffuse alveolar damage Acute interstitial pneumonia 
(AIP)
Respiratory bronchiolitis Respiratory bronchiolitis-associated interstitial 
lung disease (RBILD)
Desquamative interstitial pneumonia Desquamative interstitial pneumonia 
(DIP)
Lymphoid interstitial pneumonia Lymphoid interstitial pneumonia 
(LIP)
Table 1.1. Classification of the idiopathic interstitial pneumonias (Table adapted 
from (Khalil & O'Connor 2004))
1.1.1. Idiopathic pulmonary fibrosis (IPF)
IPF is the commonest of the idiopathic interstitial pneumonias. The peak 
incidence occurs in the sixth decade of life and the disease is more common in males 
than females. Reported estimates of incidence and prevalence in the literature vary; 
but incidence may be 7-10 cases per 100,000/year, and prevalence may be 20 per 
100,000 (Coultas et al. 1994). Several risk factors such as cigarette smoking 
(Baumgartner et al. 1997) and viral infection (Tang et al. 2003) have been proposed. 
The existence of familial cases of idiopathic interstitial pneumonia suggests there may 
be a genetic basis, and various polymorphisms, such as of surfactant protein C, 
associate with an increased incidence of IFF (Lawson et al. 2004). Nevertheless, most 
individuals who do develop IFF currently have no known predisposing risk factor.
The pathophysiological basis of IFF has been the subject of much debate over 
the last few decades. Previously it was widely thought that chronic inflammation 
injured the lung, which subsequently initiated widespread fibrogenesis. However, 
given the limited evidence for persistent inflammation in progressive lung fibrosis.
11
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and the lack of efficacy of anti-inflammatory therapeutic interventions, there is 
growing consensus that fibrogenesis results, at least in part, from multi-focal epithelial 
microinjury with subsequent disordered epithelial repair and abnormal epithelial- 
fibroblastic interactions (Reviewed in (Selman et al. 2001)). The contribution of 
epithelial cells to fibrogenesis will be discussed in more depth in a following section:
1.5.2. Epithelial injury within the lung.
Clinically, the symptoms of IPF are dyspnoea and an unproductive cough. 
Physical signs on examination are usually inspiratory crackles at the lung bases, 
sometimes with digital clubbing. Lung biopsy typically demonstrates a histological 
pattern known as Usual Interstitial Pneumonia (UIP), which is one of interstitial 
fibrosis containing areas of dense scarring, honeycombing, and scattered fibroblastic 
foci, often alternating with areas of normal lung. Radiological imaging demonstrates 
peripheral subpleural lower zone reticular opacities, possibly together with subpleural 
honeycombing, traction bronchiectasis and limited ground-glass opacity. Lung 
function tests demonstrate a restrictive airflow defect, reduced lung volumes, reduced 
carbon monoxide gas transfer and arterial hypoxaemia.
In many patients the clinical course after diagnosis is one of relentlessly 
progressive respiratory impairment and dyspnoea leading ultimately to respiratory 
failure. In a study of newly diagnosed cases of IPF (Hubbard et al. 1998), the median 
survival was only 2.9 years, although it is now apparent that a number of clinical, 
radiological, and physiological parameters have useful prognostic value in predicting 
survival in individual patients (King, Jr. et al. 2001).
Current therapeutic options for IPF essentially comprise corticosteroids, and 
immunosuppressive/cytotoxic agents (e.g. azathioprine, cyclophosphamide). 
Unfortunately, these treatments have made little impact on morbidity and mortality. 
However, improvements in our understanding of the biochemical and biological 
mechanisms of lung fibrosis have led to the development of a number of novel 
therapies, which are currently being evaluated. These will be discussed in a later 
section: 1.1.5. Novel therapies for IPF.
1.1.2. The acute respiratory distress syndrome
The acute respiratory distress syndrome (ARDS) is a syndrome comprising 
noncardiogenic pulmonary oedema and respiratory failure, and occurring within hours
12
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to days of a predisposing insult. It may occur in the context of direct lung injury, such 
as from pneumonia or aspiration, as well as in the context of indirect lung injury 
associated with trauma, sepsis, and other conditions including pancreatitis, drug 
overdose, or multiple blood transfusions. There is also some evidence to suggest that 
certain polymorphisms in inflammatory genes such as tumour necrosis factor-alpha 
(TNF-a) (Gong et al. 2005) and interleukin- 6  (IL-6 ) (Marshall et al. 2002b), 
angiotensin converting enzyme (ACE) (Marshall et al. 2002a), and surfactant proteins 
(Lin et al. 2000) may influence the incidence and outcome of ARDS and/or sepsis.
In a Scandinavian multi-centre prospective study (Luhr et al. 1999), the 
incidence of ARDS in the general population was found to be 13.5/100000/year. 221 
(14.6%) of 1515 of ICU patients that required either at least twenty four hours of care, 
or oxygen therapy (with a fraction of inspired oxygen (FiOi) of at least 0.4) and 
ventilatory support, had ARDS. The mean age of these ARDS patients was 61.3 ± 
16.5 years, and the mortality in the first 90 days following diagnosis was 41.2%.
The pathogenesis of ARDS involves initial widespread injury to epithelial and 
endothelial surfaces leading to disruption of the alveolar-capillary unit. The ensuing 
“diffuse alveolar damage” is considered to comprise exudative, proliferative, and 
fibrotic phases. The exudative phase is characterised by leakage of protein-rich fluid 
from capillaries into the alveolar space. This promotes the formation of hyaline 
membranes, containing condensed plasma proteins and fibrin, within the alveoli. 
Alveolar septa are also engorged as a result of interstitial oedema, and extravasated 
erythrocytes, inflammatory cells, and fibrin. The proliferative phase comprises 
proliferation of type II alveolar epithelial cells and fibroblasts, whilst the fibrotic 
phase is characterised by the synthesis of matrix proteins such as collagens I and III. 
This results in alveolar fibrosis, but may also lead to vascular wall remodelling and 
pulmonary arterial hypertension. In fact these phases may overlap temporally, rather 
than follow sequentially, and there is evidence that collagen synthesis may occur 
within the first 24 hours of mechanical ventilation in patients with acute lung injury 
(reviewed in (Marshall et al. 1998)).
Clinically, ARDS is manifest by impaired arterial oxygenation, and bilateral 
pulmonary infiltrates on chest X-ray, in the absence of left ventricular heart failure. 
Management is largely supportive and includes oxygen therapy combined with 
ventilatory, haemodynamic, and nutritional support. Vasodilators such as nitric oxide 
or prostacyclin may be useful in those patients with co-exisiting pulmonary arterial
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hypertension. Instillation of surfactant has been shown to improve survival in 
premature infants, but not in adults with acute respiratory distress syndrome. Most 
deaths from ARDS occur in the first two weeks after diagnosis. Recovery in survivors 
can take several months. Interestingly much of the collagen deposited within the lung 
seems to disappear in these individuals. Nonetheless, many of these patients are left 
with residual impairment in respiratory function, and reduced ability to carry out 
normal activities of daily living (Heyland et al. 2005).
1.1.3. Mechanisms of pulmonary fibrosis
Multiple mediators and complex mechanisms promote the development of 
fibrosis in fibroproliferative lung disorders such as IPF and ARDS. However a central 
early event in both IFF and ARDS is widespread epithelial cell injury and necrosis of 
type I alveolar epithelial cells. The role of epithelial injury in fibrogenesis will be 
considered in a later section: 1.5.2. Epithelial injury within the lung. The resulting 
compromise of alveolar capillary wall integrity permits the formation of a provisional 
fibrinous matrix on denuded basement membrane of the alveolar wall, reactive 
hyperplasia and proliferation of type II alveolar and possibly bronchiolar epithelial 
cells, and their production of a number of mediators which drive proliferation, 
activation and migration of underlying fibroblasts into the provisional matrix. These 
events effectively represent an excessive and aberrant healing response. The outcome 
is dependent on the nature and extent of epithelial injury, but is also affected by other 
influences such as the local oxidant/ antioxidant balance. Antioxidants such as 
glutathione protect cells from injurious reactive oxygen species and their levels are 
reduced in the epithelial lining fluid in IFF (Cantin et al. 1989).
The formation of a provisional fibrinous matrix on the damaged alveolar wall 
is enabled by the local upregulation of tissue factor (TF), the initiator of coagulation. 
This promotes the generation of thrombin which then forms insoluble fibrin from 
plasma fibrinogen. Under the influence of pro-fibrotic mediators, neighbouring 
fibroblasts migrate into the provisional matrix and the adjacent interstitium, 
proliferate, and transdifferentiate into contractile, activated myofibroblasts which 
synthesize and deposit abundant extracellular matrix proteins, including collagens 
types I and III. Localised groups of highly active collagen-synthesizing 
myofibroblasts form fibroblastic foci, which are the histological hallmarks of UIF.
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Examples of mediators implicated in lung fibrosis are shown in table 1.2. The 
most potent of these mediators is undoubtedly transforming growth factor-beta-1  
(TGF-pi); and this together with the chemokine CCL2 and connective tissue growth 
factor (CTGF) will be considered in more depth in later sections. Notably the pro- 
fibrotic effects of a number of these mediators may be counteracted by various 
protective or anti-fibrotic mediators including interferon gamma (IFN-y), 
prostaglandin E2 (PGE2), and the antioxidant glutathione. In general, fibrosis of the 
lung and other organs involves a shift in the local balance of Thi/Th2-type cytokines 
in favour of a Th2 profile. Th2 cytokines such as IL-4 and IL-13 promote fibrosis by 
stimulating fibroblast collagen synthesis (Gillery et al. 1992),(Oriente et al. 2000) 
whilst Thi cytokines such as IFN-y may inhibit fibroblast function and collagen 
synthesis (Narayanan et al. 1992) and are thus anti-fibrotic.
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Chemokines
CXCL5 (Epithelial neutrophil activating protein-78 
(ENA-78))__________________________________
CXCL8  (interleukin-8 )
CCL2 (Monocyte chemoattractant protein-1 (MCP- 
1))
CCL3 (Macrophage inflammatory protein-1-alpha 
(MIP-la)
Leiikotrieiies
LTB4, LTC4 (Leukotrienes C4, E4)
Cytokines
IL-lb
IL-4
IL-13
TNF-a
ET-1 (Endothelin-1)
Growth factors
TGF-Bi
TGF-a
CTGF
PDGF (Platelet-derived growth factor)
IGF-1 (Insulin-like growth factor-1)
Thrombin 
Factor Xa (FXa)
Protease Inhibitors
PAI-1 (Plasminogen activator inhibitor-1)
TIMP-1 (Tissue inhibitor of metalloproteinase-1)
Table 1.2. Mediators implicated in lung fibrosis
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Persistence of extracellular matrix components is dependent on the balance of 
factors which promote their synthesis and those which promote their degradation. 
Fibrin persistence may result from increased levels of plasminogen activator inhibitor- 
1 (PAI-1) in IPF, leading to inhibition of plasmin activation, and reduced fibrin 
degradation (Fujii et al. 2000). Matrix metalloproteinases (MMPs) are important in 
the degradation of matrix proteins such as collagen. In IPF levels of endogenous 
MMP inhibitors: tissue inhibitors of matrix metalloproteinases (TIMPs) appear to be 
upregulated to a greater extent than MMPs such that matrix components persist 
(Selman et al. 2000).
In a normal healing response, following deposition of limited extracellular 
matrix in the wound space, myofibroblasts contract to close the wound and then 
disappear by apoptosis. Epithelial cell proliferation then ensues to re-establish a 
covering epithelial lining. In lung fibrosis the opposite situation occurs such that 
fibroblast/myofibroblast apoptosis is reduced but epithelial cell apoptosis and necrosis 
is increased. Reduced fibroblast apoptosis may occur in response to increased levels 
of TGF-p 1 (Jelaska & Korn 2000), whereas increased epithelial apoptosis may occur 
in response to fibroblast-derived angiotensin peptides (Uhal et al. 1995).
There has been some controversy as to the importance of inflammatory cells in 
fibrogenesis in pulmonary fibrosis. Cellular inflammation is a prominent histological 
feature in non-specific interstitial pneumonia (NSIP) but not UIP. However the 
presence of both pathologies in biopsies of the same lobe of lung in number of 
patients with idiopathic interstitial pneumonia suggests that NSIP may evolve 
temporally into UIP, and that the two entities are in fact part of the same disease 
process (Strieter 2002). Thus inflammation may play a role in initiating epithelial 
injury and promoting fibroblast function in early disease by the production of pro- 
inflammatory and pro-fibrotic growth factors. In bleomycin-induced lung fibrosis in 
rodents, inflammatory cells represent a potential source of important pro- 
inflammatory mediators such as IL-lb (Maeda et al. 1996) and TNF-a (Everson & 
Chandler 1992), and pro-fibrotic mediators such as CCL2 (Sakanashi et al. 1994), 
IGF-1, PDGF (Maeda et al. 1996), and TGF-pi (Khalil et al. 2002). Furthermore IL- 
lb, TNF-a, and the Th2 cytokine IL-13 can provide a link between inflammation and 
fibrosis since these pro-inflammatory agents are able, either individually or in 
combination, to induce expression of pro-fibrotic TGF-pi in vitro (Yue et al.
17
Role o f PARj-dependent secondary mediators in lung fibrosis
1994),(Warshamana et al. 2001),(Fichtner-Feigl et al. 2006). In addition, 
overexpression of these mediators in mice promotes increased lung TGF-p i levels and 
fibrosis (Kolb et al. 2001),(Sime et al. 1998),(Lee et al. 2001).
In UIP, however, the paucity of inflammatory cells and the lack of efficacy of 
anti-inflammatory therapies argue against inflammation being important, at least in 
advanced disease. In this setting, the major cellular source of pro-inflammatory and 
pro-fibrotic mediators may comprise hyperplastic epithelial cells (Kapanci et al. 1995). 
Conversely, inflammatory cells are a more prominent feature in ARDS than in 
advanced IPF, and are more likely to contribute to fibrogenesis in ARDS, although 
hyperplastic epithelial cells remain an additional key source source of pro- 
inflammatory and pro-fibrotic mediators.
Finally two further mechanisms may contribute to fibrosis, namely fibrocyte 
recruitment and epithelial-mesenchymal transition. Fibrocytes are circulating cells 
derived from bone marrow that express both leukocyte (CD45, CD 13) and 
mesenchymal (Col 1) markers. They exhibit chemotaxis to chemokines such as CCL2 
(Moore et al. 2005) and CCL12 (Moore et al. 2006), and evidence from animal 
models suggests they are recruited to the injured lung and promote fibrosis by 
synthesizing TGF-p i and extracellular matrix components such as collagen. Finally, 
collagen-synthesizing mesenchymal cells may also be derived from type II alveolar 
epithelial cells. In a process known as epithelial-mesenchymal transition, alveolar 
epithelial cells chronically exposed to the profibrotic mediator TGF-p i 
transdifferentiate to a myofibroblast-like phenotype. This is associated with de novo 
expression of the mesenchymal marker Fibronectin-EDA (Fn-EDA) and a 
concomitant downregulation of the epithelial marker E-cadherin (E-cad) (Willis et 
al. 2005),(Kasai et al. 2005).
1.1.4. Collagen synthesis in pulmonary fibrosis
Resident cells within all organs synthesize a range of extracellular matrix 
proteins. These proteins provide structural integrity for tissues and serve to protect 
cells from damaging mechanical influences. They also exert important influences over 
cellular function. For example they enable cell attachment and migration, influence 
cell differentiation and gene expression, allow mechanically transduced signal
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transduction, and serve as important reservoirs of growth factors by virtue of these 
being able to bind certain matrix components. Extracellular matrix is thus crucial to 
the normal functioning of organs, and abnormal extracellular matrix composition or 
disordered architecture has profound deleterious consequences.
Collagens are the most abundant proteins present in extracellular matrix in 
both normal and fibrotic tissues (reviewed in (Gelse et al. 2003)). There are twenty 
eight known types of collagen. Each comprises a characteristic triple helix consisting 
of 3 polypeptide chains. Type IV collagen serves as an important structural 
component of basement membranes and comprises heterotimers of six possible 
subunit chains. Type I and III collagens assemble into large orientated supramolecular 
aggregates known as fibrils. Type I collagen is the major protein constituent of bone, 
tendon, ligaments and skin. Type III collagen is an important constituent of reticular 
fibres within the interstitium of the lungs, liver, dermis and spleen. The presence of 
types I and III collagen within the lung is crucial in providing structural integrity in an 
organ which contains intricate and extensive networks of airspaces and capillaries, 
and is exposed to considerable mechanical stresses.
Type I collagen is the most abundant of the collagens and is usually a 
heterotrimer of 2 ai(I) chains and 1 a 2(I) chain. An important mechanism by which 
factors such as TGF-pi, TNF-a, IL-4, IL-13, and thrombin promote fibrosis is by 
induction of procollagen ai(I) gene expression (Hetzel et al. 2005),(Gillery et al. 
1992),(Oriente et al. 2000),(Chambers et al. 1998). Type III collagen is a homotrimer 
of 3 ai (III) chains, and is often incorporated into composite fibrils with type I 
collagen.
Collagen genes involve a complex intron-exon pattern. Hence mRNA species 
of differing lengths can result from alternative splicing and use of different 
transcription initiation sites. Translation leads to the synthesis of preprocollagen 
which is converted to procollagen by removal of its signal peptide. Procollagen 
molecules then undergo extensive post-translational modification and incorporation 
into triple helices within the Golgi compartment. They are released from here via 
secretory vesicles into the extracellular space, where N and C-terminal peptides are 
cleaved off and assembly into fibrils occurs.
Precise regulation of synthesis of extracellular matrix components such as 
collagen is obviously critical within all tissues. However it is of particular importance
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in the lung since any deficiency of matrix components can cause alveolar airspace 
collapse and destruction, whilst any excess can distort and widen the pulmonary 
interstium thus preventing the close opposition of endothelial and epithelial 
monolayers. In both instances the capability of the lungs for efficient gaseous 
exchange will be seriously adversely affected.
1.1.5. Novel therapies for IPF
In a consensus statement of the American and European Thoracic Societies in 
2 0 0 0 , prednisolone together with an immunosuppressant such as azathioprine was 
recommended as best standard care for IPF patients. In a small trial in 1991, a 
combination of azathioprine and prednisolone was shown to provide a survival 
advantage over prednisolone (Raghu et al. 1991), but surprisingly prednisolone has 
never been compared with placebo in a randomized controlled trial in terms of its 
effect on any meaningful physiological outcome or survival. This poses a major 
problem in the evaluation of novel therapies because due to the current 
recommendations on treatment of IFF, it is considered unethical to compare any novel 
therapy directly against placebo and withhold the use of prednisolone. Hence recent 
trials have effectively compared the novel therapy plus prednisolone against 
prednisolone alone. Recent phase III randomized placebo-controlled clinical trials of 
such design with interferon gamma-lb (IFN-y-lb) (Raghu et al. 2004), pirfenidone 
(Azuma et al. 2005b), N-Acetylcysteine (Demedts et al. 2005), and anticoagulants 
(Kubo et al. 2005) have all shown limited but statistically significant benefits. It is 
hard to know whether these small benefits are clinically meaningful however. All of 
these agents have previously proved efficacious at attenuating experimentally-induced 
fibrosis in animal models (Hyde et al. 1988),(Iyer et al. 1995),(Shahzeidi et al. 
1991),(Gunther et al. 2003),(Howell et al. 2001).
In a large trial of 330 patients there was a trend for a small survival benefit 
after 58 weeks of therapy (Raghu et al. 2004) with IFN-y-lb, which became 
significant when only patients with early or mild disease were retrospectively 
considered (King, Jr. et al. 2005). IFN-y-lb may exert antifibrotic effects by 
modulating the local Thi/Thz cytokine balance in favour of a Thi profile, inhibiting
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TGF-p signalling, and inhibiting fibroblast function and collagen synthesis (reviewed 
in (Thannickal et al. 2005)).
In a trial of 107 patients, pirfenidone reduced the rate of physiological decline 
and the number of exacerbations over a 12 month period (Azuma et al. 2005b). The 
antifibrotic influence of pirfenidone may be due to its ability to downregulate 
expression of PDGF and TGF-pi, inhibit fibroblast activation and collagen synthesis, 
and function as an antioxidant (reviewed in (Thannickal et al. 2005)).
In a trial of 155 IFF patients over a 1 year period, N-Acetylcysteine 
significantly slowed the rate of physiological decline (Demedts et al. 2005). N- 
Acetylcysteine functions to replenish cellular stores of the antioxidant glutathione in 
the lung. This protects against injury mediated by reactive oxygen species and the 
potential consequent fibrosis.
In a limited trial of 56 patients over 3 years, anticoagulation demonstrated an 
impressive improvement in survival (Kubo et al. 2005). Anticoagulants function to 
inhibit generation of coagulation proteinases such as factor Xa and thrombin, and also 
the generation of fibrin. The potential pro-inflammatory and pro-fibrotic effects 
exerted by each of these will be discussed at length in a later section.
A number of other agents are also currently being evaluated as novel therapies 
for IPF, and these are outlined in table 1.3.
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Novel therapeutic agent Rationale for use
IFN-7 -lb - Promotes Thi cytokine profile
- Inhibits TGF-p signalling
- Inhibits fibroblast function and collagen synthesis
Pirfenidone - Downregulates PDGF and TGF-P 1 expression
- Inhibits fibroblast activation and collagen synthesis
- Antioxidant
N -Acetylcysteine - Replenishes levels of the antioxidant glutathione in the 
lung. Thus protects against injury from reactive oxygen 
species
Anticoagulants - Inhibits generation of FXa, Thrombin and fibrin, all of 
which are potentially pro-inflammatory and pro-fibrotic
Bosentan - Endothelin receptor antagonist. Blocks endothelin- 
dependent activation of fibroblasts and collagen synthesis
Etanecept - TNF-a antagonist. Blocks potentially pro-fibrotic effects 
of TNF-a
Imatinib mesylate 
(Gleevec)
- PDGF-receptor tyrosine kinase inhibitor. Blocks pro- 
fibrotic effects of PDGF. May also inhibit TGF-P 1 
signalling.
Zileuton - 5-lipoxygenase inhibitor. Inhibits production of pro- 
fibrotic Leukotrienes
Anti-CTGF antibodies - blocks CTGF-dependent stimulation of fibroblast function
T etrathiomolybdate - Copper chelating compound. Downregulates the 
angigogenic factor VEGF (vascular endothelial growth 
factor) and pro-fibrotic factors such as the matricellular 
protein SPARC and TGF-p 1.
TGF-pi blocking 
strategies
- Monoclonal anti-TGF-Pi antibodies
- TGF-p 1 receptor kinase inhibitors
- Inhibitors of TGF-p 1 signalling kinases
- all designed to block profibrotic effects of TGF-p 1.
Table 1.3. Novel therapeutic agents currently being evaluated for treatment of 
IPF (adapted from (Thannickal et al. 2005))
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1.1.6. Novel therapies for ARDS
As in IPF, a number of potential novel therapies are being evaluated, 
developed, or proposed, but none has yet made any impact on the considerable 
morbidity and mortality of ARDS. As mentioned above, treatment is largely 
supportive including oxygenation, protective ventilatory strategies, bronchodilators, 
inotropic support and optimization of fluid balance. Specific pharmacological 
therapies that have failed to show benefit in clinical trials to date in adult patients 
include N-Acetylcysteine, aerosolized surfactant, and the vasodilators nitroprusside, 
hydralazine, and prostacyclin (reviewed in (Ware & Matthay 2000)).
Steroids may confer some protection from fibrosing alveolitis in ARDS, and in 
a small randomized controlled trial of patients with unresolving ARDS, administration 
of methylprednisolone was associated with reduced bronchoalveolar lavage (BALF) 
type I and III procollagen aminoterminal propeptide levels, improved lung function, 
and improved survival (Meduri et al. 1998). A more recent trial has confirmed the 
beneficial effect of methylprednisolone, showing an improvement in pulmonary and 
extrapulmonary organ dysfunction, and reduced duration of mechanical ventilation 
and length of ICU stay (Meduri et al. 2007). However, a separate study suggests that 
the beneficial effects of steroids in ARDS might only be apparent in patients with co­
existing adrenal insufficiency. Notably however this did include the majority of 
patients with septic shock-related ARDS examined (Annane et al. 2006). At present 
steroid use in ARDS remains controversial.
In contrast to IPF, ARDS is not often a single disease entity, but rather the 
pulmonary manifestation of the systemic inflammatory response syndrome. In fact, 
patients with ARDS often die of non-respiratory problems. Therapeutic strategies thus 
may need to be tailored to address the systemic- rather than just pulmonary 
dysfunction. In severe sepsis, which is commonly associated with ARDS, 
administration of recombinant AFC reduces mortality by around 6% (Dhainaut et al. 
2003), and this is likely to be mediated by systemic anti-inflammatory and 
anticoagulant effects. A trial examining the efficacy of AFC specifically in ARDS, 
and led by Dr Michael Matthay in the USA is currently ongoing (personal 
communication. Dr Rachel Chambers).
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1.1.7. Association of fibroproliferative lung disorders with excessive local 
procoagulant activity
Excessive procoagulant activity is a feature of a number of respiratory diseases 
which involve inflammation and deposition of extracellular matrix, including IPF 
(Chapman et al. 1986),(Ikeda et al. 1989),(Kotani et al. 1995), pulmonary fibrosis in 
systemic sclerosis (Ohba et al. 1994), ARDS (Bachofen & Weibel 1982), chronic lung 
disease of prematurity (Dik et al. 2003), cryptogenic organizing pneumonia (Peyrol et 
al. 1990), and airway remodelling in asthma (Gabazza et al. 1999). Work outlined in 
this thesis relates to the potential role of coagulation proteinases such as thrombin in 
the development of fibroproliferative lung disorders. The mechanisms by which 
coagulation occurs and the potential interplay between coagulation and disease 
processes will now be described in more depth.
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1.2. The coagulation cascade and haemostasis
1.2.1. Coagulation pathways
Following vascular injury, an intricately controlled system involving platelets, 
plasma serine proteinases, cofactors, and inhibitors has evolved to effect the precise 
generation of thrombin, and subsequently fibrin. A fibrin clot enmeshed with platelets 
is fundamental in the restoration of integrity of the vessel wall, and thus prevents 
blood loss. The biochemical reactions involved in thrombin formation do not occur 
efficiently in solution, but rather require assembly of reactants and cofactors on 
phospholipid membranes of activated platelets and damaged cells in the presence of 
calcium ions. This effectively localizes clot formation to the site at which the process 
is initiated, and prevents unnecessary, and potentially disastrous, clotting occurring 
elsewhere in the vasculature.
Historically, formation of thrombin was thought to occur by two distinct 
pathways (figure 1.1) which converged in the activation of factor X to produce Factor 
Xa. Factor Xa then converts prothrombin to active thrombin. The extrinsic pathway 
was the pathway initiated by components outside of the circulation, and based on the 
observation by Morowitz in 1905 that introduction of tissue components into plasma 
culminated in the formation of fibrin. Conversely, the concept of the intrinsic pathway 
was based on the observation that blood placed in an artificial container clots without 
the addition of tissue “juices”, suggesting coagulation could be initiated by 
components intrinsic to blood, and on contact. However it is now appreciated that 
these pathways are not independent. If that were so, then one might not have expected 
such a severe bleeding diathesis in patients with haemophilia A and B, who are 
deficient in clotting factors VIII and IX, respectively.
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Figure 1.1. Old paradigm of thrombin generation.
Coagulation was thought to be initiated by either the intrinsic or extrinsic pathways, which converge in the 
activation of factor X to factor Xa, and the conversion of prothrombin to thrombin by factor Xa in 
conjunction with its cofactor Va. The intrinsic pathway was thought to be initiated when factor XII becomes 
activated on exposure to an endothelial surface. Subsequently, together with the accessory components 
prekallikrein and high molecular weight kininogen, factor Xlla is able to activate factor XIa. This leads to 
activation of IXa, which together with the cofactor Villa activates Xa. The extrinsic pathway was proposed 
to be initiated by circulating factor VII binding to extravascular tissue factor, and this complex is then able 
to activate Xa. Many of the reactions are dependent on calcium and require a phospholipid membrane 
surface. (Adapted from Oxford Handbook of Clinical Medicine, 2005, Longmore & Wilkinson (Eds)).
These factors were proposed to be necessary to activate factor X in the intrinsic 
pathway. However theoretically, factor X could have been activated independently of 
factors VIII and IX by the extrinsic pathway. Despite this, these patients have a 
profound inability to form effective blood clots. This suggested that the extrinsic 
pathway could not compensate for a defective intrinsic pathway, and that effective 
coagulation requires factors originally specifically ascribed to both pathways.
Current thinking regarding coagulation (reviewed in (Mann 2003) & (Hoffman 
2003)) is illustrated in figure 1.2.
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The major mechanism for initiation of coagulation is the exposure of circulating 
factor Vila to tissue factor outside the circulation, and the biological relevance of the 
intrinsic or contact pathway as a mechanism of initiation in vivo is doubtful. However, 
factors VIII and IX, previously ascribed to the intrinsic pathway, do in fact play a 
pivotal role in coagulation, and when activated and complexed together, actually 
constitute the predominant activator of factor X.
Various inflanunatory stimuli can induce tissue factor expression on 
endothelial cells (Fei et al. 1993),(Parry & Mackman 1995). A number of cell types 
not normally in contact with blood also express tissue factor (Ruf & Edgington 1994); 
and tissue factor expression on extravascular cells is upregulated by cellular injury 
(lakhiaev et al. 2004),(Nestoridi et al. 2005),(01man et al. 1995) and inflammatory 
mediators such as TNF-a (Sitter et al. 1996),(Haslinger et al. 2003). Vascular leak 
permits factor Vila to also come into contact with cells expressing tissue factor in the 
extravascular space. Factor Vila exists spontaneously but only as a very small 
proportion (around 1%) of the total circulating factor VII pool. It complexes with 
tissue factor on surfaces of tissue factor-expressing cells, and possesses proteolytic 
activity only when bound in this way. The complex of cell surface-associated tissue 
factor and factor Vila (TF/VIIa) constitutes the extrinsic factor tenase, and is able to 
catalyse the activation of circulating factors IX and X to IXa and Xa. Some of the 
factor Xa thus formed complexes with membrane TF/VIIa and catalyses further 
generation of IXa from IX. The small amount of Factor Xa produced by this extrinsic 
factor tenase, together with its cofactor Va forms a prothrombinase complex which 
converts small amounts of prothrombin to thrombin. This thrombin is insufficient for 
any meaningful coagulation response, but is essential for the later amplification of the 
process and subsequent generation of larger amounts of thrombin. It activates platelets, 
and catalyses the conversion of factors V VII, VIII and XI to Va, Vila, Villa and XIa.
Factor IXa complexes with factor Villa on the activated platelet membrane, to 
form the intrinsic factor tenase. The source of this factor IXa is the extrinsic factor 
tenase mentioned above, although in addition, factor XIa may also play a role in its 
generation. Platelet activation occurs as a result of their exposure to either i) 
subendothelial collagen in an injured blood vessel, ii) thrombin, or iii) pro- 
inflammatory mediators such as platelet activating factor (PAF) (Zimmerman et al.
2002). The intrinsic factor tenase is far more efficient than the extrinsic factor tenase, 
and produces the bulk of the factor Xa involved in coagulation. Inability to assemble
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the intrinsic factor tenase because of deficiency of factor VIII or IX is in fact the basis 
of the bleeding diathesis observed in patients with haemophilia. The large amounts of 
factor Xa produced combine with factor Va on the activated platelet membrane 
surface to form the major prothrombinase complex, which converts prothrombin to 
thrombin. Notably, this prothrombinase complex is the predominant site of conversion 
of prothrombin to thrombin. Thrombin catalyses the conversion of fibrinogen to fibrin 
and the release of fibrinopeptides A and B. This fibrin then polymerizes, is stabilized 
by Factor Xlll-induced cross-linking, and entraps any activated adhered platelets at 
the initial site of vessel injury to form a stable blood clot.
1.2.2. Inhibitors of the coagulation cascade
Under normal conditions, the net effect of inhibitors of coagulation outweighs 
the potential coagulation response, such that the blood remains fluid and devoid of 
thromboses. The main inhibitors of coagulation are antithrombin, tissue factor 
pathway inhibitor (TFPI), and the thrombin-thrombomodulin protein C system. 
Antithrombin targets and neutralizes all the activated procoagulant serine proteinases, 
including thrombin. TFPI targets the extrinsic factor tenase, and prevents the 
generation of IXa, and Xa. The thrombin-thrombomodulin-protein C system is 
initiated when thrombin binds to thrombomodulin on the vascular endothelium. 
Thrombin then rapidly activates protein C, which is localised to the endothelial cell 
surface by the endothelial protein C receptor (EPCR). Following its subsequent 
release from the cell surface, activated protein C binds to circulating protein S, and 
together these proteins inactivate factors Va and Villa.
A number of therapeutic strategies are used to inhibit coagulation. Warfarin 
inhibits the vitamin K-dependent y-carboxylation of glutamate residues, which is an 
integral process in the synthesis of coagulation proteinases VII, IX, X, and thrombin. 
Heparin binds to antithrombin, and increases its ability to inhibit thrombin, factor IXa, 
and factor Xa. Low molecular weight heparin also complexes with antithrombin but 
only increases its ability to inhibit Xa. Recombinant activated protein C has recently 
been successfully administered in sepsis (Dhainaut et al. 2003), although its efficacy 
in reducing mortality may be mediated via anti-inflammatory as well as anticoagulant 
actions (Macias et al. 2005).
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1.2.3. Regulation of fibrin turnover
Fibrin turnover is regulated by a dynamic balance between factors that 
promote its removal and factors that inhibit this process. The expression and release 
of these factors are regulated in response to a number of injurious stimuli and 
inflammatory mediators. Plasmin, the active serine proteinase that degrades fibrin, is 
converted into its active form by tissue plasminogen activator (tPA) and urokinase 
(uPA), which are synthesized and secreted primarily by endothelial cells. Both tPA 
and uPA are inhibited by the widely expressed plasminogen activator inhibitor- 1 
(PAI-1). The activity of plasmin is regulated by a number of circulating inhibitors. Its 
generation is inhibited by thrombin activatable fibrinolysis inhibitor (TAFI), and its 
function is directly inhibited by a 2-plasmin inhibitor (a 2-PI) and a 2-macroglobulin 
(a2-MG). TAFI also modifies carboxyterminal lysine residues of fibrin molecules 
rendering them less degradable by plasmin.
1.2.4. Crosstalk between coagulation and inflammation
Considerable cross-talk exists between coagulation and inflammation, and pro­
coagulant and pro-inflammatory pathways interact at a number of levels. Activation 
of coagulation may serve a useful function in an inflammatory response, in that local 
deposition of fibrin forms a physical barrier to limit and contain the inflammatory 
response to the site of injury. However excessive activation of coagulation, as occurs 
in the context of a substantial systemic inflammatory response in sepsis results in 
disseminated intravascular coagulation which is itself responsible for severe organ 
damage.
An important point of interaction between inflammation and coagulation is the 
ability of inflammatory mediators to locally upregulate the expression of tissue factor, 
and hence promote the initiation of the coagulation cascade. In in vitro studies, tissue 
factor expression is increased in response to LPS, IL-lp, or TNF-a on endothelial 
cells (Fei et al. 1993),(Parry & Mackman 1995),(Pertynska-Marczewska et al. 2004), 
macrophages (Car et al. 1991),(Rashid et al. 1996), and vascular smooth muscle cells 
(Xuereb et al. 2000). IL- 6  may also be important in upregulation of tissue factor, as in 
vivo studies have demonstrated that administration of anti-IL- 6  antibodies attenuates
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tissue factor-dependent thrombin generation in experimental endotoxaemia (van der et 
al. 1994). Inflammatory mediators such as LPS also stimulate release of platelet 
activating factor from macrophages (Leslie & Detty 1986) and thus promote platelet 
activation and thrombosis, whilst TNF-a can also impact on fibrin turnover. Injection 
of TNF-a into healthy volunteers induces a rapid transient increase in fibrinolytic 
activity associated with increased tPA and uPA levels, but a subsequent decrease in 
fibrinolytic activity associated with increased PAI-1 levels (van der et al. 1991). As 
well as promoting coagulation, inflammation can inhibit physiological anticoagulant 
mechanisms. For instance, levels of antithrombin and protein C are reduced in sepsis. 
This may relate to reduced synthesis, but in addition these proteins may be degraded 
by neutrophilic proteinases, since neutrophil elastase has been shown to degrade both 
of these mediators in vitro (Esmon & Yee 1992),(Eckle et al. 1991).
Conversely coagulation proteinases can influence inflammation via signalling 
through specific cellular receptors, known as proteinase activated receptors (PARs). 
These receptors will be discussed in detail in the following section: 1.3. Proteinase 
activated receptors. Briefly, activation of PARi, the major cellular receptor for 
thrombin, promotes inflammation by increasing vascular endothelial cell permeability 
(Rabiet et al. 1996), upregulating endothelial adhesion molecule expression (Sugama 
et al. 1992), and stimulating the release of pro-inflammatory mediators from a variety 
of cell types (Colotta et al. 1994),(Johnson et al. 1998),(Ueno et al. 1996),(Naldini et 
al. 2000). Similarly Factor Xa has been shown to be capable of inducing the 
production of a range of pro-inflammatory mediators via activation of PARi (Bachli 
et al. 2003) and PAR2 (Papapetropoulos et al. 1998), (Lee et al. 2005b) depending on 
cell type.
Fibrinogen, the circulating precursor of fibrin, may also promote inflammation. 
In vitro studies have demonstrated that fibrinogen can induce the expression and 
release of a host of pro-inflanunatory mediators from neutrophils (Walzog et al. 1999), 
macrophages (Smiley et al. 2001), endothelial cells (Qi & Kreutzer 1995) and 
fibroblasts (Liu & Piela-Smith 2000). Fibrin also serves as an important matrix to 
which inflammatory cells can adhere. In experiments involving implantation of 
synthetic biomaterials into the peritoneal cavities of mice, the inflammatory response 
was found to be fibrinogen-dependent in that fibrinogen-deficient mice failed to
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mount an inflammatory response unless the biomaterial was first precoated with 
fibrinogen (Tang & Eaton 1993).
Activated protein C (APC) is an endogenous anticoagulant which, in 
conjunction with protein S, inactivates factors Va and Villa. However, in addition to 
this role as a physiological anticoagulant, it has anti-inflammatory effects. These 
occur following its binding to EPCR and are mediated via activation of PARi 
(Riewald et al. 2002). In in vitro studies, APC attenuates endotoxin-induced 
production of TNF-a by monocytes (Yuksel et al. 2002). In animal studies, following 
exposure to endotoxin, administration of APC inhibits pulmonary leukocyte 
accumulation (Murakami et al. 1996), production of TNF-a and nitric oxide (NO), 
and hypotension (Isobe et al. 2001). Such an anti-inflammatory effect together with an 
anticoagulant effect may be the basis for the ability of APC to reduce mortality by 6 % 
in patients with severe sepsis (Dhainaut et al. 2003).
1.2.5. Crosstalk between coagulation, fibrin turnover, and fibrosis
Cross talk also exists between coagulation and fibrosis at a number of levels. 
Coagulation proteinases exert a number of pro-fibrotic effects. For example thrombin 
and factor Xa activate PARi to promote fibroblast mutagenesis and synthesis of 
extracellular matrix proteins such as collagen (Hemandez-Rodriguez et al.
1995),(Chambers et al. 1998),(Blanc-Brude et al. 2005). Thrombin similarly induces 
production of the pro-fibrotic growth factors PDGF, CTGF, and TGF-pi (Shimizu et 
al. 2000),(Chambers et al. 2000),(Bachhuber et al. 1997) from a number of cell types. 
Conversely, as well as being anti-inflammatory, the anticoagulant APC may exert 
anti-fibrotic effects. For example, APC has been shown to inhibit thrombin-induced 
PDGF expression in epithelial cells and macrophages in vitro, and to reduce lung 
PDGF expression to block lung fibrosis in response to bleomycin in mice (Shimizu et 
al. 2003).
The fibrotic environment may impact on coagulation and fibrin turnover. 
Mediators implicated in fibrogenesis such as the growth factors PDGF and TGF-|3i, 
and the CC chemokine CCL2 have been shown to induce tissue factor expression in 
vitro (Xuereb et al. 1997),(Emofsson & Siegbahn 1996),(Ranganathan et al. 1991), 
and thus may promote the initiation of coagulation. The fibrotic environment may also
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favour fibrin persistence. Constitutive PAI-1 expression is increased in fibroblasts 
isolated from fibrotic tissue (Tuan et al. 1996),(Yang et al. 2003), and TGF-pi has 
been shown to increase PAI-1 expression by numerous cell types including tracheal 
epithelial cells in vitro (Idell et al. 1994).
Thus coagulation exerts powerful influences on inflammation and fibrosis, and 
these processes themselves have a profound effect on coagulation. Excessive 
procoagulant activity is a feature of a number of respiratory diseases which involve 
inflammation and deposition of extracellular matrix. Hence crosstalk between 
coagulation, inflanunation and fibrosis may play an important part in the pathogenesis 
of these conditions.
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1.3. Proteinase activated receptors (PARs)
As alluded to previously, coagulation proteinases are able to activate a number 
of specific cellular receptors, known as proteinase activated receptors (PARs), to exert 
a host of cellular effects. Importantly many of these effects are distinct from the role 
of coagulation proteinases in haemostasis, although activation of PARi, PAR3, and 
PAR4 by thrombin contributes to activation of human and mouse platelets, and so 
clearly is relevant to haemostasis.
PARs are a family of seven-transmembrane G-protein coupled receptors. The 
family consists of four members, designated PARsw. A number of proteinases 
besides those associated with coagulation serve as agonists for PARs. The receptors 
can also be activated by small specific peptide agonists which correspond to the 
activating tethered ligand sequence intrinsic to each receptor. The agonists for each 
receptor, together with tissue localization of the receptors, and their potential 
physiological roles are shown in table 1.4.
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Receptor Physkdogical
agonists
Agonist
pepMe kK l^ization
Known/ potenW 
physioiogicW nde
PARi Thrombin 
Factor Xa 
TF-VIIa-Xa 
APC 
Plasmin
SFLLRN
TFLLRN
Brain, lung, 
heart, stomach, 
colon, kidney, 
testis
Human platelet 
activation, regulation 
of vascular tone, 
modulator of 
nociception, 
embryonic 
development, pro- 
inflammatory, pro- 
fibrotic
PARi Factor Xa 
TF-VIIa-Xa 
Trypsin 
Tryptase
SLIGKV Prostate, small 
intestine, colon, 
liver, kidney, 
pancreas, 
trachea
Regulation of vascular 
tone, mediator of 
nociception, airway 
protection, pro- 
inflammatory
PARi Thrombin None Heart, kidney, 
pancreas, 
thymus, small 
intestine, 
stomach, lymph 
node, trachea
Co-factor for PAR4, 
mouse platelet 
activation
PAR# Thrombin 
Trypsin 
Cathepsin G
GYPGQV
AYPGKF
Lung, pancreas, 
thyroid, testis, 
small intestine, 
placenta, 
skeletal muscle, 
lymph node, 
adrenal gland, 
prostate, uterus, 
colon
Platelet activation
Table 1.4. PARs, their agonists, tissue localization, and potential physiological 
role
(Adapted from (Ossovskaya & Bunnett 2004),(Hollenherg & Compton 
2002),(Hollenherg 2003) & (Chambers & Laurent 2002))
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1.3.1. Mechanism of activation of PARs
PARs display a unique mechanism of activation in that they are not activated 
by a classical circulating ligand but rather by their own intrinsic tethered ligand. Their 
agonist serine proteinase recognizes and specifically interacts with a peptide sequence 
near the receptor N-terminus and cleaves a portion off the receptor at a specific site. 
This effectively unmasks a previously anchored tethered ligand and allows it to bind 
intramolecularly to the second extracellular loop of the receptor. This interaction 
produces a conformational change at the receptor’s intracellular C-terminus allowing 
it to interact with membrane associated heterotrimeric G-proteins. An exchange of 
GTP for GDP and the dissociation of a  and py G-protein subunits follows, and 
subsequently these subunits initiate cell signalling via specific pathways. Signalling 
responses following activation of PARsi j  and 4 are each associated with a rapid 
increase in intracellular calcium, which is easily measurable in vitro, and most likely 
occurs downstream of receptor coupling to a GoCq G-protein subunit. The coupling of 
PARs to distinct G-protein subunits dictates the nature of the cellular response and 
depends on the type of PAR, and also probably the cell type and relative local 
abundance of different G-proteins (reviewed in (Hollenberg & Compton 2002)). The 
mechanism of activation of PARs is illustrated in figure 1.3.
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9
Thrombin
Tethered Ligand
s m
Cell Signalling
Figure 1.3. Mechanism of PAR activation. In this figure, activation of PARi by thrombin is illustrated. 
T he N term inus of the receptor is recogn ised  and c lea v ed  by thrombin. This liberates a  41 am ino-acid  
fragm ent and un m ask s a  tethered  ligand which binds intram olecularly to the 2 "'* extracellular loop of the  
receptor. T he resulting receptor conform ational c h a n g e  a llow s the C term inus to interact with m em b ran e- 
a sso c ia te d  G proteins, and initiate cell signalling.
Following activation of a PAR, its activating proteinase retains its ability to 
activate other similar PARs on the cell surface, such that in theory a low concentration 
of proteinase could cleave the same amount of PAR as a high concentration, but over 
a longer duration. Thus the conventional means of achieving graded cellular responses 
to differing agonist concentrations by differing degrees of receptor occupancy is not 
possible for PARs. Instead, graded responses in PARs are achieved by sensing the rate 
of generation of intracellular signalling mediators such as IP3. A fast rate of 
generation of these mediators correlates with a high extracellular agonist proteinase 
concentration.
A further unique feature of PARs is that they can be activated experimentally 
by short synthetic peptides with sequences analogous to those of their intrinsic 
tethered ligand, for instance PARi can be activated by SFLLR-NH2 or TFLLR-NH2 
peptides. However, these receptor activating peptides are generally less efficient than 
the in vivo physiological activators of the PARs because they do not enable certain
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Specific interactions to occur between receptor and proteinase which are important to 
facilitate their binding. For instance, activation of PARi by thrombin is facilitated by a 
hirudin-like sequence towards the N-terminal end of PAR] which can interact with 
thrombin’s anion-binding exosite. This sequence is also present on PARg but not 
PAR4 , which may partly explain why thrombin activates PAR4 only at 10-100 fold 
higher fold concentrations that those at which it activates PAR] (reviewed in (O'Brien 
et al. 2 0 0 1 )).
Interestingly PAR] and PAR2 can both be activated by a peptide based on the 
sequence of the PAR] tethered ligand SFLLR-NH2, although the synthetic peptide 
corresponding to the PAR2 tethered ligand SLIGRL-NH2 only activates PAR2 and not 
PAR]. This suggests that intermolecular activation between PAR] and PAR2 might 
occur physiologically following proteolytic unmasking of the PAR] tethered ligand. In 
support of this, O’Brien et al (O'Brien et al. 2000) showed that transfection of COS7 
cells with both wild-type PAR2 and a PAR] mutant, which could be cleaved but could 
not signal, was associated with a response to thrombin not seen when PAR2 alone was 
transfected. It also had important implications for experimental design, since 
responses to the SFLLR-NH2 peptide cannot be reliably attributed to PAR] activation. 
Subsequent structure activity studies identified that the TFLLR-NH2 peptide was 
selectively able to activate PAR] but not PAR2. This is the peptide utilised for in vitro 
experiments in this thesis, and the partial reverse peptide FTLLR-NH2 is used as a 
control peptide to confirm the specificity of its responses.
PARg is unusual in that it is not capable itself of generating an intracellular 
signal, but rather serves to function as a cofactor for PAR4 cleavage. Experiments 
involving expression of mouse PARg (mPARg) and/or mPAR4 in COS7 cells 
demonstrated that co-expression of mPARg and mPAR4 rendered cells responsive to 
thrombin at a far lower EC50 than if mPAR4 was expressed alone, whilst expression of 
mPARg alone did not render cells responsive to thrombin at all. Furthermore the rate 
of thrombin-induced mPAR4 cleavage was far greater when mPARg and mPAR4 were 
co-expressed than when mPAR4 alone was expressed (Nakanishi-Matsui et al. 2000). 
Nakanishi-Matsui et al (Nakanishi-Matsui et al. 2000) propose that thrombin first 
binds and cleaves PARg, but then remains tethered via PARg’s hirudin-like sequence, 
and then cleaves and activates PAR4 . Notably this cofactor action of PARg entirely 
distinct from the transactivation of PAR2 by PAR] described above. However it is 
possible that PARg is additionally capable of receptor transactivation since peptides
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corresponding to PARs-derived tethered ligand sequences have been shown to be 
capable of activating PARsi and 2 in Jurkat T cells (Hansen et al. 2004).
Interestingly the requirement for PARs in the activation of platelets is distinct 
in mice and humans. In humans, platelet activation at low concentrations of thrombin 
is mediated by PARi and at high concentrations also by PAR4 . PARg is unlikely to 
contribute since RT-PCR analysis has demonstrated its absence at the mRNA level 
(Kahn et al. 1999). In mice, plaletet activation is not dependent on PARi since 
platelets from PARi  ^ mice exhibit the same responsiveness to thrombin as those from 
wild-type mice (Connolly et al. 1996). Mouse platelets express PARg and PAR4 , and 
at low concentrations of thrombin, PARg supports cleavage of PAR4 as mentioned 
previously (Kahn et al. 1998b).
1.3.2. Regulation of PAR signalling (reviewed in (Dery et al. 1998) & (Hollenberg 
& Compton 2002))
A number of mechanisms may contribute to the cessation of signalling by 
PARs. Proteinases are likely to diffuse away from the vicinity of their receptors, and 
may be subject to degradation by proteinase inhibitors. However the potential 
presence of an activating tethered ligand permanently attached to the receptor 
necessitates physiological mechanisms for PARs to be rendered inactive.
1.3.2.1 Receptor deactivation
PARs may be subject to proteolytic inactivation. For instance, the proteinases 
neutrophil elastase, cathepsin G and proteinase 3 can each inactivate PARi by 
cleaving the receptor at a specific site C-terminal to its tethered ligand, thus 
amputating the ligand from the receptor body. These deactivated receptors are 
subsequently refractory to activation by proteinases but still responsive to 
experimental activation by synthetic peptides. (Renesto et al. 1997). Proteinase 
targeting of the tethered ligand once it is bound to the receptor’s second extracellular 
loop has also been demonstrated in vitro with thermolysin, and may represent a 
further mechanism of deactivation in vivo (Chen et al. 1996).
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1.3.2.2. Receptor desensitization
Receptor desensitization involves the uncoupling of PARs from G proteins 
and their signalling pathways. Homologous receptor desensitization involves agonist- 
dependent phosphorylation of specific C-terminal residues of the receptor by G 
protein receptor kinases, which utilise proteins known as p-arrestins as cofactors. This 
receptor phosphorylation effectively disrupts receptor interaction with G proteins and 
halts signal transduction. Heterologous receptor desensitization can occur as a result 
of C-terminal phosphorylation by other intracellular protein kinases such as protein 
kinases C and A, and may provide a means whereby PAR responses are influenced by 
other signalling pathways.
1.3.2.3. PAR endocytosis and cycling
A further means of regulating responsiveness of PARs is their endocytosis 
following activation. This process is also dependent on specific residues at the 
receptor’s C-terminal end. Following activation, cleaved receptors are rapidly 
internalized in clathrin coated pits (Hoxie et al. 1993). Some are then degraded in 
lysozomes, whilst some traffic back to the cell surface but remain unresponsive to 
further proteolytic activation (Brass et al. 1994). Receptor endocytosis also occurs 
independently of receptor activation, and PARi has been shown to cycle constitutively 
between the plasma membrane and intracellular stores (Shapiro et al. 1996).
1.3.2 4. Restoration of cellular responses
The ability of a cell to regain responsiveness to PAR activation depends on 
both the mobilization of intracellular receptor stores and the synthesis of new 
receptors. Abundant intracellular stores of PARs have been reported in endothelial 
cells (Horvat & Palade 1995), fibroblasts (Hein et al. 1994), and epithelial cells (Kong 
et al. 1997); although in all cell types recovery of responses after prolonged exposure 
to activating proteinases depends on protein synthesis of new receptors. Platelets lack 
the ability to synthesize new receptors and have limited intracellular receptor pools. 
Thus they are unable to regain responsiveness following their activation by thrombin.
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1.3.25. PAR downregulation
Unlike receptor desensitization, which involves uncoupling of the receptor 
from its G proteins, receptor downregulation involves an active reduction in the total 
amount of receptor expressed by the cell. Downregulation may de due to decreased 
receptor synthesis or to increased receptor degradation. In mesangial cells exposed to 
thrombin for prolonged periods, downregulation is associated with reduced PARi 
cellular protein but unchanged PARi mRNA, consistent with a mechanism involving 
increased receptor degradation (Zacharias et al. 1995). As such downregulation 
occurs in response to the receptors agonist proteinase it is termed homologous 
downregulation. In contrast, in these same cells, a heterologous downregulation of 
PAR I can occur as a result of inhibition of PARi gene expression by PGEi activation 
of adenylylcylase.
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1.4. Proteinase-Activated Receptor-1 (PAR,)
PARi is the major cellular receptor for thrombin, although it can also be 
activated by factor Xa, ternary complexes of Tissue Factor with Vila and Xa (Riewald 
et al. 2001), activated protein C (Riewald et al. 2002), and plasmin (Mandai et al. 
2005). As mentioned previously the efficiency of thrombin’s activation of PARi is 
facilitated by a hirudin-like binding domain C-terminal to the tethered ligand at 
PARi’s N-terminus. The attraction between this domain and thrombin’s anion binding 
exosite enables thrombin to effectively complex with PARi, whereupon it recognizes 
and cleaves the receptor immediately distal to its tethered ligand. Efficient activation 
of PARi by factor Xa is facilitated by localization of factor Xa to the cell surface. 
Two mechanisms make this possible. Firstly, it can remain associated with tissue- 
factor and factor Vila at the site of its generation. Secondly it can bind to effector-cell 
protease receptor-1 (EPR-1). Factor Xa is more effective at activating PARi as part of 
either of these conformations than as factor Xa alone (Riewald et al. 2001),(Blanc- 
Brude et al. 2001). Similarly, APC utilizes cell surface EPCR as a cofactor to 
facilitate its activation of PARi (Riewald et al. 2002).
The PARi gene has a similar structure to the other PARs and comprises a 
single large intron interrupting two exons at the region encoding the receptor’s N 
terminus. In humans PARi is located in a cluster with PAR2 and PAR3 at chromosome 
5ql3, and PAR4 is located separately at 19pl2. In mice, PARs 13 are clustered at 13d2 
and PAR4 is at 8b3 (Kahn et al. 1998a),(Xu et al. 1998). A number of PARi 
polymorphisms have been found to influence platelet receptor density (Dupont et al. 
2003) and thrombosis-related events (Smith et al. 2005),(Amaud et al. 2000), but to 
date none have been found to have any association with inflammatory or fibrotic 
diseases. The generation of a PARi  ^ mouse by Connolly et al in 1996 (Connolly et al.
1996) has been of enormous value in furthering our understanding of PARi biology. 
This mouse was generated by inserting a neocassette to displace exon 2 of the PARi 
gene. This strategy was effective since this large exon encodes the majority of the 
receptor from its intracellular C terminus to part of its N-terminus. The phenotype of 
the PARi  ^ mouse is grossly normal, although there is a 50% intraembryonic lethality 
due to a defect in vascular development (Griffin et al. 2001), implicating a role for 
PARi in endothelial function in developing blood vessels. In previous studies, PARi ^
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mice have exhibited protection from experimentally induced glomerulonephritis 
(Cunningham et al. 2000), arthritis (Yang et al. 2005), and cerebral infarction (Junge 
et al. 2003). This clearly supports the role of PARi in mediating responses to tissue 
injury. In work outlined in this thesis, PARi  ^ mice were utilized to evaluate the 
potential role of PARi in mediating responses to injury within the lung.
Following activation, PARi exerts a multitude of diverse cellular responses. 
The diversity of these responses results from PARi coupling to different G protein 
subunits and their downstream signalling pathways. Major pathways are illustrated in 
figure 1.4. In the same cell type responses to different agonists may vary. For 
example thrombin and the PARi agonist peptide TFLLR-NH2 both activate PARi on 
endothelial cells to influence barrier permeability and calcium mobilization. However 
activation by thrombin is associated with more efficient receptor coupling to O ai2/i3 
and a greater effect on barrier permeability, whereas activation by TFLLR-NH2 is 
associated with more efficient receptor coupling to GOq and a greater effect on 
calcium mobilization. (McLaughlin et al. 2005b). This phenomenon is called 
functional selectivity, and may be a potential explanation for the distinct gene 
expression profiles observed in cytokine-stimulated endothelial cells in response to 
activation of PARi by APC and thrombin (Riewald & Ruf 2005).
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Figure 1.4. Major PAR, G-protein coupled signalling pathways (Adapted from Gouglin SR , 2000, & 
Steinhoff M, 2005)
a-subunits of G,g and G ,g couple to Rho guanine-nucleotide exch a n g e  factors (G EFs) resulting in activation 
of serum  resp on se  e lem en ts (SRE), Rho, Rho k inase (ROK), and m yosin light chain (MLG) kinase. Ga^ 
activates phospholipase G-p (PLGP) to gen erate  inositol triphosphate (IP3 ) and diacylglycerol (DAG),which 
m obilize intracellular Ga^+ and activate protein k in ase G (PKG). Dow nstream  effects of Ga^+ mobilization and 
PKG activation include activation of Ga^+-regulated protein k in ases and m itogen-activated protein (MAP) 
k in ases. Ga^ a lso  activates protein k inase A (PKA) which exerts effects  on inflammation via activation of NF- 
kB. Gtt| inhibits adenylyl c y c la se . GPy subunits couple PAR, to other pathw ays including activation of 
phosphoinositde 3-k inase (PI3 K), PLGP, G -protein-coupled receptor k in ases (GRK), K+ ch an n els, and non­
receptor tyrosine k in ases.
PARi couples to Oq, a^/n , Oi, and py G-protein subunits to initiate specific 
cell signalling pathways (reviewed in (Ossovskaya & Bunnett 2004), (Dery et al. 
1998), (Coughlin 2000), (Steinhoff et al. 2005)). These cell signalling pathways 
involve multiple interactions at a number of levels, and even to this day are
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incompletely characterized. Signalling pathways downstream of PARi also interact 
with pathways downstream of other non-PAR receptors. For example, activation of 
PARi in enterocytes induces phosphorylation of the Epidermal Growth Factor (EOF) 
Receptor and subsequent downstream signalling.
O ai2/i3 is important for regulation of cytoskeletal structure and cell shape. It 
interacts with Rho guanine-nucleotide exchange factors (GEFs) which activate small 
G proteins such as Rho. This in turn activates Rho-kinase and myosin light-chain 
kinase, and these then mediate effects such as shape change in platelets and barrier 
permeability in endothelial cells. G ai2/i3 may also exert mitogenic effects via the 
activation of serum response elements in a number of gene promoters.
GOq activates phospholipase C-pi, leading to generation of inosityl 
triphosphate (IP3) and diacylglycerol (DAG). These mobilize intracellular calcium 
(Ca^^) and activate protein kinase C (PKG), which in turn activate pathways involving 
Ca^^-regulated protein kinases and mitogen-activated protein kinases. Downstream 
cellular effects of GOq include transcription, modulation of transcription factor 
expression and DNA synthesis. GOq also activates protein kinase A (PKA) which can 
exert pro-inflammatory effects via the transcription factor NF-kB.
GOi inhibits adenylylcylase and its generation of cyclic adenosine 
monophosphate (cAMP). It may promote platelet responses and exert effects on 
cellular arachidonic acid release via phospholipase A2. py subunits couple PARi to a 
number of other pathways. Activation of phosphoinositide 3-kinase (PI3K) may 
mediate effects on cytoskeletal structure, cell motility, survival and mitogenesis. py 
subunits can also activate phospholipase C, ion channels, and protein kinases.
1.4.1. Cellular effects of PARi activation
PAR I is widely distributed on a number of cell types including platelets, 
endothelial cells, fibroblasts, epithelial cells, monocytes, and neuronal cells. A 
pathological role of PARi is suggested by increased local expression in disease 
entities involving injury of the synovium (Morris et al. 1996), kidney (Grandaliano et 
al. 2001), liver (Marra et al. 1998), and lung (Bogatkevich et al. 2005). This increased 
expression may result from exposure to pro-inflammatory and pro-fibrotic mediators
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such and IL-lb, TNF-a and TGF-pi (Mbebi et al. 2001). A number of the cellular 
effects of PARi activation outlined below may be pathological in the disease setting.
1.4.11. Platelet aggregation
In humans, thrombin induces platelet activation via PARi and PAR4 , although 
this occurs primarily via PARi at low thrombin concentrations. Thrombin also 
influences platelet aggregation independently of PARs via binding to platelet 
membrane glycoprotein G Plpa. Thrombin-activated platelets change shape and 
release serotonin, adenosine triphosphate, and thromboxane A2. P-selectin and CD40 
ligand are also translocated to the platelet membrane which promotes their binding to 
endothelial cells (Stenberg et al. 1985), (Henn et al. 1998). Conversely as mentioned 
previously, platelet activation in mice is PARi independent, and is instead mediated 
by PAR3 and PAR4 .
14.1.2. Endothelial function
PARi activation on endothelial cells by thrombin promotes expression of 
tissue factor (Bartha et al. 1993), and adhesion molecules such as E and P-selectin, 
and ICAM-1 (Sugama et al. 1992),(Shankar et al. 1994). This promotes initiation of 
coagulation and platelet adhesion, but also mediates trafficking of inflanunatory cells 
to sites of injury. Thrombin also increases endothelial vascular permeability via 
change in cell shape by effects on the cytoskeleton (Siflinger-Bimboim & Johnson 
2003), (McLaughlin et al. 2005b) and via the release of histamine from mast cells 
(Cirino et al. 1996). Interestingly, activation of PARi on the endothelium by APC is 
associated with cellular effects that are distinct to those that occur in response to 
thrombin. APC reduces rather than enhances endothelial barrier permeability 
(Feistritzer & Riewald 2005). Furthermore in vitro gene expression profiling studies 
using cytokine-perturbed human endothelial cells, thus representing the endothelium 
in sepsis, have revealed a number of genes that are differentially regulated in response 
to thrombin and APC. In these studies thrombin induced a number of genes associated 
with inflanunation, such as IL- 6  and IL-8 , whereas APC induced far fewer genes but
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suppressed expression of inflammatory genes such as NF-kB family members, and 
proapoptotic genes such as p53 (Riewald & Ruf 2005).
1.41.3. Vascular tone
In the vasculature, activation of PARi on endothelial cells and underlying 
smooth muscle cells can affect vascular tone. Thrombin induces relaxation of smooth 
muscle via the release of nitric oxide from endothelial cells (Derkach et al. 2000). 
Conversely it induces strong contractile responses in smooth muscle in blood vessels 
from which the endothelial layer has been removed (Ku & Zaleski 1993). It is 
probable that the relative expression of PAR; on endothelial and smooth muscle 
layers may govern the resulting vascular tone and blood flow in any organ. Notably 
however, the observation that PAR;-deficient mice have normal cardiac function and 
blood flow suggests that PAR; is only one of many influences in this regard (Darrow 
et al. 1996).
1.4.14. Cell growth, proliferation and survival
Thrombin promotes proliferation of mesenchymal cell types including 
fibroblasts, vascular smooth muscle cells, and endothelial cells. These mitogenic 
effects are also apparent in response to PAR; activating peptides (Strukova et al. 
2001),(McNamara et al. 1993),(Herbert et al. 1994), and additionally in response to 
factor Xa in fibroblasts, and may be dependent on secondary mediators such as 
platelet derived growth factor (PDGF) (Blanc-Brude et al. 2001). PAR; activation also 
influences turnover of extracellular matrix components, and thrombin stimulates 
procollagen synthesis in fibroblasts and smooth muscle cells (Chambers et al. 1998), 
(Dabbagh et al. 1998). Interestingly, PAR; activation can apparently promote both 
cell survival and cell death. It promotes survival of neurones exposed to p-amyloid 
(Pike et al. 1996), but promotes apoptosis and increased epithelial permeability of 
intestinal epithelial cells (Chin et al. 2003).
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1.4.15. Pro-inflammatory and pro-flbrotic effects
As described above, PARi activation can promote inflammation by 
influencing inflammatory cell trafficking via upregulation of endothelial adhesion 
molecule expression. Its ability to promote mitogenesis and extracellular matrix 
protein synthesis in fibroblasts are central to its pro-fibrotic role. PARi activation has 
also been reported to be capable of inducing apoptosis of lung epithelial cells (Suzuki 
et al. 2005). Epithelial cell apoptosis is implicated as promoting fibrosis and its 
inhibition attenuates the fibrotic response to bleomycin in rats (Wang et al. 2000b). 
The basis of this effect may be a loss of the inhibitory influence exerted by epithelial 
cells on lung fibroblast proliferation.
Importantly, PARi activation may promote both inflammation and fibrosis by 
the generation of secondary mediators from a variety of cell types, and there is a 
wealth of published reports documenting this. Table 1.5 lists examples of pro- 
inflammatory and pro-fibrotic secondary mediators released in response to PARi 
activation and their documented cellular source. Pro-inflammatory mediators include 
the chemokines RANTES and IL-8 ; the cytokines TNF-a, IL-1 and IL-8 ; and COX-2: 
the enzyme that is necessary for synthesis of pro-inflammatory prostanoids. Pro- 
fibrotic mediators include the growth factors PDGF, TGF-|3i, CTGF, and bFGF which 
promote fibroblast proliferation, migration, and/or extracellular matrix protein 
synthesis; and thrombospondin-1 , which may exert a profibrotic influence via its 
ability to activate TGF-pi. CCL2 and FT-1 exert both pro-inflammatory and pro- 
fibrotic effects. CCL2 induces mononuclear cell and eosinophil chemotaxis, but also 
promotes fibroblast function. FT-1 enhances release of proteinases and cytokines 
from inflammatory cells, but also promotes fibroblast chemotaxis and proliferation.
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Pro-inflammatory
mediators
Cellular source
RANTES Synovial fibroblasts (Hirano et al. 2002)
CCL2 Monocytes (Colotta et al. 1994)
Endothelial cells (Colotta et al. 1994),(Marin et al. 2001) 
Ovarian luteinized granulosa cells (Hirota et al. 2003) 
Endometrial stromal cells (Hirota et al. 2005)
Dermal fibroblasts (Bachli et al. 2003)
Hepatic stellate cells (Fiorucci et al. 2004)
TNF-a Glial cells (Lee et al. 2005a)
IL-1 Monocytes (Naldini et al. 2000)
IL-6 Monocytes (Naldini et al. 2000)
Retinal epithelial cells (Scholz et al. 2004)
Lung epithelial cells (Asokananthan et al. 2002)
IL-8 Endothelial cells (Marin et al. 2001)
Retinal epithelial cells (Scholz et al. 2004)
Lung epithelial cells (Asokananthan et al. 2002) 
Ovarian luteinized granulosa cells (Hirota et al. 2003) 
Endometrial stromal cells (Hirota et al. 2005)
Dermal fibroblasts (Bachli et al. 2003)
00X2 Endothelial cells (Houliston et al. 2002) 
Endometrial stromal cells (Hirota et al. 2005) 
Colonic fibroblasts (Seymour et al. 2003)
Pro-fibrotic
mediators
Cellular source
PDGF Alveolar macrophages (Tani et al. 1997)
Endothelial cells (Shankar et al. 1994)
Lung fibroblasts (Blanc-Brude et al. 2001)
Vascular smooth muscle cells (Stouffer & Runge 1998) 
Lung epithelial cells (Shimizu et al. 2000)
CTGF Lung fibroblasts (Chambers et al. 2000)
TGF-Pi Vascular smooth muscle cells (Stouffer & Runge 1998)
bFGF Vascular smooth muscle cells (Stouffer & Runge 1998)
FT-1 Endothelial cells (Eto et al. 2001)
TSP-1 Endothelial cells (McLaughlin et al. 2005a)
Table 1.5. Pro-inflammatory and pro-fibrotic mediators induced in response to 
PARi activation
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During the course of this thesis, lung levels of the PAR-i inducible mediators 
CCL2, CTGF, and TGF-pi were examined following experimental lung injury in 
PAR 1-deficient mice. Thus they will be now each be described in more depth.
14.1.6. CCL2 (Monocyte Chemoattractant Protein-1)
CCL2, also previously known as monocyte chemoattractant protein-1, is a 
member of the CC chemokine family. Chemokines are small secreted proteins of 
around 60-90 amino acids in length. They all share a similar structure, and are 
classified into families depending on the patterns of their N-terminal cysteine residues. 
CC chemokines have 2 adjacent cysteine residues near their N-terminus, and CXC 
chemokines have a single amino acid between 2 cysteine residues. CX3C chemokines 
have 3 amino acids between 2 cysteine residues, and C chemokines have a single 
cysteine residue at their N-terminus. The major chemokine families are CC and CXC 
chemokines, and members of these families tend to be chemotactic for mononuclear 
cells and neutrophils, respectively. In humans CCL2 is localised within a cluster of 
CC chemokines on chromosome 17, and the murine ortholog of CCL2, which is also 
known as JE, is localised within a cluster on chromosome 11. Notably a second 
murine homolog of CCL2, known as MCP-5/CCL12, has been described. This is also 
situated within the cluster on chromosome 1 1 , and actually is more similar than 
mouse CCL2 in terms of structure to human CCL2 (Sarafi et al. 1997).
CCL2 is widely expressed on a host of cell types, and expression has been 
shown to increase in response to mediators associated with injury and inflammation, 
including IL-1, TNF-a (Sica et al. 1990), IL- 6  (Biswas et al. 1998), LPS (Colotta et al. 
1992), thrombin (Colotta et al. 1994),(Bachli et al. 2003), factor Xa (Bachli et al. 
2003), and also viral infection (Bussfeld et al. 2000). Expression appears to be 
dependent on the transcription factors AP I and NF-kB, and binding sites exist for 
these exist within the CCL2 promoter.
Chemokines promote cellular effects by binding and activating their seven 
transmembrane G-protein coupled receptors. Signalling pathways are initiated by G- 
protein a  and py subunits, and involve activation of adenylylcyclase, phospholipase C, 
tyrosine kinases, and ion channels (reviewed in (Keane & Strieter 2000)). The cellular 
receptor for CCL2 (and also CCL12) is CCR2. CCL2 is chemotactic for monocytes.
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but also NK cells (Allavena et al. 1994), T lymphocytes (Carr et al. 1994), basophils 
(Bischoff et al. 1993), and eosinophils (Dunzendorfer et al. 2001). The mechanism of 
chemotaxis involves immobilization of CCL2 on gylcosaminoglycans on the surfaces 
of endothelial and other cells (reviewed in (Moser & Loetscher 2001)). Presentation 
of CCL2 to CCR2-expressing cells results in integrin activation and arrest, and 
subsequent transendothelial migration. Cellular migration is mediated by cytoskeletal 
reorganization, the development of cell polarization, and movement along a gradient 
of increasing CCL2 concentration on surfaces of extravascular cells and extracellular 
matrix.
In addition to mediating chemotaxis of inflammatory cells, CCL2 influences 
the balance of Thl to Th2-type cytokines in favour of a Th2 profile. CCL2 enhances 
production of the Th2 cytokine IL-4 by antigen-stimulated OVA-specific TCR 
transgenic T cells (Karpus et al. 1997). In addition, CCL2-deficient mice produce low 
levels of the Th2 cytokines IL-4, IL-5 and IL-10 constitutively, and are unable to 
mount the Th2 inunune response following OVA sensitization and challenge that is 
characteristically observed in wild-type mice (Gu et al. 2000). Interestingly, CCL2 
may be protective in a mouse model of endotoxaemia. In this model, mortality is 
reduced by administration of recombinant CCL2, but increased by administration of 
anti-CCL2 antibodies. The basis of this effect has been suggested to relate to the 
CCL2-induced increase in Th2 cytokines such as IL-10 and decrease in Thl cytokines 
such as IL-12 and TNF-a (Zisman et al. 1997). However, despite the observed 
protection in this model, there is still compelling evidence for a pathological role for 
CCL2 as a pro-inflammatory mediator. CCL2 tissue levels correlate with interstitial 
cellular infiltration following injury to the lung (Smith 1996), kidney (Prodjosudjadi 
et al. 1996), large bowel (Banks et al. 2003), brain (Mahad & Ransohoff 2003), and 
liver (Copple et al. 2003).
In addition to its ability to promote inflanunation, CCL2 also promotes 
fibrosis. Both anti-CCL2 gene therapy and CCR2 deficiency attenuate 
experimentally-induced lung fibrosis in mice (Inoshima et al. 2004),(Moore et al. 
2001),(Gharaee-Kermani et al. 2003). The basis of the proBbrotic nature of CCL2 
may be its ability to induce TGF-Pi and procollagen gene expression in fibroblasts 
(Gharaee-Kermani et al. 1996), to downregulate epithelial cell production of the anti- 
fibrotic prostanoid PGE2 (Moore et al. 2003), or to recruit collagen-synthesising
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fibrocytes (Moore et al. 2005). Observations of a direct correlation of BALF CCL2 
levels with severity of lung injury in ARDS (Goodman et al. 1996), and of serum 
CCL2 levels serving as a useful biomarker of disease progression in IFF (Suga et al. 
1999) support the idea that CCL2 may be involved in the development of human 
fibroproliferative lung diseases.
1.4.1.7. Connective tissue growth factor (CTGF)
CTGF is a 38kDa polypeptide growth factor, which is encoded by a gene on 
chromosome 6  in humans, and chromosome 10 in mice. The protein consists of four 
conserved domains: an insulin-like growth factor (IGF)-binding protein domain, a von 
Willebrand factor type C domain, a thrombospondin type 1 repeat domain, and a 
heparin-binding domain at the C-terminus (figure 1.5).
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Figure 1.5. Gene organisation of CTGF. T h e CTGF g e n e  c o n s is ts  of 5  e x o n s . Exon 1 e n c o d e s  a  sp ecific  
am ino acid s e q u e n c e  w hich a llow s CTGF to b e  exported  from th e  en d op lasm ic  reticulum to th e Golgi 
apparatus. E xon s 2 to 5  e n c o d e  4  co n serv ed  m odular d om an s, w hich h a v e  putative functions in IGF binding, 
oligom erisation, cell attachm ent, and dim érisation respectively .
CTGF was originally discovered as a secreted product of cultured human 
endothelial cells (Bradham et al. 1991), although it has since been shown to be 
expressed by other cell types such as fibroblasts and myocytes; and may, in the 
context of tissue injury, be additionally expressed in inflammatory cells (Allen et al.
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1999), and epithelial cells (Pan et al. 2001). CTGF is an immediate early gene induced 
in response to TGFp (Igarashi et al. 1993), but is also induced in response to glucose 
and insulin (Paradis et al. 2001), mechanical stretch (Schild & Trueb 2002), hypoxia 
(Kondo et al. 2002), serum (Wenger et al. 1999), angiotensin II (Finckenberg et al.
2003), and thrombin acting via activation of PARi (Chambers et al. 2000). Conversely, 
CTGF expression in fibroblasts in response to TGFp can be inhibited by TNF-a 
(Abraham et al. 2000) and PGE2 (Ricupero et al. 1999). Expression is likely to require 
NF-KB transcriptional activity since there are NF-KB binding sites within the CTGF 
promoter. CTGF plays an important physiological role in processes such as 
embryogenesis, angiogenesis, tissue differentiation, and wound healing, but is 
presumed to be pathological in organ fibrosis (reviewed in (Leask & Abraham 2003)). 
Although the evidence supporting the role for CTGF in organ fibrosis is currently not 
as strong as for other growth factors such as TGF-pi, CTGF is highly expressed in the 
bleomycin model of lung injury (Lasky et al. 1998), as well as in patients with fibrotic 
lung disease (Allen et al. 1999),(Pan et al. 2001), and fibrosis of other major organs 
and tissues (reviewed in (Moussad & Brigstock 2000)). CTGF exerts pro-fibrotic 
effects in vitro by directly stimulating fibroblast function; and overexpression of 
CTGF by adenoviral gene transfer has been shown to induce transient pulmonary 
fibrosis in mice (Bonniaud et al. 2003). There is also evidence to suggest that CTGF 
may act synergistically with TGF-p to promote long-term tissue fibrosis (Mori et al. 
1999). The molecular basis for the actions of CTGF are incompletely understood, but 
may result from interactions with other proteins and glycosaminoglycans. CTGF has 
been shown to interact with a number of cell surface molecules capable of signal 
transduction, such as IGF-I and IGF-II (Kim et al. 1997), the integrin avp3 (Babic et 
al. 1999), and lipoprotein receptor-associated protein (LRP) (Gao & Brigstock 2003). 
CTGF can also be internalised from the cell surface in endosomes, and directed to a 
juxtanuclear organelle, prior to being translocated to the cytosol. Here its 
phosphorylation by protein kinase C may allow it to play a specific role in the cytosol. 
In addition, such phosphorylation may allow translocation of CTGF to the nucleus to 
directly influence gene transcription (Wahab et al. 2001). More recently CTGF has 
also been shown to be capable of rapidly activating a number of intracellular 
signalling molecules in human mesangial cells (Wahab et al. 2005).
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14.1.8. Transforming growth factor-beta-1 (TGF-Pi)
Transforming growth factor beta exists as three isoforms in humans (TGF-pi,- 
p2, and -ps). It is able to exert powerful influences over a number of biological 
processes, such as proliferation, differentiation, migration, and apoptosis. Each 
isoform is the product of a separate gene, and TGF-p i is located on chromosome 19 in 
humans and on chromosome 7 in mice. All isoforms are initially synthesized as large 
precursor proproteins, which are later processed intracellularly to yield the mature 
proteins. This processing gives rise to two products, which subsequently assemble 
into two distinct dimers. The 65-75kDa dimer from the N-terminal region is known as 
the latency-associated peptide (LAP), whilst the 25kDa dimer from the C-terminal 
region is called mature TGF-p. The LAP enables transit of TGF-p away from the cell 
and renders it biologically inactive; and the complex of LAP with mature TGF-p is 
known as latent-TGF-p (L-TGF-p). L-TGF-p localizes to the extracellular matrix via 
binding to latency binding protein (LTBP). Of the three TGF-p isoforms, TGF-p i has 
been most widely studied in the context of experimental fibrosis and fibrotic disease. 
It is widely accepted as one of the key pro-fibrotic mediators in the bleomycin model 
(Khalil et al. 1989), as well as in patients with fibrotic lung disease (Khalil et al. 
1991),(Khalil et al. 1996). TGF-P i is one of the most potent inducers of fibroblast 
procollagen production examined to date and promotes the differentiation of 
fibroblasts into highly activated myofibroblasts (Zhang et al. 1996), the predominant 
fibroblast phenotype present in active fibrotic lesions. TGF-p i is also able to induce 
expression of other pro-fibrotic factors in fibroblasts, most notably CTGF (Igarashi et 
al. 1993).
Activity of TGF-p may be controlled on a number of levels, namely 
transcription, stability of mRNA, translation, storage of latent TGFp, and activation of 
latent TGFp. Agents reported to increase transcription of TGF-Pi include IL-lb (Yue 
et al. 1994), CCL2 (Gharaee-Kermani et al. 1996), TGF-pi itself, PDGF (Villiger & 
Lotz 1992), bFGF (Qian et al. 1996), angiotensin 11 (Campbell & Katwa 1997), and 
lL-13 in combination with TNF-a (Fichtner-Feigl et al. 2006). Activation involves 
removal of LAP from L-TGFp, and can occur physiologically following interaction 
with plasmin, thrombospondin-1 , reactive oxygen species, and the avP6  and avpS 
integrins expressed on epithelial cells (reviewed in (Khalil 1999), & (Sheppard 2004)).
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Activation can also be induced experimentally in vitro by extremes of temperature or 
pH, chaotropic agents, or substances such as SDS and urea.
TGF-p signalling (reviewed in (Bartram & Speer 2004)) is complex, and 
involves a series of signalling intermediates known as Smad proteins (Figure 1.6). 
Following association of active mature TGF-p with cell surface TGF-p type II 
receptors (TpRII), adjacent TGF-p type I receptors (TpRI) are recruited into a 
heterotrimeric complex. This in turn leads to phosphorylation of TpRI, and 
subsequent recruitment and phosphorylation of Smad2 and/or Smad3. This 
phosphorylation enables these Smads to dissociate from the receptor, and form a 
complex with Smad4, which then translocates to the nucleus to influence gene 
transcription. This process can be inhibited by Smad6 and/or Smad7. This classical 
TGF-p 1 Smad signalling pathway also interacts with non-Smad signalling pathways at 
a number of levels. Such pathways may be initiated by TGF-p i itself, or indeed by a 
different ligand-receptor complex. The Smad signalling pathway may be modulated 
by phosphorylation of Smads by MAP Kinases, and equally Smads may 
phosphorylate non-Smad proteins of separate pathways thus modulating their activity.
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L atent
F igu re  1.6. T h e  p a th w a y  o f  TG F-p a c tiv a tio n  a n d  s ig n a lin g . From TGF-p m e s se n g e r  RNA (m RNA), 
e a ch  TGF-p isoform is initially sy n th esized  a s  a  larger precursor m olecu le . This is proteolytically c leaved  
( 1) and secreted  a s  an inactive protein (2) contain ing a  la ten cy -associa ted  peptide (LAP). This is 
seq u e stere d  in the extracellular matrix by binding to latency binding protein (LTBP) (not shown). Following 
activation with re lea se  of the LAP (3), TGF-p binds to the type II receptor (4). This lead s  to recruitment of 
the type I receptor (5). T he co n secu tively  active type II receptor k in ase  phosphorylates the type I receptor, 
which p ropagates the signal dow nstream  through phosphorylation of particular S m a d s, ie, S m ad 2  and  
S m ad 3  (6). S m ad 2 and S m ad 3  then form a  com p lex  with S m ad 4  (7). T he com p lex  tran sloca tes  to  the  
n u cleu s, w here it activates target g e n e s  (8). P = p h osp h ate  m olecu le .
(Figure taken from Bartram U, 200 4 )
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1.5. Lung epithelial cells
Injury and activation of lung epithelial cells plays an important role in the 
development of fibroproliferative- and other lung disorders. In the following section, 
epithelial cells will be considered further in terms of their functions and roles in both 
normal physiology and in disease.
1.5.1. Function of epithelial cells in normal lung physiology
Epithelial cells constitute a continuous lining of the entire respiratory tract, 
including the nasal passages, large airways, and extending down to the alveoli situated 
deep within the lung parenchyma. Besides acting as a physical barrier, epithelial cells 
perform a number of critical roles that are essential for maintaining normal lung 
function. In the airways, epithelial cells promote removal of particulate matter from 
the lungs by secretion of mucus and co-ordinated beating of cilia to propel it, and any 
entrapped particles, upwards to the central airways from where it is coughed out, and 
then either expectorated or swallowed. Airway epithelial cells also produce a number 
of mediators which regulate tone of underlying smooth muscle tone. In the distal 
respiratory tract, alveolar epithelial cells are closely opposed to capillary endothelial 
cells, and are fundamental in enabling gaseous exchange between the alveolar cavity 
and the blood. Alveolar epithelial cells also secrete surfactant, which prevents 
airspace collapse by lowering surface tension on the alveolar surface. In addition, 
certain lung epithelial cells throughout the respiratory tract promote innate immune 
responses by release of pro-inflammatory mediators in response to specific stimuli, 
and thus recruit inflammatory cells to sites of epithelial injury. Bioactive mediators 
produced constitutively, and in response to injury by epithelial cells have profound 
effects on the function of resident inflammatory cells, neighbouring epithelial cells 
and underlying mesenchymal cells.
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1.5.11. Airway epithelial cells
Airway epithelial cells are pseudostratified in the proximal bronchi but form a less 
complex monolayer in more distal parts of the bronchial tree. The majority of 
epithelial cells lining the airway are ciliated columnar cells, but additionally present 
are basal cells, goblet cells, Clara cells, and neuroendocrine cells. Basal cells are small 
epithelial cells which contact the basement membrane but not the airway lumen. They 
are a stem cell population from which other airway epithelial cells develop. They are 
the second most common cell type in proximal airways, but their relative proportion is 
far less distally. Goblet cells and Clara cells are primarily secretory cells. Goblet cells 
predominate in larger airways, and secrete mucus, although mucus is also produced 
by abundant tracheobronchial glands extending into the submucosa and emptying into 
the airway lumen. Clara cells are the predominant cell type of the bronchiolar 
epithelium. They form a simple columnar and non-ciliated epithelium, but exhibit 
some functional similarity with more proximal airway epithelial cells, including 
expression of Clara Cell Specific Protein (CCSP)(Broers et al. 1992), (Cowan et al.
2000),(Yao et al. 1998) and Surfactant Protein A (Broers et al. 1992). Clara cells 
function as stem cells of the distal airways with the ability to differentiate into more 
Clara cells, ciliated cells, or Goblet cells. Neuroendocrine cells are very sparsely 
distributed along the basement membrane in distal airways and secrete hormones and 
active peptides. They are thought to play an important role in lung development.
In addition to native epithelial cells, a number of other cell types migrate to 
and subsequently reside within or adjacent to lung epithelial cell layers. Abundant 
sensory nerves from subepithelial plexuses innervate airway epithelial cells, 
particularly neuroendocrine cells. Immune cells, such as macrophages, lymphocytes, 
dendritic cells, and mast cells also reside within epithelial cell layers. By interaction 
with these, the lung epithelium is able to influence adaptive as well as innate immune 
responses.
15.1.2. Alveolar epithelial cells
Repeated branching of the bronchial tree terminates in respiratory bronchioles, which 
subsequently lead to alveolar ducts, and finally to alveolar sacs. Around 99% of the 
internal surface area of the lung is covered by alveolar epithelial cells (reviewed in 
(Crandall & Matthay 2001)). Two morphologically distinct types of alveolar epithelial
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cells exist: Type I cells comprise about 40% of the alveolar epithelial cell population 
but cover 90% of its surface area (Stevens & Lowe 1992). They are large flattened 
squamous cells joined to each other by tight junctions, and to neighbouring type II 
cells by gap junctions. They are highly adapted for their principal function of gas 
exchange; although they also have other functions including regulation of alveolar 
water and ion transport (Johnson et al. 2002), processing of peptides within the 
alveolar lumen (Nagae et al. 1993), and modulation of alveolar macrophage function 
via the expression of ICAM-1 (O'Brien et al. 1999). Because of their large surface 
area and complex cytoplasmic extensions, each cell may form part of the epithelial 
surface of more than one alveolus. Type II alveolar epithelial cells comprise 60% of 
the alveolar epithelial cell population but cover only 10% of the alveolar surface area. 
They are cuboidal cells typically situated in the comers of alveoli. They have 
microvilli on their luminal surface, and are highly metabolically active. Their 
cytoplasm contains abundant organelles, including mitochondria, endoplasmic 
reticulum, and lamellar bodies. The latter represent storage granules of synthesised 
surfactant. Type II cells have multiple functions. They have important progenitor 
function, and are effectively the stem cell of the alveolus. Type II cells are able to 
proliferate to produce additional type II cells, but can also differentiate into type I 
cells. They synthesise and release surfactant: a mixture of phospholipids and specific 
proteins, which forms a layer over the wall of the alveolar sac, and prevents alveolar 
collapse by reducing surface tension. Type II cells play an important role in 
controlling alveolar fluid balance via regulation of apical membrane sodium channels 
(Eaton et al. 2004). They can influence the immune response by releasing agents such 
as RANTES, CCL2 (O'Brien et al. 1998), and GM-CSF (Christensen et al. 1995) to 
attract and/ or stimulate alveolar macrophages and other inflammatory cells. Type II 
cell-derived surfactant protein-A (SP-A) may also modulate certain aspects of 
function of alveolar macrophages including their release of reactive oxygen species 
(Weissbach et al. 1994).
1.5.2. Epithelial injury within the lung
Epithelial injury is common to a number of important lung disease entities. 
The outcome is governed by the nature and site of this injury. For instance, in asthma, 
chronic inflammation initiated by allergen exposure, and associated with eosinophils
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and IgE-dependent mast cell-derived mediators, results in widespread epithelial injury 
to bronchi and bronchioles, but not alveoli. This promotes airway mucosal 
inflammation and oedema, increased mucus production, and bronchial smooth muscle 
contraction. In COPD an inflammatory response distinct from that in asthma, and 
involving a predominance of macrophages, cytotoxic T cells, and neutrophils affects 
predominantly small airways and lung parenchyma. This is associated with 
bronchiolar and alveolar epithelial injury, and results in small airway fibrosis and 
alveolar destruction and emphysema.
ARDS and IPF are associated with a predominantly initial alveolar epithelial 
injury. Since around 99% of the internal surface area of the lung is covered by 
alveolar epithelial cells, the alveolar epithelium is exposed to a multitude of 
potentially injurious insults, and is thus susceptible to injury. In ARDS, these injuries 
affect both endothelial and epithelial cells, leading to loss of endothelial/epithelial 
barrier integrity, alveolar flooding, and inflammation. In IPF multiple idiopathic 
injuries are thought to occur sequentially throughout large areas of the lungs. In both 
instances, a subsequent abnormal repair response involving abnormal epithelial- 
mesenchyme interactions may promote alveolar fibrosis.
1.5.3. The bleomycin model and epithelial injury
In the experimental work outlined in this thesis, pulmonary fibrosis was 
induced in C57/BL/6 mice by the administration of intra tracheal bleomycin. The 
multiple biological mechanisms involved in the development of human lung fibrosis 
are of a complexity that is impossible to recreate in an in vitro system. An animal 
model is able to provide a realistic representation of many of these mechanisms, and 
is fundamental to any study that aims to further understanding of disease processes. 
C57/BL/6 mice were used because they are known to be particularly sensitive to 
bleomycin-induced lung fibrosis (Kolb et al. 2002),(Brody et al. 2002). Susceptibility 
may relate to production of a greater proportion of the Th2 cytokines IL-4 and IL-13 
in response to injury, since following bleomycin these cytokines are upregulated in 
bleomycin-sensitive C57/BL6 mice but not bleomycin-resistant BALBc mice 
(Cavarra et al. 2004).
Following intra-tracheal administration of bleomycin, the early response is 
characterized by a dramatic increase in microvascular leak and inflammatory cell
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recruitment (Thrall & Scalise 1995). Inflammation in the bleomycin model is 
associated with a increasing levels of number of cytokines, including the Thi cytokine 
tumour necrosis factor-alpha (TNF-a) (Piguet et al. 1989),(Ortiz et al. 
1998),(Gurujeyalakshmi et al. 2000),(Cavarra et al. 2004), although in subsequent 
progression to fibrosis, Th: cytokines such as IL-4 and IL-13 (Cavarra et al. 2004) are 
likely to be important. The inflammatory response is succeeded by intra-alveolar 
fibrosis, focally dense fibrosis, and subpleural fibrosis which are most prominent at 14 
and 21 days after instillation (Izbicki et al. 2002). It should be noted that murine 
bleomycin-induced lung injury represents a model of lung injury and fibrosis; it does 
not represent a model of any specific human disease. However key features of the 
bleomycin model such as widespread epithelial injury and activation, fibroblast 
proliferation and collagen synthesis, and production of pro-fibrotic mediators by 
resident lung cells, are central to the bleomycin model and to the pathophysiology of 
fibroproliferative lung disorders such as ARDS and IFF. Intra-tracheal bleomycin 
induces an acute inflammatory lung injury progressing to fibrosis that may more 
closely reflect the pathophysiology of ARDS than that of IPF. However, microarray 
studies have confirmed that gene expression profiles of human IPF lung have many 
similarities to those of bleomycin-injured mouse lung (Kaminski 2003).
Bleomycin is a chemotherapeutic agent which exhibits dose-dependent 
pulmonary toxicity. It exerts its toxic effect by binding to guanine-cytosine-rich 
portions of DNA, together with divalent metal ions including iron and copper. The 
bound iron is able to produce highly reactive free radicals from molecular oxygen, 
which in turn can cleave DNA (Dorr 1992). The lung is particularly susceptible to 
bleomycin-induced injury since it lacks bleomycin hydrolase, a naturally occurring 
cysteine proteinase found in other organs, which degrades it (Bromme et al. 1996). 
The pulmonary response to bleomycin depends on the route of administration. Intra­
tracheal bleomycin immediately affects the alveolar and bronchiolar epithelium, and 
ultimately leads to peri bronchiolar fibrosis; whereas intravenous or intraperitoneal 
administration initially affects pulmonary endothelial cells, and ultimately leads to 
perivascular and subpleural fibrosis (Harrison, Jr. & Lazo 1987).
Common to all routes of administration of bleomycin is early widespread 
epithelial damage. Necrosis of type 1 alveolar epithelial cells ensues immediately 
following bleomycin injury. Their vulnerability is probably largely due to their 
exposed attenuated cytoplasm. Type 11 alveolar epithelial cells are also lost following
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bleomycin injury, although this may be via apoptosis rather than necrosis. Excessive 
epithelial apoptosis following bleomycin has been proposed to be a mechanism 
promoting fibrogenesis by releasing neighbouring lung fibroblasts from an inhibitory 
influence of lung epithelial cells (Hagimoto et al. 1997). Epithelial apoptosis is 
promoted by a number of mechanisms including exposure to reactive oxygen species 
(Wallach-Dayan et al. 2005), TNF-a (Wang et al. 2000a), and Fas ligand (Hagimoto 
et al. 1997). The mechanism appears to involve binding of angiotensin peptides to the 
ATI receptor on the epithelial cells. These angiotensin peptides may be produced in 
an autocrine fashion by epithelial cells themselves in response to the aforementioned 
mediators (Li et al. 2003), or by neighbouring fibroblasts (Uhal et al. 1995).
The cellular source of reactive oxygen species following bleomycin are type II 
alveolar epithelial cells and macrophages (Inghilleri et al. 2005). The importance of 
reactive oxygen species in bleomycin-induced damage is supported by the observation 
that administration of the antioxidant N-acetyl cysteine attenuates the extent of 
bleomycin-induced lung injury (Hagiwara et al. 2000). Epithelial cells influence the 
oxidant/ antioxidant balance following bleomycin by regulation of intracellular levels 
of antioxidants. For instance, levels of glutathione are decreased in type II alveolar 
epithelial cells following bleomycin injury (Karam et al. 1998). Conversely, levels of 
the antioxidant thioredoxin are increased in airway epithelial cells following 
bleomycin, and may afford protection from injury in these cell types (Gon et al. 2001).
An important function of type II alveolar epithelial cells is the production and 
secretion of surfactant, comprising phospholipids and specific surfactant proteins, to 
prevent alveolar collapse. Lung levels of phospholipids and surfactant apoproteins B 
and C are reduced in the bleomycin-injured lung (Osanai et al. 1991),(Savani et al.
2001), and, their deficiency may predispose to alveolar atelectasis, leading to 
hypoxaemia and respiratory insufficiency. Studies involving surfactant protein C- 
knockout (SFTPC ) mice have additionally suggested that surfactant protein C may 
additionally limit lung inflammation, inhibit collagen accumulation, and promote 
resolution of normal lung following bleomycin injury (Lawson et al. 2005).
Epithelial and endothelial cell loss results in inadequate epithelial/ endothelial 
barrier integrity. Vascular leak, possibly in concert with dyregulation of epithelial gap 
junction proteins (Abraham et al. 1999) and the water channel aquaporin-5 (Gabazza 
et al. 2004) produce alveolar flooding with protein rich oedema fluid. Local activation 
of coagulation is initiated by upregulation of tissue factor on a number of resident
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lung cells and extravasation of coagulation proteinase zymogens and fibrinogen from 
the vasculature. This allows generation of coagulation proteinases such as thrombin, 
and ultimately the formation of fibrin, which is deposited as hyaline membranes on 
the denuded basement membrane of the alveolar walls. Such hyaline membranes are 
classical pathological features of the bleomycin model (Jones & Reeve 1978) and 
ARDS (Anderson & Thielen 1992). Following bleomycin, but also in 
fibroproliferative lung disorders, alveolar fibrin persistence is maintained by a 
procoagulant and antifibrinolytic environment. Fibrin may exert a pro-fibrotic effect 
in vivo, since administration of u-PA, which favours fibrin clearance, attenuates 
bleomycin-induced fibrosis (Gunther et al. 2003).
Evidence for the ability of epithelial cells to promote a pro-coagulant state 
comes from in situ hybridisation studies, which show that tissue factor expression is 
upregulated predominantly on alveolar epithelial cells following bleomycin (Olman et 
al. 1995). Others have shown that epithelial cells also express PAI-1 and uPA, at least 
in vitro (Gross et al. 1991), which raises the possibility that they may also have the 
potential to modulate fibrinolysis as well as coagulation.
Following bleomycin, type II alveolar epithelial cells adopt a hyperplastic 
activated phenotype (Karam et al. 1998),(Kunugi et al. 2001),(Folkesson et al. 
1998),(Aso et al. 1976), and these are a characteristic feature of this model; but also of 
ARDS (Stanley et al. 1992) and of IPF (lyonaga et al. 1997),(Sakai et al. 1997). Small 
airways are also affected by bleomycin injury (Daly et al. 1998), (Kawamoto & 
Fukuda 1990), and in a process known as bronchiolization, bronchiolar epithelial cells 
proliferate and colonize alveolar spaces; and some of the cuboidal epithelial cells in 
the region of alveolar injury after bleomycin are likely to be derived from the distal 
conducting airways (Kawamoto & Fukuda 1990),(Betsuyaku et al. 2000). The role of 
airway epithelial cells in the injury/ healing response to bleomycin is further 
supported by the observation of changes in gene expression following bleomycin in 
these cell types (Betsuyaku et al. 2001, Betsuyaku et al. 2003).
The inflammatory response following bleomycin involves polymorphonuclear 
cells, lymphocytes and monocytes/ macrophages. Clearly the initiation and 
propagation of this response involves a number of distinct mediators and processes, 
and is dependent on a range of resident lung cell types, although it seems likely that 
epithelial cells play an important part in this regard. Bleomycin stimulates the release 
of mediators which promote inflammatory cell recruitment in vitro, in particular, the
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neutrophil chemoattractants: LTB4, IL-8 and G-CSF, and the mononuclear cell 
chemoattractant CCL2 (Sato et al. 1999). It is likely that oxidative stress is initially 
involved in the expression and release of pro-inflammatory mediators (reviewed in 
(Crapo 2003)), but additional mechanisms may include activation of toll-like receptor 
2. Both alveolar (Armstrong et al. 2004) and small airway epithelial cells (Ritter et al. 
2005) express abundant toll-like receptor 2 (TLR2), and bleomycin has been recently 
shown to stimulate cytokine secretion via TLR2 in monocytes (Razonable et al. 2005).
Epithelial cells are also a potential source of a number of potent pro-fibrotic 
mediators which have been implicated as promoting the development of injury and 
fibrosis in the bleomycin model. TNF-a is produced by type II alveolar epithelial cells 
following lung injury (Song et al. 1998), and administration of antibodies directed 
against TNF-a attenuate alveolar damage and fibrosis in response to bleomycin 
(Piguet et al. 1989). The CC chemokines M IP-la and CCL2; and the CXC chemokine 
MIP-2 (the murine homolog of IL-8) are expressed by injured alveolar and/or 
bronchial epithelial cells (Smith et al. 1994),(Lundien et al. 2002),(Witherden et al.
2004),(Vanderbilt et al. 2003). Antibodies directed against M IP-la (Smith et al. 1994) 
and MIP-2 (Keane et al. 1999b), and anti-CCL2 gene therapy (Inoshima et al. 2004) 
all attenuate the fibrotic response after bleomycin. Lung epithelial cells also produce 
TGF-p 1 (Azuma et al. 2005a) and PDGF (Song et al. 1998) following bleomycin 
injury, and similarly, the extent of fibrosis is attenuated by administration of TGF-pi 
blocking antibodies (Giri et al. 1993), and by administration of the PDGF receptor 
tyrosine kinase inhibitor: imatinib mesylate (Daniels et al. 2004).
Expression of the avp6 integrin is increased on injured airway (Pilewski et al. 
1997) and injured alveolar epithelium, but is absent from both these cell types in the 
normal lung (Breuss et al. 1995). A major mechanism for TGF-pi activation in vivo is 
likely to occur via this integrin, since avPb-integrin  ^ mice are protected from 
bleomycin-induced lung fibrosis (Munger et al. 1999). Hyperplastic proliferating 
epithelial cells are evidently an important source of TGF-p i production following 
bleomycin, and yet they may specifically adapt to be resistant to its antiproliferative 
effects by downregulation of the TGF-p Receptor-1 that is necessary for TGF-pi 
signal transduction (Khalil et al. 2002).
Finally, other mediators characteristically associated with inflammation and/ 
or fibrosis following bleomycin, including IL-1, IL-6, IL-4, IL-13, amd CTGF are all
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produced by injured or proliferating lung epithelial cells (Cavarra et al. 2004),(Howell 
et al. 2001),(Mattoli et al. 1991),(Bartalesi et al. 2005),(Pan et al. 2001), implicating 
epithelial cells as a potential source of these mediators.
Following epithelial injury, hyperplastic epithelial cells proliferate and spread 
along the alveolar septa and differentiate into type I cells in order to repair the 
alveolar epithelial defect. Type II alveolar epithelial cells produce a number of growth 
factors which can act in an autocrine fashion to stimulate epithelial repair. These 
include hepatoma-derived growth factor (HDGF) (Mori et al. 2004), hepatocyte 
growth factor (HGF) (Douglas et al. 2002), and Granulocyte Macrophage Colony 
Stimulating Factor (GM-CSF) (Sato et al. 2000). Diminished production of the latter 
following bleomycin may be a mechanism promoting fibrogenesis (Christensen et al.
2000). In addition, in the context of fibrogenesis, differentiation of type II into type I 
cells may be impaired, leading to increased numbers of dysfunctional type II cells and 
transitional epithelial cell types (Kasper & Haroske 1996). Thus epithelial cells are 
potentially key players in both initiating and perpetuating injury, but also in 
promoting subsequent resolution and repair following bleomycin. Their influence on 
injury/repair is likely to depend on the nature of their interactions with neighbouring 
resident lung cells such as myofibroblasts, and the local milieu of bioactive mediators 
present.
1.5.4. Epithelial injury in fibroproliferative lung disorders
As mentioned previously, the bleomycin model recapitulates key 
pathophysiological and biochemical features of human fibroproliferative lung 
disorders and has enabled major progress in our understanding of them. Widespread 
epithelial injury and activation is pivotal to both ARDS and IPF, although the 
pathogenesis of these disorders differs to some extent.
As mentioned earlier, the pathogenesis of ARDS involves exudative, 
proliferative, and fibrotic phases that follow widespread epithelial and/or endothelial 
injury. Key pathogenetic events are illustrated in figure 1.7.
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Figure 1.7. Hypothetical scheme of pathogenetic events in ARDS leading to fibrosing alveolitis
Epithelial injury lead s to lo s s  of vulnerable type I alveolar epithelial ce lls , and p ossib ly  airw ay epithelial cells . 
C o-ex isten t endothelial injury lea d s  to sw ollen  activated  endothelial c e lls  w hich prom ote recruitm ent of 
inflammatory ce lls  by upregulation of a d h es io n  m o lecu le  and ch em ok in e  ex p ress io n . A ctivated endothelial 
ce lls  contract cau sin g  vascu lar leak and facilitating trafficking of leu k ocytes through th e interstitium into the  
alveolar a irsp ace, which is flood ed  with protein-rich o e d e m a  fluid. Local upregulation of t is su e  factor 
togeth er with vascu lar leak perm its generation  of thrombin and fibrin. E xtensive protein-rich fibrin-containing 
hyaline m em b ran es form on th e d en u d ed  b a se m e n t m em brane of th e alveolar wall. Activated neutrophils, 
m acrop h ages, and epithelial c e lls  r e le a se  pro-inflam m atory and pro-fibrotic factors which perpetuate  local 
cellular injury and inflammation, but a lso  prom ote recruitment, proliferation, and activation of resident 
fibroblasts. M yofibroblasts sy n th es ize  and d ep o sit extracellular matrix proteins su ch  a s  co llagen  within 
interalveolar sep ta e  and in a r ea s  of fibrinous matrix (hyaline m em b ran es) within th e a lveo lu s.
The epithelial injury in ARDS may additionally involve airway as well as 
alveolar epithelial cells, since bronchial epithelial cells are present in BALF of these
66
Role o f  PARi-dependent secondary mediators in lung fibrosis
patients (Perkins et al. 2006). In the exudative phase, loss of endothelial/epithelial 
barrier integrity induces alveolar flooding and fibrin deposition. The hyaline 
membranes within alveoli that are observed in the bleomycin model (Jones & Reeve 
1978) are a hallmark feature of ARDS (Anderson & Thielen 1992). In contrast to IFF, 
inflammation is an undisputed prominent feature of ARDS, and is predominantly 
neutrophilic in the early stages, but macrophages may be the dominant inflammatory 
cell type later (Hashimoto et al. 2000). The proliferative phase of ARDS involves 
proliferation of epithelial cells and fibroblasts. Their synthesis of extracellular matrix 
components such as collagen constitutes the fibrotic phase and ultimately leads to 
fibrosing alveolitis. This latter is a conunon pathological change observed in most 
patients dying with ARDS (Lamy et al. 1976). Hyperplasia of type II alveolar 
epithelial cells is characteristic of ARDS (Stanley et al. 1992) as well as the 
bleomycin model. These cells represent a likely source of many of the pro- 
inflammatory and pro-fibrotic mediators found in BALF.
Surfactant function is abnormal in ARDS, and levels of BALF phospholipids, 
SP-A, and SP-B are all reduced in patients (Gregory et al. 1991). This is likely to be 
attributable, at least in part, to reduced synthesis by injured epithelial cells, as has 
been shown in injured murine lung (Savani et al. 2001). However, leakage into the 
circulation is probably also a contributing factor, and increased levels of surfactant 
proteins B and C are measurable in serum of ARDS patients, and may serve as 
biomarkers of physiological severity (Doyle et al. 1997). Surfactant deficiency in 
ARDS leads to end-expiratory alveolar collapse, atelectasis, an increase in right-to- 
left shunt and hypoxaemia. Surfactant replacement improves lung physiology and 
mortality in severe neonatal respiratory distress syndrome, but has thus far not proved 
efficacious in adults.
Lungs in patients with ARDS are difficult to ventilate because of increased 
compliance as a result of alveolar flooding, fibrin deposition, and atelectatic alveoli. 
Consequently high pressures (particularly positive end expiratory pressure: PEEP) are 
needed to keep alveoli open and facilitate gas exchange. However, these may cause 
ventilator-induced lung injury. In animal models, this has been shown to be associated 
with production and release of a number of pro-inflammatory cytokines (von 
Bethmann et al. 1998) including MIP-2, the murine homolog of IL-8 (Held et al.
2001). Likely sources of these mediators are hyperplastic type II alveolar epithelial 
cells, and pulmonary microvascular endothelial cells (reviewed in (Pinhu et al. 2003)).
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Mechanical stretch induces expression and release of IL-8 from A549 alveolar 
epithelial cells (Vlahakis et al. 1999) in vitro, and levels of this mediator in BALF are 
raised in experimental ventilator-induced lung injury (Park et al. 2005) in animals, but 
also correlate with physiological severity and outcome in ARDS patients (Chollet- 
Martin et al. 1993).
Activated hyperplastic epithelial cells are a pathological feature of IPF 
(lyonaga et al. 1997),(Sakai et al. 1997), just as they are of ARDS and of the 
bleomycin animal model. The pathogenetic mechanisms of IPF are illustrated in 
figure 1.8.
Clusters of activated and proliferating fibroblasts/ myofibroblasts occur in the 
vicinity of areas of focal epithelial cell destruction and exposed basement membrane. 
Adjacent hyperplastic epithelial cells represent the likely source of the pro-fibrotic 
mediators driving synthesis of extracellular matrix proteins by these fibroblastic foci. 
In support of this, immunohistochemical studies involving IPF biopsies have 
demonstrated that the major site of localization of TNF-a and TGF-pi is type 11 
alveolar epithelial cells (Kapanci et al. 1995). Injured and/ or activated airway 
epithelial cells may also play a role in the production of pro-fibrotic mediators in IPF, 
and bronchiolization is apparent in IPF (Chilosi et al. 2003) just as it is in the 
bleomycin model. Prominent bronchial immunostaining for osteopontin (Kadota et al. 
2005) and endothelin-1 (Saleh et al. 1997) is apparent in lungs of IPF patients, 
supporting airway epithelium as a potential source of pro-fibrotic mediators.
A number of epithelial-derived proteins are detectable in the serum of IPF 
patients, which most likely relates to increased release from injured or activated 
epithelial cells, and subsequent leakage into the circulation. Examples of such proteins 
are Cytokeratin 19 (Nakayama et al. 2003), SP-A and SP-D (Greene et al. 2002), 
Carcinoembryonic Antigen (Hadjiliadis et al. 2001), HGF (Yamanouchi et al. 1998), 
and KL-6 (Yokoyama et al. 1998). These proteins have been shown to have potential 
value as biomarkers of disease severity and/ or monitoring response to treatment.
Finally, TGF-pi has also been shown to have the potential to promote 
transition of alveolar epithelial cells toward a myofibroblast-like phenotype in vitro 
(Willis et al. 2005),(Kasai et al. 2005). Cells co-expressing both epithelial and 
mesenchymal markers have been identified in lungs of IPF patients (Willis et al.
2005), consistent with these cells being of a transitional phenotype somewhere
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between epithelium and mesenchyme. If such epithelial-mesenchymal transition is 
able to occur in vivo, it may represent an important further role for epithelial cells in 
fibrogenesis in IPF.
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Figure 1.8. Hypothetical scheme of pathogenetic events in IPF
Idiopathic epithelial injury le a d s  to lo s s  of typ e I a lveolar epithelial c e lls  and ex p o su re  of underlying  
b a sem en t m em b ran e. V ascu lar leak  and local upregulation of tis s u e  factor e x p ress io n  resu lts in generation  
of thrombin and fibrin. T ype II a lveolar ep ithelial c e lls  proliferate and  sp read  over d en u d ed  b a sem en t  
m em b ran e and un dergo reactive hyp erplasia . Distal bronchiolar epithelial c e lls  m ay a ls o  proliferate and  
sp read  into th e a lveolar s p a c e  (bronchiolization). A ctivated epithelial c e lls  r e le a s e  pro-fibrotic factors  
inducing recruitm ent, proliferation, and activation of resident fibrob lasts. M yofibroblasts m ay prom ote  
epithelial cell a p o p to sis  and disruption of th e b a se m e n t m em b ran e thus preventing norm al epithelial repair. 
M yofibroblasts a lso  s y th e s ize  and  d ep o sit extracellu lar matrix proteins su c h  a s  co llagen  within interalveolar  
s e p ta e  and in a r ea s  of fibrinous matrix within th e  a lv eo lu s . Normal matrix d egradation / turnover d o e s  not 
occu r b e c a u s e  of a  local im b alan ce b etw een  TIMP and MMP activity.
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1.6. Summary, hypothesis and specific aims of this thesis
Pulmonary fibrosis is a pathological process common to a number of 
respiratory diseases including ARDS and IPF. These conditions are associated with 
major morbidity and mortality, and are currently untreatable. Excessive local 
procoagulant activity and epithelial cell injury/ reactive hyperplasia are characteristic 
features of these conditions, and likely to be important in their pathogenesis. In this 
chapter, the role of the major thrombin receptor PAR] in promoting pro-inflammatory 
and pro-fibrotic cellular effects of thrombin has been reviewed, along with the likely 
key contribution of epithelial cells to fibrogenesis.
Preliminary data obtained by Dr David Howell prior to the commencement of 
this thesis suggested that PAR]  ^ mice exhibited a reduction in lung collagen 
accumulation following intratracheal bleomycin administration. However, the 
biological basis of this protection were not known.
1.6.1. Hypothesis;
This thesis therefore specifically addressed the hypothesis that.
PARj activation promotes lung injury and fibrosis via the release o f a number o f 
specific secondary mediators; with the pulmonary epithelium representing an 
important cellular source o f these mediators.
1.6.2. Aims:
The specific aims of this thesis were:
1. To determine the contribution of PAR] to lung inflammation and fibrosis in 
response to lung injury by evaluating these responses in PAR]  ^ and WT mice 
following bleomycin-induced lung injury
2. To identify the secondary mediators by which PAR] drives inflammation and 
fibrosis following lung injury by comparing the levels of PAR] inducible
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mediators in lungs of PARf^' and WT mice following bleomycin-induced lung 
injury.
3. To determine whether PARi activation on lung epithelial cells promotes the 
release of pro-inflammatory and pro-fibrotic secondary mediators by using 
cultured lung epithelial cells.
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2. MATERIALS & METHODS
2.1. Materials
As mentioned previously PARi  ^ mice were originally generated by the 
insertion of a neocassette into the PARi gene to disrupt exon 2 which encodes 
transmembrane domains 1-7 (Connolly et al. 1996). The resulting DNA construct was 
electroporated into embryonic stem cells, where it incorporated into chromosomal 
DNA by homologous recombination. Neomycin-resistant clones were implanted into 
mouse blastocyst cavities, and resulting chimeras were bred and genotyped. PARi  ^
offspring of these were then extensively backcrossed for 10 generations onto the 
C57/BL/6 background (Cunningham et al. 2000). A colony of homozygous PARi  ^
mice was subsequently established at UCL through collaboration with Prof P Tipping 
(Monash University, Australia). A colony of C57/BL/6 mice obtained from Harlan 
UK (Oxon, UK) were established at the same time at UCL, and served as wild-type 
controls.
ELISA kits for mouse IL-6, TNF-a, and IL-10 were from RnD systems (Oxon, 
UK), and for mouse CCL2 from BD Pharmingen (San Diego, CA, USA). Paired 
antibodies MAB679 and BAF279 for the human CCL2 ELISA were obtained from 
RnD systems', and human recombinant CCL2 protein standard was from Peprotech 
(Rocky Hill, NJ, USA).The lactate dehydrogenase (LDH) activity assay kit was from 
Sigma-Aldrich (Dorset, UK). Antibodies specific for mouse CCL2 (sc-1784), 
mouse/human CTGF (L-20) and mouse/human TGF-pi (sc-146: which recognizes 
latent and active TGF-pi) were obtained from Santa Cruz Biotechnology Inc (San 
Diego, CA, USA). Mouse specific PARi antibodies, raised against the peptide 
SFFLRNPSENTFELVPL-NH] (abbreviated SFFL), in rabbits, and purified by affinity 
chromatography (Jenkins et al. 1993), were a generous gift from Professor Eleanor 
Mackie (University of Melbourne, Australia). Recombinant human thrombin and 
factor Xa were obtained from Calbiochem (Darmstadt, Germany).
A549, BEAS-2B, HFL-1, and MLF cell lines were obtained from the 
American Type Culture Collection (ATCC) via LGC Promochem (Middlesex, UK). 
The MLE-15 cell line was a generous gift from Professor Jeffrey A. Whitsett 
(Cincinatti Children’s Hospital Medical Center, Cincinatti, Ohio, USA). Primary
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human lung alveolar epithelial cells were a generous gift from Professor Terry Tetley, 
Lung Cell Biology, NHLI, Imperial College, London.
DMEM and F12-K tissue culture media were from Gibco BRL, Paisley, UK. 
DCCM-1 tissue culture medium was from Biological Industries (Kibbutz Beit Haemek, 
Israel). Tissue culture flasks and plates were all obtained from Nunc (Roskilde, 
Denmark). TFLLR-NH2 and FTLLR-NH2 peptides were synthesized by Professor 
Robert Mecham (University of Washington, St Louis, MO, USA). The AYPGKF 
peptide was kindly provided by Dr James Moffat (Kings College London). The PARi 
antagonist RWJ-58259 was a gift from Dr Claudia Derian (Johnson & Johnson 
Pharmaceutical R&D, Philadelphia, USA). The protein kinase C inhibitor Ro-31-8425 
and pertussis toxin were obtained from Calbiochem. Mink lung epithelial cells stably 
transfected with the PAI-1-promoter-luciferase reporter gene, for use in the TGF-pi 
bioassay, were kindly provided by Dr Dan Rifkin (Department of Cell Biology, New 
York University School of Medicine, New York, USA).
Primers used in real-time RT-PCR studies are listed in table 2.1. Murine 
CTGF, TGF-p 1 and 36B4 primers were designed by Dr Bin Shan (Tulane University, 
New Orleans, USA). All other primers were designed in-house at UCL with the 
assistance of Dr Chris Scotton (Centre for Respiratory Research, UCL).
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Gene Primers Product size
Mouse PARi F o r  5 ' -AGCCAGCCAGAATCAGAGAG-3 ' 
R ev  5 ' - AGGGGGACCAGTTCAAATGTA-3 '
96bp
Mouse CTGF F o r  5 ' -GCAGCGGTGAGTCCTTCC-3 '
R ev  5 ' -AATGTGTCTTCCAGTCGGTAGG-3 '
232bp
Mouse TGF-P 1 F o r  5 ' -GGATACCAACTATTGCTTCAGCTCC-3 '  
R ev  5 ' -AGGCTCCAAATATAGGGGCAGGGTC-3 '
155bp
Mouse 36B4 F o r  5 ' - CGACCTGGAAGTCCAACTAC- 3 '  
R e v  5 ' -ATCTGCTGCATCTGCTTG-3 '
109bp
Mouse CCL2 F o r  5 ' -AGCTCTCTCTTCCTCCACCAC-3' 
R ev  5 ' - CGTTAACTGCATCTGGCTGA-3 '
l l l b p
Mouse/Human 18S F o r  5 ' -TTGACGGAAGGGCACCACCAG-3 '  
R ev  5 ' -GCACCACCACCCACGGAATCG-3'
131bp
Human PAR] F o r  5 ' - CCATCGTTGTGTTCATCCTG- 3 '  
R e v  5 ' -GACCCAAACTGCCAATCACT-3'
148bp
Human PAR4 F o r  5 ' -GAAGGCTGTACTGGGTCGAA-3 '  
R ev  5 ' - AAGTGACCTCCGCTAGTGACA-3 '
119bp
Human CTGF F o r  5 ' - GCAGGCTAGAGAAGCAGAGC- 3 '  
R ev  5 ' - TGGAGATTTTGGGAGTACGG- 3  '
108bp
Human TGF-P, F o r  5 ' -AAGGGCTACCATGCCAACT-3 '  
R e v  5 ' - CCGGGTTATGCTGGTTGTA-3 '
103bp
Human CCL2 F o r  5 ' -AGCAAGTGTCCCAAAGAAGC-3' 
R e v  5 ' - CATGGAATCCTGAACCCACT-3 '
94bp
Table 2.1: Primers used for real-time RT-PCR
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2.2. Bleomycin model of lung injury and fibrosis
2.2.1. Surgical procedures, and harvesting of tissue and lavage fluid
Mice were housed in a specific pathogen-free facility, and all procedures were 
performed on mice aged between 6 and 12 weeks of age in accordance with the Home 
Office Animals Scientific Procedures Act (HMSG 1986). Bleomycin (Nippon Kayaku 
Co. Ltd, Tokyo, Japan) or saline was administered by a single intra tracheal injection 
(1 mg/kg body weight in 50pl saline) into a surgically exposed trachea under halothane 
anaesthesia. Mice were later sacrificed by intraperitoneal injection of pentobarbitone, 
and severing of the abdominal inferior vena cava.
For real time RT-PCR and lung inflammatory mediator analysis, lungs were 
carefully removed and immediately snap-frozen and pulverized under liquid nitrogen. 
For assessment of total lung collagen, histological and immunohistochemical analysis, 
lungs were perfused with 5 ml of normal saline via the right side of the heart. For 
measurement of total lung collagen and RNA studies, lungs were removed, blotted 
dry and the trachea and major airways excised. Lungs were then weighed before being 
snap-frozen and pulverized under liquid nitrogen. Lungs for histological and 
immunohistochemical analysis were fixed following perfusion: the trachea was 
cannulated and lungs were insufflated with 4% paraformaldehyde in phosphate- 
buffered saline (PBS) at a pressure of 20 cm H2O, followed by removal of the heart 
and inflated lungs en bloc, and immersion for 4 hours in fresh fixative. Subsequently, 
lungs were transferred to 15% sucrose in PBS and left overnight at 4®C, prior to 
transfer to 70% ethanol. For BALF analysis, the trachea was cannulated via a ventral 
neck incision. Normal saline was instilled in 0.5ml aliquots over 15 seconds, left in 
situ for 30 seconds, and withdrawn over 15 seconds and stored in polypropylene tubes 
on ice. The procedure was repeated five times and greater than 90% of the total 
instillate was recovered.
2.2.2. Assessment of BALF total cell number, total protein, and LDH activity
BALF cells were pelleted by centrifugation (300 g for 10 minutes at 4°C). 
Pellets were re-suspended in 1ml 10% FCS (Foetal Calf Serum, Invitrogen, Paisley, 
UK) in DMEM (Dulbecco's Modified Eagle's Medium, Gibco BRL) and cells were
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counted with a standard haemocytometer. Total protein and LDH activity in BALF 
supernatants were assessed as per the manufacturers' protocols, using the 
bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA), and an LDH 
activity assay kit (Sigma).
Increases in BALF protein were taken to represent vascular leak and/or loss of 
endothelial/epithelial barrier integrity. The BCA assay utilizes the biuret reaction, 
which is the reduction of Cu^^ to Cu^^ by protein in an alkaline medium. Each Cu^  ^
ion then complexes with 2 molecules of bicinchoninic acid (BCA) to form a water- 
soluble purple-coloured reaction product which exhibits a strong absorbance at 562nm 
that is linear with increasing protein concentrations over a broad working range of 
20|Lig/ml to 2000|Xg/ml. The amount of protein in samples can be derived by 
comparing sample absorbances with those of samples of known albumin 
concentration assayed in parallel. The assay was performed by adding lOpl of each 
sample or standard (in duplicate) to single wells of a 96-well microwell plate. 200pl 
of freshly reconstituted BCA working reagent (consisting of 50 parts reagent A and 1 
part of reagent B), was added, the plate briefly agitated, and then incubated at 37°C 
for 30 min prior to reading the absorbance at 550nm on a Titertek Multiscan 
MCC/340 plate reader (Labsystems, Finland).
Increases in BALF LDH activity were taken to represent cellular injury as 
LDH is a cytoplasmic enzyme released from cells in the context of loss of membrane 
integrity. The Sigma LDH activity assay is based on the reduction of NAD by LDH. 
The NADH formed converts a tétrazolium dye into a coloured compound which is 
measurable at an absorbance wavelength of 490nm. The assay was performed by 
adding 80pl of each sample to a single well of a 96-well microplate. Subsequently 
40|il of freshly reconstituted assay mixture (consisting of equal parts of assay 
substrate, enzyme and dye solutions) was added. The plate was covered and incubated 
in the dark at room temperature for 20-30 minutes. Absorbance was then read on a 
Titertek Multiscan MCC/340 plate reader (Labsystems) at 490nm.
2.2.3. Assessment of IL-6, CCL2, TNF-cx, and IL-10 levels in lung homogenates.
Lung tissue homogenates were prepared based on a method described by 
Keane et at (Keane et al. 1999a). Frozen lung powder was mixed with 0.5ml PBS
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with added protease inhibitors (Compleat Mini, Roche Diagnostics, Sussex, UK) in 
polypropylene tubes. Samples were homogenised (3 x 20 seconds on ice) with a 
Polytron PT1035 mechanical homogeniser (Kinematica GmbH, Litau, Switzerland), 
filtered through a 1.2pm filter (Sartorius, Goettingen, Germany) and aliquots were 
frozen at -80°C until use. IL-6, CCL2, TNF-a and IL-10 levels in homogenates were 
measured by ELISA, (IL-6 sensitivity >1.6pg/ml; CCL2, sensitivity >15.6pg/ml; 
TNF-a sensitivity >5.1pg/ml; IL-10 sensitivity >4.0pg/ml) according to
manufacturer's instructions. 50pl aliquots of homogenate filtrate were analysed in 
duplicate. Data was expressed as pg/lung. This value was derived from the measured 
concentration (pg/ml) of the mediator by the following equation:
[Mediator] in lung (pg/lung) = 0.5 x ([mediator] in sample x lung wt/aliquot wt)
2.2.4. Determination of total lung collagen
Total lung collagen was determined by measuring hydroxyproline content in 
aliquots of pulverised lung as described previously (Campa et al. 1990),(Chambers et 
al. 1994),(Mutsaers et al. 1998), and assuming that lung collagen contains 12.2% w/w 
hydroxyproline (Laurent et al. 1981). Hydroxyproline was quantitated by reverse- 
phase high performance liquid chromatography (HPLC) of 7-chloro-4-nitrobenzo- 
oxao-l,3-diazole (NBD-Cl)-derivatised acid hydrolysates. (NBD-Cl was from Sigma). 
The basis for this assay is that the secondary amino acid hydroxyproline reacts with 
NBD-Cl to generate a chromophore with maximum light absorbance at 495nm. NBD- 
Cl also reacts with primary amino acids but these reactions occur far slower, and do 
not result in the generation of significant light absorbance at 495nm.
For each sample, approximately lOmg of lung powder was accurately 
weighed, and hydrolysed in 3ml 6M HCl for 16 hours at 110°C in a sealed pyrex glass 
tube. Hydrolysates were decolourised with activated charcoal, filtered through an 
acid-resistant 0.65pm filter (Millipore ltd., Watford, UK), and diluted 1 in 100. A 
200pl aliquot of this diluted hydrolysate was then dried down by centrifugal vacuum 
concentration using a SPD131DDA Speedvac (Thermo Electron Corporation, 
Cambridge, UK). The resulting residue was re-dissolved in lOOpl HPLC grade H2O, 
buffered with lOOpl 0.4M potassium tetraborate (pH 9.5) (Sigma) and reacted with
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100|xl 36mM NBD-Cl (in methanol). Samples were wrapped in aluminium foil to 
protect them from light and incubated in a water bath at 37°C for 20 minutes. The 
reaction was then stopped by the addition of 50|il 1.5M HCl. At this point 150|il of 
3.33x Buffer A was also added (buffer A is described in table 2.2). Samples were 
then filtered through a 0.22|xm filter (Millipore) into a polypropylene insert within an 
Amber Snap Seal vial (Laboratory Sales ltd., Rochdale, UK). These vials were then 
loaded onto the HPLC autosampler and the samples were sequentially injected onto 
the column by an automated injector.
The HPLC apparatus employed for these measurements was a Beckman 
System Gold HPLC (Beckman Coulter, Bucks, UK) with a reverse-phase cartridge 
column (LiChroCART LiCrospher 250mm length x 4mm diameter, 5p,m particle size, 
100 RP-18; BDH/Merck, Lutterworth, UK) protected by a directly coupled pre­
column (LiChrosorb, 4mm x 4mm, 5pm, 100 RP-18; BDH/Merck). Columns were 
continuously maintained at 40°C in a heated column oven. Immediately prior to 
injection of samples onto the HPLC column, all running buffers were degassed, and 
the HPLC system equilibrated in running buffer A for 40 minutes.
Standards of 50pmol/L hydroxyproline (Sigma) were included among the 
samples to enable calibration and quantitation. NBD-Cl derivatives in samples and 
standards were eluted with an acetonitrile gradient, which was achieved by changing 
the relative proportions of running buffers over time. Conditions and buffers 
employed in this process are shown in table 2.2.
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Column 250 x Anm, 5|W%
Mobile phase Buffer A - aqueous acetonitrile (8% v/v)
50mM sodium acetate, pH 6.4
B u ffe r s  - aqueous acetonitrile (75% v/v)
Column flow rate 1.0 ml/min
Column temperature 40°C
Wavelength for detection 495nm
Elution gradient Time (min) % Buffer B
0 0
5 5
6 80
12 80
12.5 0
25 0
Table 2.2. Conditions and buffers for the separation of hydroxyproline by 
reverse-phase HPLC
Eluted amino acids were detected by monitoring absorbance at 495nm. 
Hydroxyproline elutes as a discrete peak between 5 and 7 minutes following its 
injection onto the column. Quantitation of the hydroxyproline content in each sample 
was determined by comparing peak areas of the hydroxyproline peak of each sample 
with those of the standards of known hydroxyproline concentration.
Total lung collagen was expressed as mg/lung and derived from the equation:
Total lung collagen =
peak area x 10 x 100 x 5 x 1/1000 x 100/12.2 x 131/1000000 x lung weight/powder weight
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2.2.5. Histological analysis
Individual lobes of mouse lungs were placed in processing cassettes, 
dehydrated through a serial alcohol gradient, and embedded in paraffin wax blocks. 
Blocks were cooled to 4°C and 4jxm sections were cut using a microtome. Prior to 
immunostaining, these 4pm thick lung tissue sections were dewaxed in xylene, 
rehydrated through decreasing concentrations of ethanol, and washed in PBS.
2.2 5.1. Immunohistochemistry for CTGF, TGF-pi, PARi, and CCL2
For CTGF, TGF-pi, and PARi immunostaining, antigens were unmasked by 
microwaving sections in lOmM citrate buffer, pH 6.0 (2 x 10 min). For CCL2 
immunohistochemistry, antigen unmasking was found not to be useful in prior 
optimization studies, and therefore was omitted. Immunostaining was undertaken 
using the avidin biotinylated enzyme complex method (Vector Laboratories, 
Burlingame, CA, USA) with antibodies against CTGF (Santa Cruz) at a concentration 
of 0.4 pg/ml, TGF-Pi (Santa Cruz) at a concentration of 1 pg/ml, SFFL (PARi) at a 
concentration of 0.14 pg/ml, and CCL2 (Santa Cruz) at a concentration of 0.5pg/ml 
with equivalent concentrations of polyclonal non-immune IgG controls. After 
incubation with the appropriate biotin-conjugated secondary antibody (all from Dako, 
Glostrup, Denmark), and subsequently streptavidin-HRP solution (Dako), colour 
development was performed using 3,3’-diaminobenzidine tetrahydrochloride (DAB, 
Vector Laboratories) as a chromogen. Sections were counterstained using Gill-2 
haematoxylin (Thermo-Shandon, Pittsburgh, PA, USA), dehydrated through a series 
of incubations in increasing concentrations of ethanol and then xylene, and mounted 
using a Sakura Coveraid automatic coverslipping machine and Tissue-Tek 
coverslipping film (Bayer Diagnostics, Basingstoke UK). Specificity of the signal 
obtained was confirmed by showing that no positive staining was detectable when the 
primary antibody was substituted with an equivalent concentration of non-immune 
polyclonal IgG, or when it was omitted altogether. In addition, because there were no 
published reports of the use of the Santa Cruz L-20 CTGF antibody in 
immunostaining of bleomycin-injured murine lung, a western blot of lung
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homogenates was performed (figure 2.1) to demonstrate that this antibody reacted 
with a species of approximately the correct size of CTGF (38kDa). Homogenates 
were prepared as already described. Western blotting methods employed in this work 
are described in detail later in this chapter (Please see section 2.3.)
Figure 2.1. W estern blot of m ouse lung hom ogenates for CTGF. A s in g le  im m u n o re a ctiv e  
b a n d  with a n  a p p ro x im a te  s i z e  o f 3 8 k D a , c o n s is t e n t  with C T G F , w a s  o b ta in ed
98kDa
SOkDa
36kDa
22kDa
2.2.S.2. Semi-quantitative image analysis of CTGF and TGF-pi immunostaining
A semi-quantitative image-analysis technique was used to evaluate the extent 
of immunostaining for these two proteins per lobe using a JVC KY-F55BE digital 
camera (JVC, Yokohama, Japan) and KS300 software (Carl Zeiss Vision GmbH, 
Eching, Germany). The colour intensity representative of positive immunostaining 
following saline or bleomycin instillation was established after visual inspection of all 
sections, and a threshold defined. Individual lobes were examined blind to 
experimental group (x 100 magnification) using an Olympus BX40 microscope 
(Olympus, London, UK). For each field of view, the percentage of area staining of 
greater intensity than the defined threshold was taken to represent the percentage of
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positive immunostaining. For each lobe, 2 separate non-overlapping fields of view, 
which appeared to be the most positively stained, were chosen. They were discarded if 
non-representative areas such as airway epithelium occupied greater than 15% of the 
field of view, or fields exhibited obvious staining artefact or overlapped the pleural 
surface. The data is expressed as mean percentage of positive immunostaining per 
lobe.
2.2.5.3. Histological evaluation of lung architecture
Two different staining methods were used to evaluate lung architecture. A 
modified trichrome staining method was used to assess lung fibrosis. This method 
demonstrates all tissue elements differently based on the use of differring permeability 
of tissues to dyes of varying molecular size. The large Chicago Sky Blue 6GX dye 
permeates collagen fibrils causing areas of fibrosis to appear blue. However the 
pictures depicting fibrosis displayed in the results section of this thesis are of a low 
power magnification and are not intended to enable visualization of collagen, but 
rather to enable an appreciation of gross lung architecture. In order to enable 
appreciation of inflammatory cell infiltration in elderly mice, a heamatoxylin and 
eosin method was used. Automated staining of sections was performed using a Sakura 
DRS 601 Diversified Stainer (Bayer Diagnostics). Solutions and incubation times 
through which the sections were processed are shown in table 2.3 (modified 
Trichrome), and table 2.4 (H&E).
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Time: ScÉiHont - A -
1 3 min Xylene
2 3 min Xylene
3 2 min 100% Industrial Methylated Spirit (IMS)
4 2 min 90% IMS
5 2 min 70% IMS
6 5 min Lugol’s iodine
7 3 min Sodium Thiosulphate
8 1 min Wash in H2O
9 10 min Celestine Blue
10 1 min Wash in H2O
11 30 secs Distilled H2O (dH20)
12 5 min Haematoxylin
13 30 secs Wash in H2O
14 20 secs Acid Alcohol (1% HCl in 70% ethanol)
15 30 secs Wash in H2O
16 2 min Wash in H2O
17 30 secs 90% IMS
18 8 mins Orange G (0.2% in Picric alcohol (100% ethanol saturated with 
picric acid))
19 5 secs dH20
20 7 min Red Mix (Ponceaux 2R 0.5% & Acid Fuchsin 0.5% in 1% Glacial 
acetic acid)
21 20 secs dH20
22 30 secs Phosphotungstic acid (1% in AD)
23 20 secs dH20
24 80 secs 0.5% Chicago SkyBlue 6BX in 1% glacial acetic acid
25 20 secs 1% glacial acetic acid
26 20 secs 70% IMS
27 20 secs 90% IMS
28 1 min 100% IMS
29 1 min Xylene
30 1 min Xylene
31 2 min Xylene
Table 2.3: Solutions and incubation times for modified Trichrome staining
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S ^ N o : T b m t V -
1 3 min Xylene
2 3 min Xylene
3 2  min 100% Industrial Methylated Spirit (IMS)
4 2  min 90% IMS
5 2  min 70% IMS
6 2  min 50% IMS
7 1 min dHzO
8 5 min Haematoxylin
9 1 0  sec Wash in H2O
1 0 1 0  sec Wash in H2O
11 08 sec Acid alcohol
1 2 30 secs Wash in H2O
13 2  min Wash in H2O
14 6  min Eosin
15 15 secs Wash in H2O
16 30 secs 50% IMS
17 45 secs 70% IMS
18 1 min 90% IMS
19 1 min 100% IMS
2 0 2  min 100% IMS
2 1 1 min Xylene
2 2 2  min Xylene
23 2  min Xylene
Table 2.4: Solutions and incubation times for H&E staining
(Reagents used in these staining protocol were obtained from the following suppliers: 
Acid Fuchsin, Haematoxylin, IMS, Xylene, Phosphotungstic acid, potassium iodide: 
BDH; Picric acid, sodium thiosulphate, iodine, Celestine Blue, Chicago Sky Blue 
6 BX, Ponceau 2R: Sigma; Orange G: Raymond A Lamb, Eastbourne, Sussex, UK; 
Glacial acetic acid: Fisher Scientific, Loughborough, Leicestershire, UK).
2 2.5.4. Histological evaluation of fibrin
In order to demonstrate fibrin fibres, a modified staining technique, based on that of 
Lendrum et al (LENDRUM et al. 1962) and involving a Ponceaux de Xylidine and 
Acid Fuchsin mix, was employed. Solutions and incubation times through which the 
sections were processed are as shown in table 2.5.
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Step No: Time:
1 3 min Xylene
2 3 min Xylene
3 2  min 100% Industrial Methylated Spirit (IMS)
4 2  min 90% IMS
5 2  min 70% IMS
6 5 min LugoTs iodine
7 3 min Sodium Thiosulphate
8 1 min Wash in H2O
9 1 0  min Celestine Blue
10 1 min Wash in H2O
11 30 secs Distilled H2O (dH2 0 )
12 5 min Haematoxylin
13 30 secs Wash in H2O
14 2 0  secs Acid Alcohol (1% HCl in 70% ethanol)
15 30 secs Wash in H2O
16 2  min Wash in H2O
17 30 secs 90% IMS
18 8  mins Orange G (0.2% in Picric alcohol (100% ethanol saturated with 
picric acid)
19 5 secs dH2 0
2 0 7 min Red Mix (Ponceaux 2R 0.5% & Acid Fuchsin 0.5% in 1% Glacial 
acetic acid)
2 1 2 0  secs dH2 0
22 30 secs Phosphotungstic acid (1% in AD)
23 2 0  secs dH2 0
24 2 0  secs 50% IMS
25 2 0  secs 70% IMS
26 2 0  secs 70% IMS
27 2 0  secs 90% IMS
28 1 min 100% IMS
29 1 min Xylene
30 1 min Xylene
31 2  min Xylene
Table 2.5: Solutions and incubation times for histological demonstration of fibrin.
2.2.6. Real Time RT-PCR analysis of lung tissue for CTGF and TGF-Pi mRNA 
levels
Total RNA was isolated from frozen powdered lung tissue with TRIzol reagent 
(Gibco-BRL) as per the manufacturer's instruction. TRIzol is a solution of phenol and 
guanidine isothiocyanate. It effectively disrupts cells and dissolves cell components, 
whilst maintaining the integrity of RNA. Following addition of chloroform and 
centrifugation the disrupted cell suspension separates into upper aqueous and lower
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organic phases. RNA remains exclusively in the aqueous phase and is precipitated 
from it by the addition of isopropanol.
RNA pellets were redissolved in 17^1 DEPC H20 (Ambion, Cambridge, UK), 
and this RNA solution was DNase treated with DNA-free (Ambion) as per the 
manufacturers instruction to remove contaminating genomic DNA. Optical density of 
samples was assessed on an Ultrospec 3000 spectrophotometer (Amersham 
Biosciences, Bucks, UK), and the quantity of RNA in each sample derived from the 
absorbance at 260nm. 0.5-l)Lig RNA from each sample was then mixed with running 
buffer containing ethidium bromide, and ran on a 1% agarose formaldehyde gel. 
Images of the RNA were captured with a Syngene Gene Genius Bio-imaging system 
(Synoptics, Cambridge, UK). A ratio of approximately 2:1 of intensities of the 28S 
(upper band) to the 18S (lower band) confirmed that the RNA was not significantly 
degraded.
Subsequent steps (as described hereafter) were undertaken by Dr Bin Shan of 
Tulane University, New Orleans, USA as part of an ongoing collaboration between Dr 
Rachel Chambers and Professor Joseph Lasky. Reverse transcription (RT) was carried 
out with 2 |xg of total RNA in a reaction volume of 20 pi using Cloned AMV First- 
Strand cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA) following the provided 
instructions. Oligo (dT)2o was used as the primer for RT. Real-time PCR was 
conducted using iQ SYBR Green Supermix on an iCycler iQ Real-time Detection 
System following the manual and analysed using iCycler iQ Real-time PCR Detection 
System Software Version 3.0A (all Bio-rad, Hercules, CA, USA). Cycling conditions 
were optimized such that the PCR efficiency was 100% (±5%).
For CTGF each cycle was 95®C, 30 seconds; then 58®C, 30 seconds. For TGF- 
pi each cycle was 95°C, 15 seconds; then 64®C, 45 seconds. For 36B4, each cycle was 
95°C, 20 seconds; then 57.5°C, 30 seconds. The specificity of the PCR product was 
confirmed by melting curve analysis and gel electrophoresis. Single products of the 
expected size were obtained: 36B4: 109bp; CTGF: 232bp; TGF-pl: 155bp. A detailed 
description of the basis of calculation of relative mRNA abundance is described later 
in this chapter (please see section 233,1). Briefly, crossing point (Cp) values were 
derived from the amplification plots. CTGF mRNA levels in each sample were 
normalized for 36B4 using the equation C T G F / 3 a l l o w i n g  
direct comparison between samples. Similarly, an equivalent equation was used to
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derive TGF-pi mRNA levels. The lowest mean value was then assigned an arbitrary 
value of 1 and the values of the other samples scaled accordingly.
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2.3. Epithelial cell culture studies
2.3.1. Epithelial cells and experimental conditions
The MLE-15 cell line was originally generated by Wikenheiser et al 
(Wikenheiser et al. 1993). Spontaneously occurring tumours were isolated from 
transgenic mice harbouring the SV40 T antigen under the control of the human SP-C 
promoter region, and colonies of epithelial cells were allowed to grow out from 
minced tumour tissue. MLE-15 represents a clonal cell line derived in this way. These 
cells display features of type II lung alveolar epithelial cells, namely: polygonal 
morphology, microvilli, cytoplasmic multivesicular bodies and multilamellar 
inclusion bodies, and expression of SP-A and SP-B mRNA. These cells maintain this 
epithelial phenotype for 30-40 passages in culture. MLE-15 cells require culturing in 
HITES medium which contains a number of growth factors and hormones necessary 
to support their growth and phenotype. For experimental work described in this thesis, 
MLE-15 cells were maintained in HITES medium consisting of RPMI 1640 (Gibco- 
BRL) supplemented with 2% Foetal Calf Serum (FCS), 5pg/ml insulin, lOfig/ml 
transferrin, 30nM sodium selenite, lOnM hydrocortisone, lOnM p-estradiol, 4mM L- 
glutamine, lOnM HEPES, and 200units/ml penicillin/streptomycin (all Sigma).
The A549 cell line is a continuous cell line derived from lung carcinomatous 
tissue. They retain many but not all phenotypic features characteristic of primary 
human type II alveolar epithelial cells, including cuboidal type Il-epithelial like 
morphology (Foster et al. 1998), apical microvilli (Alink et al. 1980), the presence of 
intracellular lamellar bodies (Foster et al. 1998),(Shapiro et al. 1978), the expression 
of pro-surfactant protein C (pSP-C) (Vaporidi et al. 2005), the synthesis of 
phospholipids (Shapiro et al. 1978), and the ability to form polarised cell monolayers 
in vitro (Foster et al. 1998). For experimental work described in this thesis, A549 cells 
were maintained in F12K (Gibco-BRL) with 10% FCS, 200 units/ml 
penicillin/streptomycin and 4mM L-glutamine.
The BEAS-2B cell line was originally generated by isolating epithelial cells 
from normal human bronchial epithelium, infecting those cells with an adenovirus 1 2 - 
SV40 virus hybrid, and then cloning them. Some investigators maintain BEAS-2B in 
a serum-free medium supplemented with growth factors and hormones because of 
concerns that serum may promote squamous differentiation of these cells, just as it
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may in primary bronchial epithelial cells. However, a number of the supplements 
required when serum is absent have previously been demonstrated to affect the 
production of pro-inflammatory and pro-fibrotic mediators by epithelial cells in vitro. 
Furthermore such effects involve specifically those mediators being examined in this 
thesis. For instance, amongst the recommended supplements for BEAS-2B culture: 
the epidermal growth factor family of cytokines may modulate expression of CCL2 
(Mascia et al. 2003) and CTGF (Wenger et al. 1999); glucocorticoids can influence 
expression of CCL2 (Natori et al. 1997) and CTGF (Matsuda et al. 2005); insulin can 
influence expression of CCL2 (Mamounas et al. 1991) and TGF-p (Romberger et al. 
1995); transferrin can influence expression of CCL2 (Wang et al. 1997); and retinoic 
acid can influence expression of CTGF (Freemantle et al. 2002) and TGF-p (Niles et 
al. 1994). Therefore, where BEAS-2B were used for experiments outlined in this 
thesis, they were maintained in a basic buffered medium with essential nutrients, 1 0 % 
foetal calf serum, and without specific growth factor, steroid, or hormone supplements. 
Under similar conditions, BEAS-2B have been shown to retain electron microscopic 
features of epithelial cells, and express cytokeratin 18: a marker of columnar 
epithelium and not of squamous epithelium (Zhu et al. 1999). For experimental work 
described in this thesis, BEAS-2B cells were maintained in RPMI 1640 with 10% 
FCS, 200 units/ml penicillin/streptomycin and 4mM L-glutamine.
Epithelial cell lines used for in vitro experiments were between passages 4-8 
for MLE-15 cells, and between passages 12-25 for A549, BEAS-2B, HFL-1 and MLF 
cells. The HFL-1 (human foetal lung fibroblast) cell line was used as a PARi- 
expressing positive control in some experiments. MLE-15, A549 and BEAS-2B cells 
were incubated in a humidified atmosphere containing 5% CO2. HFL-1 and MLF 
were maintained in DMEM (Gibco-BRL) with 10% FCS at 37°C in a humidified 
atmosphere containing 1 0 % CO2.
Cells were propagated in 75cm^ or 175cm^ culture flasks. Upon reaching 
visual confluence, the medium was aspirated, and the cell layer washed with 1 0 ml 
PBS. This was then aspirated and trypsin (0.05% w/v)/ EOT A (0.02% w/v) (Gibco- 
BRL) was added (2ml for a 75cm^ flask; or 4ml for a 175cm^ flask). Flasks were 
incubated at 37°C until cell detachment from the tissue culture plasticware was 
observed by inspection using inverted microscopy. Trypsin was then neutralised by 
the addition of 10ml FCS. The cell suspension was aspirated and pelleted by
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centrifugation at 300g for 5 minutes at room temperature. Cells were resuspended in 
fresh medium with the appropriate supplements and FCS. Cell suspensions were then 
either divided 1 in 4 and added to fresh flasks or alternatively adjusted to the 
appropriate seeding density (using a haemocytometer) and plated for experiments. 
Volumes of media in flasks were kept at 20ml in 75cm^ flasks, and 40ml in 175cm^ 
flasks. For experiments, cells were seeded at 2 x 10^  cells/ml in 6 -well plates (2ml per 
well) or 12 well plates (1ml per well), and grown until they reached 90% confluency 
at which point they were washed in PBS and then quiesced for 24 hours in serum-free 
basic medium without supplements prior to their use in experiments.
Primary human type II alveolar epithelial (ATII) cells were isolated from lung 
of grossly normal appearance obtained following resection for lung carcinoma. This 
was undertaken by Dr Andrew Thorley (NHLI, London) with approval of the Royal 
Brompton and Harefield Hospital Ethical Committee. Tissue was perfused with sterile 
0.9% sodium chloride and inflated with trypsin (0.25% in HBSS (HEPES-buffered 
salt solution)), and incubated at 3TC  for 45 minutes; trypsin was replaced twice 
during this time. The tissue was finely chopped in the presence of newborn calf serum 
(NCS). The chopped tissue was then incubated with DNase (250pg/ml) and the 
mixture passed through a 400pm filter, followed by a 40pm filter to remove large 
tissue debris. The cell suspension was then centrifuged at 1300 rpm (290g) for 10 
minutes and the resulting pellet re-suspended in DCCM-1 media containing 50pg/ml 
DNase. The cells were incubated in tissue culture flasks for two hours at 3TC  in a 
humidified incubator to allow differential adherence and removal of contaminating 
mononuclear cells.
After two hours, non-adherent ATII cells were removed by aspirating the 
media and the cell suspension centrifuged at 1300 rpm (290g) for 10 minutes. The cell 
pellet was then re-suspended in DCCM-1 containing 10% NCS and 1% penicillin- 
streptomycin-glutamine (PSG) at a concentration of 1 x 10  ^cells/ml. Cells were then 
seeded at 1 x 10  ^ATII cells per well on plates that had previously been coated with 
300pl of a 1% solution of Vitrogen-100. Cells reached confluence by 48 hours. Even 
spread and distribution of monolayers was confirmed under light microscopy. 
Monolayers were also demonstrated to stain uniformly for alkaline phosphatase 
activity, a marker of an epithelial cell phenotype. Confluent monolayers of ATII cells
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were quiesced for 24 hours in serum-free basic medium without supplements prior to 
their use in experiments.
For experiments involving the PARi antagonist RWJ-58259, and the protein 
kinase C inhibitor Ro-31-8425, these compounds were pre-incubated for 20 minutes 
with cells in fresh medium, and the concentration of DMSO vehicle was standardised 
so that all samples contained the same concentration of DMSO. Subsequently 
thrombin or factor Xa (Calbiochem) or TFLLR-NH2 of the required concentrations 
were added to reach the desired final concentration.
Where factor Xa was used in experiments, it was at a concentration of 25nM 
as it is unlikely that higher concentrations are physiologically relevant within the lung 
in vivo, based on the observations that the plasma concentration of the zymogen factor 
X is only 170nM (Halkier.T 1991), and the amount of factor Xa in BALF of injured 
rat lung has been reported to be only 1.4nM (Chan et al. 2006). The circulating 
concentration of prothrombin is around lOOOnM, but a physiologically relevant 
concentration (in the lung) of thrombin is probably around 10nM-25nM, based on the 
observation of BALF concentrations of around 6 nM in healthy volunteers, and 13nM 
in systemic sclerosis patients (Hemandez-Rodriguez et al. 1995).
2.3.2. In vitro models of lung epithelial cell responses
Results outlined in chapters 2 and 3 of this thesis are those obtained using 
cultured cells, in particular: the transformed murine distal lung epithelial cell line: 
MLE-15, the transformed human lung bronchial epithelial cell line: BEAS-2B, and 
the transformed human lung alveolar epithelial cell line: A549. Primary human lung 
alveolar epithelial cells have also been used where possible.
There are specific and distinct limitations to in vitro experiments using both 
primary cells, and transformed cell lines. Primary cells are more difficult to obtain, 
and tend to have more stringent requirements for maintenance in vitro. When grown 
in vitro, primary type II alveolar epithelial cells have an inherent propensity to lose 
characteristic phenotypic features such as apical microvilli (Diglio & Kikkawa 1977), 
lamellar body inclusions, production of phospholipids (Mason et al. 1977), and 
synthesis of surfactant proteins (Shannon et al. 1992). When grown on tissue culture 
plastic, these cells progressively adopt a type I alveolar epithelial cell-like phenotype 
(Danto et al. 1992),(Rannels et al. 1989), although manipulation of the culture
91
Role o f PARi-dependent secondary mediators in lung fibrosis
conditions can largely prevent this process. For instance, culturing cells on plastic 
coated with laminin and collagen (Olsen et al. 2005), or on a floating collagen gel 
above a fibroblast feeder layer (Rannels et al. 1989) both help maintain morphological 
features of type II alveolar epithelial cells.
The limited availability of such primary cells made it largely impractical to 
attempt a programme of in vitro research using exclusively primary human lung 
epithelial cells. Conversely cell lines are readily available, can be passaged a number 
of times without significant phenotypic change, and tend to have less stringent 
requirements for maintenance in vitro. However they may retain fewer phenotypic 
features of their cell type of origin than primary cells.
All in vitro studies have limitations, whether they involve transformed cell 
lines or primary cells. In such studies, biological responses are being examined out of 
context, in that the normal interactions with neighbouring cells and biological 
mediators, and the precise physiological conditions present in vivo cannot be 
replicated adequately in vitro. Therefore an in vitro experiment at best shows that a 
certain cell type has the potential to respond similarly in vivo to how it does in vitro. 
Nonetheless, experiments using cultured cells play a fundamental and important part 
of characterisation of biological responses and mechanisms of disease.
2.3.3. Assessment of epithelial cell gene expression by {in-house) real-time RT- 
PCR studies
2.3 3.1. RNA isolation
Cells were maintained in 6 -well plates for RNA studies. Cell layers were lysed 
by the addition of 1ml TRIzol (Gibco-BRL) per well, and RNA extracted as per the 
manufacturers instruction. RNA pellets were redissolved in 17pl DEPC H2O (Ambion, 
Cambridge, UK), and this RNA solution was DNase treated with DNA-free (Ambion) 
as per the manufacturers instruction to remove contaminating genomic DNA. Optical 
density of samples was assessed on an Ultrospec 3000 spectrophotometer (Amersham 
Biosciences, Bucks, UK), and the quantity of RNA in each sample derived from the 
absorbance at 260nm. 0.5-Ipg RNA from each sample was then mixed with running 
buffer containing ethidium bromide, and ran on a 1% agarose formaldehyde gel.
92
Role o f PARi-dependent secondary mediators in lung fibrosis
Images of the RNA were captured with a Syngene Gene Genius Bio-imaging system 
(Synoptics, Cambridge, UK). A ratio of approximately 2:1 of intensities of the 288 
(upper band) to the IBS (lower band) confirmed that the RNA was not significantly 
degraded.
2.3.3.2. cDNA synthesis
cDNA was prepared from Ijig of RNA using an RNA PCR Core kit (Applied 
Biosystems, CA, USA), and reactions were performed according to the manufacturer’s 
instructions. Briefly, the following mix was prepared, and incubated at room 
temperature for 10 minutes, 42°C for 15 minutes, 99°C for 5 minutes, then 5°C for 5 
minutes:
4 pi MgCl
2 pi lOx PCR Buffer 
8  pi dNTP mix
1 pi random hexamers
3 pi RNA (equivalent to Ipg)
1 pi RNase Inhibitor
1 pi reverse transcriptase
2.3.3.3. Primer design
The primers were designed using internet based programmes. The Ensembl 
database (http://www.ensembl.org/) was used to locate the genomic and RNA 
accession codes. Spidey (http://www.ncbi.nlm.nih.gov/lEB/Research/Gstell/Spidev/) 
was used to align the genomic and RNA sequences in order to locate intron/exon 
boundaries. Primers were designed to span introns, eliminating the possibility of 
amplifying genomic DNA. The mRNA sequence was copied into the primer- 
designing software, PrimerS (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3 www.cgi). The parameters were set at: product size 85-130 bp; 
primer size 18-22 nucleotides long; primer melting temperature 58°C to 62°C with an 
optimum of 60°C and a maximum temperature difference of 0.5°C; primer GC % was
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40 % to 60 % with an optimum of 50 %; maximum self-complimentarity was set at
6.0 and maximum 3’ self-complimentarity of 2.0 and finally, the maximum poly-X 
was set at 4 to avoid runs of nucleotides. The primers were then selected from the list 
and run in silico using FastPCR software. A BLAST search 
(http://www.ncbi.nlm.nih.gov/BLAST) was also performed to check that the forward 
and reverse primers were specific for the intended sequence. Primers were 
subsequently manufactured by Invitrogen (Paisley, UK). In this thesis, real-time RT- 
PCR was used to assess gene expression of murine and human PARi, CCL2, CTGF 
and TGF-Pi in cultured cells.
2.3.3 4. Real-time RT-PCR
Real time RT-PCR was conducted using the Platinum SYBR Green qPCR 
SuperMix, with Ing of cDNA and forward and reverse primers each at a final 
concentration of 500nM, on a Roche LightCycler 1.5 and analysed using LightCycler 
Real-time PCR Detection System Software Version 3.5 (all from Roche, Sussex, UK). 
Cycling conditions were: 2 min at 50°C (one cycle), 2 min at 95°C (one cycle); then 5 
secs at 95°C, 5 secs at 55°C, and 15 secs at 72°C (45 cycles). In this system the 
measurable fluorescence intensity directly correlates with the amount of PCR product 
formed. The more abundant the product, the earlier (i.e. the lower the cycle number) 
the increase in fluorescence is detected. Whenever a new pair of primers was used for 
the first time, a non-template control PCR reaction involving these primers, but in the 
absence of cDNA, was set up to ensure product was not formed in the absence of 
template cDNA.
2.3.3.S. Optimisation of magnesium concentration for each primer pair
Prior to the use of primers in analysis of mRNA levels in experimental 
samples, their optimal magnesium concentration was established. This was achieved 
by performing a number of RT-PCR reactions in parallel, each with template cDNA 
from a sample known to express the gene targeted by the primers, but with differing 
concentrations of Mg '^  ^ in the SYBR Green PCR supermix. The optimal Mg^^ 
concentration was chosen on the basis that it was the one associated with the steepest 
logarithmic amplification plot, and typically also the lowest cycle number at which
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detectable amplification occurred. This was the concentration subsequently always 
employed for this primer pair. An example of a titration is shown in figure 2.2.
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2.3.3 6. Primer efficiency calculation
The efficiency of each primer pair was assessed by determining crossing points (Cp) 
for RT-PCR reactions with each of a series of half logarithmic dilutions of template 
cDNA. Crossing point (Cp) values were defined as the earliest point of the linear 
region of the logarithmic amplification plot. Log concentrations of samples were 
plotted against crossing point values, and the slope of the plot determined. Efficiency 
was then given by the equation: Efficiency = An example of an assessment
of primer efficiency is given in figure 2.3. Primers which amplified the product with 
absolute efficiency would have an efficiency of 2  (or 1 0 0 %) since the amount of 
product would increase by a factor of 2  during each reaction cycle.
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133.1. Real-time RT-PCR analysis
For each gene, crossing point (Cp) values were determined from the linear 
region of the logarithmic amplification plot and normalised by subtraction of the Cp 
value for 18S (generating a ACp value). The response to stimulation with thrombin, 
Factor Xa, TFLLR-NH2, FTLLR-NH2 or AYPGKF was determined by subtraction of 
the average ACp of the time-point matched control samples from each ACp value for 
stimulated samples (AACp value). All the primer pairs used in real-time RT-PCR 
were found to have an efficiency of approximately 1.8. Therefore in the exponential 
phase of PCR using these primers, the amount of product is increased by a factor of 
1.8 in each cycle. Fold change was thus calculated using the formula 1.8 '^^^^  ^(where 
AACp was converted to an absolute value). The specificity of the products obtained 
by PCR was confirmed by melting curve analysis. A representative melting curve 
analysis demonstrating a single melting point indicative of a single PCR product is 
shown below in figure 2.4.
Figure 2.4. Melting curve an a ly sis  of CTGF PCR products, confirm ing products  
have a sin g le  melting tem perature and th u s represent a sin g le  sp e c ie s .
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2.3.4. Human CCL2 ELISA
The initial optimisation of this ELISA was already established in the 
laboratory by Dr Paul Mercer (Centre for Respiratory Research, UCL). Each well of a 
96 well ELISA plate was coated with 50p,l 2pg/ml MAB679 (RnD systems)^ serving 
as a capture antibody, in bicarbonate coating buffer, left for 5 hours at room 
temperature, and then washed. lOOpl of PBS/1 % BSA was added to each well and the 
plate was left overnight at 4®C. SOjLll of either CCL2 standard (Peprotech) or sample 
was added, and the plate was incubated for 2 hours at room temperature (RT). 
Following washing, 50|xl BAF279 (lOOng/ml) (RnD systems), serving as a 
biotinylated detector antibody, was added to each well, and left for 2 hours at RT. The 
plate was washed, and 50pl of 2pg/ml dilution of streptavidin-HRP (Dako) was added 
for 30 minutes. After washing, 50(xl TMB substrate (BD Pharmingen) was added to 
each well. After 30 minutes, colour development was quenched with 0.19M H 2 SO 4 , 
and absorbances were measured at 450nm.
2.3.5. CTGF western blotting
Medium was aspirated from monolayers of A549 cells which had been 
quiesced for 24 hours in the absence of serum in 6  well plates. 1ml fresh F12K 
medium either with or without 25nM thrombin was added to each well of cells. After 
4 hours, the medium was drained, and the monolayer was washed once with PBS, and 
cells were lysed by adding lOOpl of 8 M Urea. 20^1 of 5x Laemlli buffer (constituents 
as shown below) was also added to the monolayer, which was subsequently frozen at - 
80°C for 24 hours.
5jc  Laemlli Buffer (5ml) stock:
3.125ml IM Tris HCl pH 6 .8  
Ig SOS (Sigma)
2ml 20% glycerol (BDH)
4.375ml H2O
Cell lysates were collected by scraping with a rubber policeman at 4°C. 6 pl of 
2-|3-mercaptoethanol was then added to each sample (to a final concentration of 5%).
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Samples were boiled for lOmin at 96°C, pulse-spun down briefly on a table-top 
centrifuge (10 seconds). Either 30|xl of sample or 5|il of SeeBlue® Plus 2 protein 
ladder (Invitrogen) was then added to each well of a 10-well acrylamide gel.
This gel consisted of a 10% acrylamide separating gel and a 4% stacking gel. 
Their constituents are as shown below. The separating gel was allowed to set in a 
1mm gel cast cassette (Invitrogen). Once set, the stacking gel was poured over the 
separating gel, and a 10-well comb was inserted to form individual wells. This was 
removed once the stacking gel was set.
10ml 10% separating gel:
3.33ml 30% acrylamide (National diagnostics, Hull, UK)
3.75ml IM Tris HCl pH 8 .8  
0.1ml 10% SDS (Sigma)
2.71ml dHzO
0.1ml 10% anunonium persulphate (Sigma)
0.01ml TEMED (Sigma)
5ml 4% stacking gel:
0.65ml acrylamide (National diagnostics)
0.625ml IM Tris HCl pH 6 .8  
0.05ml 10% SDS (Sigma)
3.62ml dHzO
0.05ml 10% ammonium persulphate (Sigma)
0.01ml TEMED (Sigma)
Proteins were separated on the gel, across which a potential difference of lOOV was 
applied, in a XL SureLock™ tank (Novex, San Diego, CA, USA) containing 
Tris/Glycine/SDS running buffer (Invitrogen). Following separation, the gel was 
removed from the cassette and proteins were transferred onto a Hybond-ECL 
nitrocellulose membrane (Amersham) using a horizontal semi-dry transfer method. 8  
pieces of Whatman filter paper (Whatman pic, Maidstone, Kent, U.K.) saturated with 
transfer buffer were placed on the lower electrode of a Multiphor II (Pharmacia LKB, 
Sweden) horizontal semi-dry electroblot module. On top of these was placed the 
nitrocellulose membrane, then the gel, and above this was placed a further 8  pieces of
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saturated Whatman filter paper. Transfer buffer consisted of Tris/Glycine/SDS 
running buffer with 5% methanol (BDH). The top electrode was attached above the 
assembly of filter papers, membrane, and gel, and proteins were transferred using a 
current of 80mA (approximately 1mA per cm^ of gel) for 2 hours. The quality of 
protein transfer was assessed by briefly staining the membrane with 2% Ponceau Red 
solution (Sigma), followed by destaining by quick washing in double distilled water 
and then in PBS containing 0.1% Tween20 (%ma)(PBST).
The membrane was blocked with PBST containing 5% dry non-fat milk for 
120 minutes at RT, which was then discarded. Subsequently, 4ml of a 1:1000 dilution 
of goat anti-human/mouse CTGF antibody (L20: Santa Cruz) in PBST/5% milk was 
added and incubated using an orbital roller for 16 hours at 4°C. The membrane was 
washed three times with PBST, and then a horseradish peroxidase-conjugated rabbit 
anti-goat IgG (Dako) was added at a 1:2000 dilution in PBST/5% milk for 60 minutes 
followed by three washes in PBS-tween. Excess wash solution was drained off, and 
2ml of ECL Plus (Amersham) was spread over the membrane and incubated for 1 
minute. Excess reagent was drained, and the membrane was exposed in a dark room 
to autoradiography film (Kodak), for between 30 secs and 10 minutes, which was then 
developed using an automated Kodak M35A X-Omat Processor (Kodak).
Membranes were also stripped and reprobed with a rabbit anti-human actin 
antibody (Santa Cruz) at a 1:2000 dilution for 2  h at room temperature, followed a 
HRP-conjugated goat anti-rabbit secondary antibody (Dako, 1:2000 dilution) and 
enhanced chemiluminescence with ECL Plus (Amersham) as outlined above to allow 
assessment of equality of protein loading. Stripping was undertaken by immersing the 
membrane in a buffer containing:
100 mM 2-p-mercaptoethanol (Sigma)
2% SDS (Sigma)
62.5 mM Tris-Cl pH 6.7
The membrane was incubated at 50°C for 30 min in stripping buffer and then rinsed 
thoroughly with PBST.
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2.3.6. CTGF protein detection by immunoflourescence
CTGF protein expression was also examined by immunocytofluorescence. 
2x10^ A549 cells in BOOpl F12K/ 10% FCS were seeded in each well of a 8  well Lab- 
tek chamber slide (Nunc), and left to adhere to the slide in a humidified atmosphere 
with 5% C02 at 37°C overnight. Medium was then removed, and replaced with 
serum-free medium for a further 24 hours. This medium was aspirated, and cells were 
then exposed to thrombin (25nM) in 200pl serum-free F12K for 4 hours. Cells were 
washed 3 times in PBS, and then fixed and permeabilised using ice-cold methanol for 
45 seconds, before being washed again in PBS at 4°C.
Fixed cells were incubated with goat anti-human/mouse CTGF antibody (L20, 
Santa Cruz), at a dilution of 1:50 in 200pl PBS at room temperature (RT) for 60 
minutes. Cells were washed 3 times in PBS and then non-specific binding sites were 
blocked by incubation for 5 minutes at RT with normal rabbit serum (Dako) at a 
dilution of 1:20 in 200|il PBS. After a further PBS wash, cells were incubated for 30 
minutes with rabbit anti-goat-FITC conjugated antibody (1:50 in FBS)(Dako) at RT in 
the dark. This medium was aspirated, and the side-walls of the chambers were 
carefully removed. The slide was washed a further 3 times with PBS. Coverslips 
were mounted onto each slide using 3 drops of vectorshield mounting medium 
(Vector Laboratories) containing the 4 ’6-Dimidino-2-phenyindole (DAPI) high 
sensitivity nucleic acid stain. Images were captured using an inverted fluorescence 
microscope (Zeiss Axioskop 2) and photographed using an Olympus C-35DA-2 
camera (Olympus).
2.3.7. Mink lung epithelial cell bioassay for TGF-P
TGF-p in cell culture supernatants was measured using a mink lung epithelial 
cell bioassay. This assay was originally developed by Abe et at (Abe et al. 1994) and 
is based on the ability of TGF-P to specifically induce PAI-1 gene expression in mink 
lung epithelial cells stably transfected with an expression construct containing a 
truncated PAI-1 promoter fused to the firefly luciferase reporter gene. Exposure of 
these cells to TGF-p increases in luciferase activity in cell lysates in a dose-dependent 
manner. Importantly, the promoter fragment is only minimally influenced by other 
known inducers of PAI-1 expression such as bFGF, PDGF-BB, rIL-la, and BGF.
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Hence the assay is highly specific for TGF-P activity. In order to measure total TGF- 
P levels, the latent pool of TGF-p must first be activated by the addition of acid to 
samples, or heating them at 80°C for 10 minutes. The latter method was utilised for 
experiments outlined in this thesis because previous work in the laboratory had shown 
that acidification of samples interfered with the bioassay.
For all experiments, the assay was performed by plating stably transfected 
mink lung epithelial cells (as described above: MLEC) at a density of 1.6 x 10"^  
cells/well in DMEM with 10% FCS in a 96-well tissue culture plate. After allowing 
cells to adhere for 3 hours the media was aspirated and cells were washed in serum- 
free medium. lOOpl recombinant porcine TGF-pi (R&D Systems) standards (0.1- 
Ipg/ml in the same culture medium as the samples) or heat-activated samples (diluted 
by between 4 and 6 -fold so that TGF-p values were within the assay range) were 
added in triplicate to the plated MLEC. The plate was incubated for 14 hours at 37°C 
in a humidified atmosphere containing 5% CO2. Media was then aspirated and the 
cells were washed in PBS, which was also then aspirated. Subsequently lOOpl of 
luciferase reporter gene assay lysis buffer (Roche) was added to each well, and the 
plate agitated for 25 minutes. 20pl of each lysate was then transferred into the 
corresponding well of a 96-well opaque white optiplate (Nunc). The luciferase 
substrate (Promega, Hampshire, UK), was automatically added, and a luminescence 
reading obtained using the Tropix TR717 Microplate Luminometer (Applied 
Biosystems). Actual values for active TGF-P in samples were derived by comparison 
of luminescence readings against those of the standard curve generated in parallel 
using known concentrations of porcine TGF-p 1 .
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2.4. Statistical analysis and expression of data
2.4.1. Statistical methods utilised
All data in figures are presented as mean ± standard error of the mean. 
Statistical comparison was performed between two treatment groups by Student’s t 
test (Microsoft Excel)', and between multiple treatment groups by One-Way ANOVA 
with Student-Newman-Keuls (parametric data) or Dunn’s test (non-parametric data) 
for post-hoc pair-wise multiple comparisons, using Sigmastat software (SYSTAT 
Software Inc, Chicago, IL, USA). Assessment of CCL2 and TGF-|3 release in response 
to thrombin or Factor Xa over a time-course was by analysed by Two-Way ANOVA 
with Student-Newman-Keuls or Dunn’s test for post-hoc pair-wise comparison 
(SigmaStat). A p  value of less than 0.05 was considered significant.
2.4.2. Description of fold changes in pro-inflammatory and pro-fibrotic 
mediators in response to bleomycin in mice
When there were no apparent differences at baseline (saline-instilled) between 
the two mouse genotypes, fold changes in levels of mediators in response to 
bleomycin were expressed relative to a common baseline (i.e. the average of both 
saline-instilled WT and saline-instilled PARf^' mice). Where there were significant 
differences at baseline, fold changes in response to bleomycin were expressed relative 
to levels in saline-treated mice of the same genotype.
2.4.3. Description of in vitro gene expression studies
mRNA levels in response to treatment were expressed relative to their 
respective time-point matched control. Relative mRNA levels (to control) in response 
to thrombin and TFLLR-NH2 on A549 and BEAS-2B cells were combined into single 
graphs and the media controls replaced by a single dotted line for the sake of 
simplicity.
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2.4.4. Description of the effect of inhibitors on mediator mRNA/ protein levels in 
vitro
As mentioned previously, the concentration of DMSO vehicle was 
standardised amongst all samples and controls. A series of concentrations of inhibitor 
were used in parallel. Fold increases of mediator levels in response to stimulus (e.g. 
thrombin) were calculated relative to their respective controls, which each contained 
the same amount of inhibitor and vehicle as stimulated samples. The percentage 
increase in response to stimulus without inhibitor was defined as 1 0 0 %.
Percentage increase with inhibitor present is therefore given by the equation:
(fold increase above control with inhibitor/ fo ld  increase above control without inhibitor) x 100
The percentage inhibition is therefore: 100 - percentage increase.
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3. RESULTS
3.1. The response to bleomycin-induced lung injury in the 
PARi-knockout (PARi ) mouse
3.1.1. Introduction
As has been described previously, levels of coagulation proteinases are 
increased in fibroproliferative lung disorders (Chapman et al. 1986),(Ikeda et al. 
1989), (Kotani et al. 1995),(Ohba et al. 1994),(Bachofen & Weibel 1982),(Dik et al. 
2003),(Peyrol et al. 1990). Thrombin that is generated following extravascular 
activation of coagulation is able to exert potent pro-inflammatory and pro-fibrotic 
effects via the activation of its major cellular receptor PARi. Direct evidence 
supporting an important potential role for PARi in injury responses is provided by 
studies showing that PARi deficiency affords protection from experimentally-induced 
injuries to the kidney (Cunningham et al. 2000), synovium (Yang et al. 2005) and 
brain (Junge et al. 2003) in mice. In this thesis, the biological relevance of PARi to 
injury within the lung was examined. Responses of wild-type (WT) and PARi  ^ mice 
were compared following inflammatory and fibrotic responses initiated by the intra­
tracheal administration of bleomycin. (These experiments were undertaken following 
basic preliminary data obtained with Dr David Howell suggesting PARi deficiency 
conferred a reduction in lung collagen accumulation 14 days following bleomycin- 
induced lung injury. Those results are displayed in Appendix Al).
3.1.2. PARi deficiency affords protection from bleomycin-induced lung 
inflammation
The early response to intra-tracheal administration of bleomycin in mice is 
characterized by a dramatic increase in microvascular leak and inflammatory cell 
recruitment (Thrall & Scalise 1995). The effect of PARi deficiency on these processes 
was examined by assessing lung weight, BALF total cell number and BALE protein 6  
days after bleomycin injury. BALF protein content was taken to represent vascular 
permeability and epithelial/endothelial barrier integrity. (Since lung weight, BALF
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total cell number, and BALF protein were not significantly different in saline-instilled 
PARi  ^ and saline-instilled WT mice, fold increases in response to bleomycin for each 
of these parameters were calculated relative to the average of all the saline-instilled 
mice of both genotypes).
Lung weight was first examined to assess the extent that it increased in 
response to bleomycin in WT and PARi  ^ mice. The basis for this increase in lung 
weight is likely to be cellular infiltration, and congestion with protein and fluid. The 
increase in lung weight 6  days following bleomycin (Figure 3.1.1, Panel A), in lungs 
that had been lavaged, was 41.6 ± 2.9% in WT (p<0.01), but only 18.9 ± 3.6% in 
PARi  ^ mice (p<0.01). (A similar attenuation in lung weight in PARf^' mice 6  days 
following bleomycin was obtained in a separate similar experiment involving non- 
lavaged lungs shown in Appendix A2).
There was no significant difference in BALF total leukocyte numbers between 
both genotypes given intratracheal saline (Figure 3.1.1, Panel B). BALF total 
leucocyte numbers increased by 104.7 ± 17.8% in WT (p<0.05), and there was a non­
significant trend for a 29.8 ± 22.7% increase in PARi  ^ mice. This represents an 
attenuation of the characteristic bleomycin-associated increase in BALF cell number 
in PARi  ^ mice. The relative proportions of leucocyte subsets within BALF were not 
further examined in this thesis, although in previous work by Dr David Howell, they 
were found to be similar in PARi  ^ and WT mice following bleomycin.
There was no difference between BALF total protein levels in WT and PARi  ^
mice given intratracheal saline (Figure 3.1.1, Panel C). Following instillation of 
bleomycin, BALF protein increased by 11.4 ± 0.7 fold in WT (p<0.05), but only by
6.0 ± 1.1 fold in PARi  ^ mice (p<0.05). This represents an attenuation of the 
characteristic bleomycin-associated increase in BALF total protein in PARi  ^ mice.
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Figure 3.1.1: Increases in lung weight, BALF total inflammatory cell number 
and BALF total protein concentration in response to bleomycin are attenuated 
in PARf^* mice.
(A) Total weight of excised lungs, (B) total number o f inflammatory cells in 
BALF, and (C) total protein concentration in BALF obtained 6  days after 
intratracheal instillation o f saline or bleomycin. Data represent the mean ± SEM of 
values obtained in 9-11 mice per group. **p<0.01; *p<0.05 difference between 
bleomycin-treated PARf^' and bleomycin-treated W T mice, ns: no significant 
difference between genotype. t t p < 0  01; tp<0.05 compared with saline-treated 
mice (One W ay ANOVA with Student-Newman-Keuls (A & B) and D unn’s (C) 
post-hoc tests).
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3.1.3. Potential PARi-dependent mediators involved in bleomycin-induced lung 
inflammation.
To begin to examine the mechanism by which PARi-deficiency affords 
protection from acute inflammation in this model, pulmonary levels of CCL2, IL-6 , 
TNF-a, and IL-10 were measured (Figure 3.1.2). CCL2 and IL- 6  are PARi inducible 
pro-inflammatory mediators which are known to be elevated following bleomycin 
administration. TNF-a is a Thi-type cytokine which exerts pro-inflammatory effects 
via triggering local expression of cytokines and chemokines, and which has been 
implicated as an important mediator of bleomycin-induced lung injury (Piguet et al. 
1989),(Ortiz et al. 1998). Conversely, IL-10 is a Th2-type cytokine which has been 
implicated as having an anti-inflammatory and/or anti-fibrotic influence on 
bleomycin-induced lung injury (Kradin et al. 2004),(Arai et al. 2000).
Lung homogenates were prepared from all treatment groups at 6  days, and 
CCL2, IL-6 , TNF-a, and IL-10 levels were measured by ELISA. Since CCL2, IL-6 , 
and IL-10 levels were not significantly different in saline-instilled PARi  ^ and saline- 
instilled WT mice, fold increases in response to bleomycin for each of these 
parameters were calculated relative to the average of all saline-instilled mice of both 
genotypes.
There was no significant difference in lung CCL2 levels after saline 
instillation between PARi  ^ and WT mice (Figure 3.1.2, Panel A). CCL2 levels 
increased in both genotypes in response to bleomycin injury. CCL2 increased by 6.5 ± 
0.4 fold (p<0.05) in WT; and by 4.2 ± 0.9 fold (p<0.05) in PARi  ^ mice, representing 
a significant attenuation in bleomycin-associated CCL2 increase in PARi  ^ mice. In 
contrast, the increases in IL- 6  and IL-10 levels were similar in both bleomycin- 
instilled WT and bleomycin-instilled PARi  ^ mice, compared with saline-treated 
controls (Figure 3.1.2, Panels B and C).
Interestingly, there was significantly more TNF-a in saline-instilled PARi  ^
than saline-instilled WT mice (p<0.05). (Figure 3.1.2, Panel D). In this case, because 
there was a difference in TNF-a levels in saline-instilled mice of each genotype, the 
fold increases in TNF-a were calculated relative to the average of the saline-instilled 
group of the same genotype, and not relative to the average of all saline-instilled mice 
of both genotypes (as with the other fold increases described in these results). In
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response to bleomycin, the increase in TNF-a in WT mice (WT saline to WT 
bleomycin) was 2.0 ±0.1 fold (p<0.05) but was only 1.2 ± 0.1 fold (ns) in PARi  ^
mice (PARi  ^ saline to PARi  ^ bleomycin).
3.1.4. Comparison of early injury and local fîbrin deposition following bleomycin 
in PARi and WT mice
BALF lactate dehydrogenase (LDH) is a useful indicator of lung damage 
(reviewed in (Drent et al. 1996)) since cell damage or death results in release of LDH 
into the extracellular space. To examine whether attenuated responses in PARi  ^ mice 
may result from a difference in the immediate injury caused by bleomycin compared 
to that in WT mice, BALF LDH activity was measured 24 hours following bleomycin 
or saline. LDH activity was increased by a similar amount in each genotype (Figure
3.1.3, panel A), suggesting that attenuated responses in PARi  ^ mice are unlikely to 
be due to differences in the initial lung injury caused by bleomycin.
Fibrin has been shown to exert a pro-fibrotic influence in vitro (Gray et al. 
1995). It accumulates in the alveolar space in response to bleomycin in mice (Olman 
et al. 1996), and is a prominent histological feature of ARDS. In order to examine 
whether fibrin generation might differ between the two genotypes, the extent of fibrin 
deposition was examined in PARi  ^ and WT mice 7 days following bleomcyin or 
saline instillation: a time point around which procoagulant activity has been shown to 
peak in the bleomycin model. (Tani et al. 1991). Very few fibrin fibres were found in 
saline-instilled animals (Figure 3.1.3, Panels B & C). After bleomycin, fibrin fibres, 
visible as fine red strands, were essentially only seen in inflammatory foci associated 
with bleomycin injury. The extent of fibrin deposition within these inflammatory foci 
appeared equivalent for PARi  ^ and WT mice (Figure 3.1.3, Panels D & E). These 
findings suggest that attenuated responses in PARi  ^ mice are independent of fibrin 
formation.
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Figure 3.1.2: PARj' '^ mice have reduced lung levels of CCL2 but not IL-6, IL- 
10, or TNF-a following intratracheal bleomycin.
Figure shows levels of CCL2 (A), IL - 6  (B), IL -10 (C), and TN F-a (D) protein, as 
measured by ELISA, in lung homogenates 6  days after intratracheal saline or 
bleomycin. Data represent the mean ± SEM of values obtained in 8-11 mice per 
group. *p<0.05 difference between PARf^" and WT mice receiving the same 
treatment, ns: no significant difference between genotype. tp<0.05 compared with 
saline-treated mice (One Way ANOVA with Student-Newman-Keuls post-hoc 
tests).
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Figure 3.1.3: Increases in BALF LDH activity and fibrin deposition following 
bleomycin are similar in PARf^’ and WT mice.
A. LDH activity in BALF obtained 24 hours after intratracheal instillation of saline 
or bleomycin. Data represent the mean ± SEM of 5 mice per group, f  p<0.05 
comparison with saline treated mice (One W ay ANOVA with Student-Newman 
Keuls post-hoc tests). (B-E): Representative images (x 400 original magnification) 
of fibrin staining in lung sections from mice treated 7 days previously with saline 
(B & C) or bleomycin (D & E). (F = fibrin fibres).
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3.1.5. PARi deficiency affords protection from bleomycin-induced lung fibrosis
The effect of PARi deficiency on lung weight increase, and lung collagen 
accumulation, as indeces of fibrosis, 14 days after intratracheal instillation of 
bleomycin or saline, was assessed. (Since lung weight and lung collagen were not 
significantly different in saline-instilled PARi  ^ and saline-instilled WT mice, 
percentage increases in response to bleomycin for each of these parameters were 
calculated relative to the average of all saline-instilled mice of both genotypes).
Data for lung weight are shown in Figure 3.1.4. PARi  ^ and WT mice 
demonstrated no significant difference in lung weight following saline instillation 
(Figure 3.1.4, Panel A.). There was a significant increase in lung weight in response 
to bleomycin in WT mice (by 52.8 ± 9.9%; p<0.01), and a trend for a smaller increase 
in response to bleomycin in PARi  ^ mice (29.4 ± 7.0%; ns). There was a also a 
significant difference in lung weight between bleomycin-instilled WT and bleomycin- 
instilled PARi  ^ mice (p<0.05). These data demonstrate an attenuation in the 
characteristic bleomycin-associated increase in lung weight at 14 days in PARi  ^ mice.
PARi  ^ and WT mice demonstrated no significant difference in lung collagen 
following saline instillation (Figure 3.1.4, Panel B). There was a significant increase 
in lung collagen in response to bleomycin in WT mice (by 64.2 ± 10.0%; p<0.01), and 
a trend for a lesser increase in PARi  ^ mice (by 26.8 ± 11.0%; ns). There was a 
reduction in lung collagen accumulation in response to bleomycin by 58.2 ± 17.1% in 
PARi  ^ relative to WT mice. The extent of collagen deposition and distortion of lung 
architecture, as seen histologically, following bleomycin injury was markedly greater 
for WT than for PARi  ^ mice (Figure 3.1.4, Panels C to F).
Figure 3.1.4 (please see overleaf): Lung weight increase and lung collagen accumulation 
is attenuated in PARf mice at 14 days.
(A) Total lung weight of excised lungs from mice 14 days after saline and bleomycin 
instillations. (B) Total lung collagen (in these same animals), as measured by reverse-phase 
HPLC quantitation of lung hydroxyproline in acid hydrolysates of pulverized lung. Data 
represent the mean ± SEM of values obtained in 9-11 mice per group. **p<0.01, *p<0.05 
difference between bleomycin-treated PARi  ^ and bleomycin-treated WT mice, ns: no 
significant difference between genotype. ttp<0.01 compared with saline-treated mice (One 
Way ANOVA with Student-Newman-Keuls post-hoc tests). (C-F): Representative images (x 
40 original magnification) of mice treated previously with saline (C & D) or bleomycin (E & 
F).
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3.1.6. Potential PARi-dependent mediators involved in bleomycin-induced lung 
fibrosis.
To begin to examine the mechanism by which PARi-deficiency affords 
protection from experimental lung fibrosis, the pulmonary levels of two potent PARi- 
inducible pro-fibrotic mediators known to be elevated in this model were assessed.
Initially attempts were made to identify CTGF by western blotting of lung 
homogenates, and then assess relative protein expression by densitometry of specific 
immunoreactive bands. The bands obtained by this method (please see Materials and 
Methods, Figure 2.1), however, were faint and inconsistent between separate 
experiments. Attempts were therefore made to optimise protein extraction by altering 
the salt concentration within the extraction buffer, and altering the methods of 
disrupting tissue using differing freeze-thaw and mechanical homogenisation 
protocols. Unfortunately, immunoreactive CTGF bands of sufficient quality to allow 
quantification were still not reproducibly obtained. Instead, since immunostaining for 
CTGF and TGF-|3i was both specific and reproducible, a method of quantification of 
positive inununostaining, employing image analysis of light microscopy images 
captured by digital camera, was therefore devised as a means of assessment of 
expression of these proteins within the lung (please see Materials and Methods: 
2.2.5.1 & 2.2.S.2 for more detail of this methodology).
Figures 3.1.5 and 3.1.6 show representative immunohistochemical staining 
for CTGF and TGFpi following intratracheal instillation of bleomycin or saline in 
WT and PARi  ^ mice at 14 days. CTGF immunostaining was predominantly localised 
to bronchiolar epithelium in saline-instilled mice (Figure 3.1.5, panels A and B). In 
bleomycin-instilled mice immunostaining was further associated with infiltrating 
macrophages and interstitial spindle-shaped cells (Figure 3.1.5, panels C and D), but 
was less intense for PARf^‘ than for WT mice.
In contrast, TGF-Pi immunostaining was predominantly localised to alveolar 
macrophages, and both bronchiolar and alveolar epithelium in saline-instilled mice 
(Figure 3.1.6, panels A and B). In bleomycin-instilled mice, the intensity of staining 
increased markedly and was associated with the alveolar wall, infiltrating 
macrophages, and extracellular matrix associated with fibrotic foci (Figure 3.1.6, 
panels C and D). Staining intensity was again attenuated in bleomycin-injured PARf 
'' compared with correspondingly injured WT mice.
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Figure 3.1.5: Immunostaining for CTGF is reduced in the lungs of PAR// 
mice. (A-D) Immunostaining for CTGF on representative lung tissue sections from 
PA R // and WT mice 14 days after saline and bleomycin instillations, original 
magnification x 200. (A & B) In saline-instilled mice, positive immunostaining 
(brown) was predominantly localised to bronchiolar epithelium (BE). (C & D) In 
bleomycin-instilled mice, immunostaining was also associated with alveolar 
macrophages (AM), interstitial spindle-shaped cells (F), and adjacent extracellular 
matrix (ECM), but was less intense in PA R // mice. (E) Quantitation of 
immunostaining (semi-quantitative immunohistochemical image-analysis). Data 
represent mean ± SEM of values obtained in at least 4 mice per group. *p<0.05 
difference between PA R // and W T mice following instillation of saline or 
bleomycin, f  p<0.05 difference in bleomycin-instilled compared with saline- 
instilled mice of the same genotype (One W ay ANOVA with Dunn’s post hoc 
tests).
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Figure 3.1.6:
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Figure 3.1.6: Immunostaining for TGF-p^ is reduced in the lungs of PAR,  ^
mice. (A-D) Immunostaining for TGF-P, on representative lung tissue sections 
from PAR, and WT mice 14 days after saline and bleomycin instillations, 
original magnification x 200. (A & B) In saline-treated mice, positive 
immunostaining (brown) was weak and localised to bronchiolar epithelium (BE), 
alveolar macrophages (AM), and alveolar epithelium. (C & D) In bleomycin- 
treated mice, immunostaining increased markedly on the alveolar wall (AW), 
infiltrating macrophages (AM), and extracellular matrix associated with fibrotic 
foci (ECM), but was less intense in PAR,  ^ mice. (E) Quantitation of 
immunostaining (semi-quantitative immunohistochemical image analysis). Data 
represent mean ± SEM of values obtained in at least 4 mice per group. *p<0.05 
difference between PAR,  ^ and WT mice following instillation o f saline or 
bleomycin. fp<0.05 difference in bleomycin-instilled compared with saline- 
instilled mice of the same genotype (One Way ANOVA with Dunn’s post-hoc 
tests).
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Semi-quantitative image-analysis revealed that CTGF and TGF-P i 
immunoreactivity was increased following bleomycin injury in both mouse genotypes 
(p<0.05) (Figure 3.1.5, panel E and Figure 3.1.6, panel E), and further that 
following bleomycin injury, PARi deficiency was associated with marked reductions 
of 63.1 ± 4.2% and 60.4 ± 6.0% in immunoreactivity for CTGF and TGF-Pi (both 
p<0.05) relative to correspondingly instilled WT mice. Of interest, CTGF and TGF-Pi 
immunoreactivity was also lower (both p<0.05) for saline-instilled PARi  ^ compared 
with saline-instilled WT mice.
In order to examine whether differences in immunostaining between WT and 
PARi  ^ were associated with corresponding differences at the mRNA level, CTGF 
and TGF-p 1 mRNA levels were assessed in bleomycin-instilled PARi  ^ and WT mice 
at 7 and 14 days by quantitative real-Time RT-PCR. RNA was extracted using TRIzol 
reagent and sent to Dr Bin Shan of Tulane University, USA, where cDNA synthesis 
and real-time RT-PCR was undertaken. Quantitation of the relative abundance of 
CTGF and TGF-Pi in each sample was undertaken by relating crossing points for 
amplification of CTGF and TGF-pi products with crossing points for amplification of 
the housekeeping gene 36B4 product within each sample (please see Materials and 
Methods: 2.2.6 for more detailed description of the analysis).
Figure 3.1.7 shows that PARi deficiency had no effect on CTGF mRNA 
levels at baseline (saline treatment). At 7 and 14 days, CTGF mRNA levels were 
increased by 3.6 ± 1.1 fold and 3.4 ± 0.7-fold (both p<0.05) for bleomycin-instilled 
WT mice relative to saline-instilled controls. At 7 days following bleomycin 
instillation, PARi deficiency was associated with a marked reduction of 78.8 ± 5.0% 
(p<0.05) in CTGF mRNA levels relative to correspondingly injured WT mice. At 14 
days, there was a trend for a reduction in CTGF mRNA levels of 43.7 ± 11.4% in 
bleomycin-instilled PARi  ^ relative to bleomycin-instilled WT mice, but this failed to 
reach statistical significance.
Figure 3.1.8 shows that TGF-Pi mRNA levels were similar in the two 
genotypes at baseline. At both 7 and 14 days, there was a trend towards an increase in 
TGF-pi mRNA levels in response to bleomycin injury in WT but not in PARi ^mice 
relative to saline-instilled controls, although this failed to reach statistical significance 
(Figure 3.1.8).
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Figure 3.1.7: Pulmonary CTGF mRNA levels induced in response to 
bleomycin are attenuated in PAR) / mice.
Relative abundance of CTGF mRNA, measured by real Time RT-PCR, is 
normalized for the internal control gene 36B4, and expressed in arbitrary units. (A) 
Relative abundance of CTGF mRNA in the lung 7 days after intratracheal saline or 
bleomycin. (B) Relative abundance of CTGF mRNA in the lung 14 days after 
intratracheal saline or bleomycin. Data represent the mean ± SEM of values 
obtained in 8  mice per group. **p<0 .0 1  difference between bleomycin-treated 
PARf^’ and bleomycin-treated WT mice, ns: no significant difference between 
genotype. tp<0.05 compared with saline-treated mice (One Way ANOVA with 
Student-Newman-Keuls post-hoc tests).
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Figure 3.1.8: Pulmonary TGF-pj mRNA levels are unchanged in response to 
bleomycin in both WT and FARj' '^ mice.
Relative abundance of TGF-P^ mRNA, measured by Real Time RT-PCR, is 
normalized for the internal control gene 36B4, and expressed in arbitrary units. (A) 
Relative abundance of TGF-p^ mRNA in the lung 7 days after intratracheal saline 
or bleomycin. (B) Relative abundance of TGF-Pj mRNA in the lung 14 days after 
intratracheal saline or bleomycin. Data represent the mean ± SEM of values 
obtained in 8  mice per group, ns: no significant difference between genotype, ns: 
not significant (One Way ANOVA)
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3.1.7. Summary
PARi deficiency is associated with an attenuation of the inflammatory 
response following bleomycin, as evidenced by diminution of bleomycin- 
induced increases in lung weight and BALF protein levels and leucocyte 
numbers at day 6 .
The attenuated inflammatory response in PARi  ^ mice is associated with 
reduced lung levels of CCL2, but not IL- 6  or IL-10.
BALF LDH increased to an equivalent extent 24 hours after bleomycin 
instillation in WT and PARi  ^ mice, suggesting that the initial injury to 
bleomycin is similar in both genotypes.
Fibrin deposition in inflammatory foci was similar in WT and PARi  ^ mice 7 
days after bleomycin, suggesting that attenuated responses in PARi  ^ mice are 
independent of fibrin formation.
PARi deficiency is associated with an attenuation of the fibrotic response 
following bleomycin, as evidenced by diminution of bleomycin-induced 
increases in lung weight and lung collagen at day 14.
The attenuated fibrotic response in PARi  ^ mice is associated with reduced 
lung CTGF and TGF-pi protein levels and CTGF mRNA levels.
There were no significant increases in TGF-Pi mRNA levels following 
bleomycin in either genotype.
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3.2 The effect of PARi activation on lung epithelial cell 
CCL2 and CTGF expression
In Chapters 3.2 and 3.3, some of the data presented pertains to the effect of PARi 
activation on CCL2, CTGF, and TGF-p i mRNA levels in lung epithelial cells. It 
should be noted that in these experiments, RNA extracted from the same set of 
epithelial cells, exposed to various PARi agonists and/or inhibitors, was utilized in 
separate real-time RT-PCR reactions by using separate specific PCR primer pairs for 
CCL2, CTGF, and TGF-Pi.
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3.2A Effect of PARi activation on lung epithelial CCL2 
expression
3.2A.1. Introduction
Hyperplastic epithelial cells represent a potential source of pro-fibrotic 
mediators in fibroproliferative lung disease (Selman & Pardo 2006),(Kbalil et al. 1991) 
and in the bleomycin model (Azuma et al. 2005a). Since protection from bleomycin- 
induced lung injury and fibrosis in PARi  ^ mice is associated with reduced lung levels 
of the PARi-dependent mediators CCL2, CTGF, and TGF-pi (Chapter 3.1), it 
follows that each of these mediators might be involved in promoting inflammation 
and/or fibrosis following PARi activation in the setting of lung injury. Therefore the 
influence of PARi activation on the expression and release of these mediators by lung 
epithelial cells was investigated.
CCL2 may play an important role in inducing both inflammation and fibrosis 
following bleomycin injury. CCL2 is a potent chemoattractant for inflammatory cells, 
but can also promote fibrosis by upregulating TGF-p i and procollagen gene 
expression in fibroblasts (Gharaee-Kermani et al. 1996), downregulating epithelial 
cell production of the anti-fibrotic PGE2 (Moore et al. 2003), and recruiting collagen- 
synthesising fibrocytes (Moore et al. 2005). Levels of CCL2 in BALF (Goodman et al. 
1996) and serum (Suga et al. 1999) correlate with extent of lung injury and disease 
progression in ARDS and IFF. These observations implicate CCL2 in the 
pathogenesis of fibroproliferative lung disorders.
3.2A.2. Immunolocalisation of PARi in mouse lung following bleomycin injury
PARi is known to be widely expressed by a number of cell types present 
within the lung. PARi immunostaining has previously been shown to increase 
following bleomycin injury in the rat lung (Howell et al. 2001). To investigate 
whether PARi was similarly expressed in mouse lung, and to determine on which cells 
PARi was most obviously immunolocalized to, inununostaining for PARi was
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performed on lung sections from WT mice instilled with either saline or bleomycin at 
7 and 14 days (Figure 3.2A. 1 and 3.2A.2). PARi was predominantly localized to 
bronchiolar epithelial cells, alveolar macrophages, and endothelial cells in saline- 
instilled control mice (Figure 3.2A.1, Panels A & B). Following bleomycin injury, 
the intensity of immunostaining per cell was most obviously increased on type II 
alveolar epithelial and bronchial epithelial cells (Figure 3.2A.1, Panels C & D; and 
Figure 3.2A.2, Panels C & D), but also on alveolar macrophages (Figure 3.2A.1, 
Panel C) and spindle-shaped cells within the fibrotic matrix (Figure 3.2A.1, Panel D).
To further evaluate whether bleomycin-induced lung injury might influence 
local PAR] gene expression, PAR] mRNA levels following bleomycin were 
additionally assessed by real-time RT-PCR in cells recovered from BALF 
(predominantly macrophages) 14 days after bleomycin or saline administration. 
Lavaged cells were pooled from 10 mice instilled with intra tracheal saline, and from 
3 mice instilled with intra tracheal bleomycin. Pools of cells from several mice were 
necessary because of the low number of cells and corresponding low yield of 
extractable RNA from bronchoalveolar lavage of a single mouse. Cell numbers in 
lavages of saline-instilled mice were much lower than in bleomycin-instilled mice. 
This necessitated pooling of lavages from a greater number of saline-instilled than 
bleomycin-instilled mice. Pooling of lavaged cells should also have made mRNA 
levels more representative of the group of mice from which cells were pooled rather 
than of individual mice. Relative abundance of PAR] mRNA was established 
following normalization of the abundance of the PAR] product to that of the 18S 
housekeeping gene product within each pooled sample (please see Materials and 
Methods: 2.3.3.T for more detailed description of this analysis). PAR] mRNA 
levels were 5 .3  times more abundant in bleomycin-treated compared to saline-treated 
mice (Figure 3.2A.1, Panel E). Taken together, these data support the notion that 
lung injury increases local expression of PAR].
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Figure 3.2A.1; PAR, expression is increased in response to bleomycin injury:
Representative lung tissue sections from WT mice 7 days (A & C) and 14 days (B 
& D) after saline and bleomycin instillations, immunostained with anti-SFFL 
(PAR,) antibody (original magnification is x 200). (A & B) Normal lung 
architecture after saline instillation: positive immunostaining is confined to the 
bronchiolar epithelium (BE) with weak positive staining also associated with type 
II alveolar epithelial cells (AE). (C) At seven days after bleomycin injury, the 
intensity of immunostaining associated with bronchiolar and type II alveolar 
epithelial cells increased markedly. Strong immunostaining was also apparent on 
alveolar macrophages (AM) at this time-point. (D) At fourteen days after 
bleomycin injury, immunostaining was again associated with bronchiolar and 
alveolar epithelial epithelium, but also alveolar macrophages and interstitial 
spindle-shaped (fibroblast-like) cells (F). (E) BALF cell PAR, mRNA is increased 
following bleomycin instillation. Figure shows relative PAR, mRNA abundance in 
pools of lavaged cells 14 days after instillation of saline (10 mice) or bleomycin (3 
mice).
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Figure 3.2Æ 2:
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Figure 3.2A.2: PARj localises to epithelial cells in the bleomycin-injured 
murine lung: High Power (x 1000) images o f lung sections from W T mice 
showing positive PAR, im m unolocalising to both bronchial and type II alveolar 
epithelial cells. (A and B) PAR, im munostaining 7 days after instillation o f saline: 
localisation with weak intensity to alveolar and bronchial epithelium. (C and D) 
PAR, im m unostaining 7 days after instillation of bleomycin: localisation with 
strong intensity to alveolar and bronchial epithelium.
3.2A.3. Co-localisation of PARi with CCL2 to lung epithelial cells following 
bleomycin injury
Epithelial cells have been shown to express CCL2 (Antoniades et al. 1992) in 
the IPF lung. In this thesis, CCL2 immunolocalisation was examined in sections of 
mouse lung 6  days following bleomycin. Immunolocalisation of PAR] was also 
performed in parallel in serial sections in order to determine whether CCL2 and PAR] 
co-localised to the same cell types following bleomycin-injury. One might expect that 
PAR] and CCL2 would co-Iocalise to the same cell types if PAR] activation induces 
expression and release of CCL2 from resident lung cells following lung injury.
127
Role o f  PARj-dependent secondary mediators in lung fibrosis
CCL2 immunoreactivity was faint in sections of mice 6  days following saline 
instillation (Figure 3.2A.3, Panel B) After bleomycin injury, the intensity of CCL2 
immunostaining associated with alveolar and bronchial epithelium increased 
markedly. This immunostaining was cell-associated as well as extracellular matrix- 
associated. Furthermore, comparison of serial sections demonstrated that following 
bleomycin injury, prominent immunostaining for both CCL2 and PARi was evident 
on the same cell types, in particular alveolar and bronchial epithelial cells, in adjacent 
areas of lung (Figure 3.2A.3, Panels C & D).
3.2A.4. Confirmation of PARi gene expression by lung epithelial cells in vitro
A  series of in vitro studies were undertaken to pursue the notion that PARi 
activation on lung epithelial cells induces expression and release of CCL2, CTGF and 
TGF-Pi These studies utilised the murine MLE-15 distal lung epithelial cell line, and 
the human A549 alveolar and BEAS-2B bronchial lung epithelial cell lines. In 
addition, I obtained primary human alveolar epithelial cells through collaboration with 
Dr Terry Tetley and Dr Andrew Thorley (NHLI, London) to validate salient findings 
obtained in experiments using cell lines.
In the first instance, in order to confirm that the PARi gene was expressed in 
mouse and human lung epithelial cells, total RNA was extracted from cultured 
monolayers of unstimulated cells, reverse transcribed, and subjected to PCR analysis 
using PARi-specific primers. Primer design and optimisation and PCR cycling 
conditions were all optimised in-house (please see Materials and Methods: 2.3.3 
for more details). Mouse PARi primers amplify a 96bp product corresponding to a 
specific sequence in the mouse PARi gene; and human PARi primers amplify a 148bp 
product corresponding to a a specific sequence within the human PARi gene. Mouse 
lung fibroblasts (MLF) and human foetal lung fibroblast line HFL-1, each known to 
express PARi, were used as positive controls. Figure 3.2A.4 shows that products of 
the expected size were obtained for the MLE-15 mouse distal epithelial cell line, the 
A549 alveolar and BEAS-2B bronchial epithelial cell lines, and for human primary 
alveolar epithelial cells, confirming expression of PARi by these cells at the mRNA 
level in vitro.
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F igure 3.2A .3:
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Figure 3.2A.3: CCL2 immunostaining increases following bleomycin, and is 
co-expressed with PARj on epithelial cells following bleomycin in wild-type 
mice.
Representative serial lung sections from WT mice 6  days after saline and 
bleomycin instillations, stained with anti-SFFL (PAR;) antibody (A & C), or anti- 
CCL2 antibody (B & D), depicting immunostaining for both PAR, and CCL2 on 
bronchial (BE) and alveolar epithelial cells (AE) following bleomycin 
administration. (Original magnification x 200; Sections are 4pm apart).
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Figure 3.2A.4: Confirmation of PARj gene expression in lung epithelial cells
Images show products amplified by RT-PCR of total RNA isolated from cultured 
unstimulated monolayers of the indicated cell types. Products were run on a 2% 
agarose gel. (A) 96bp product amplified by murine PAR, primers in mouse lung 
fibroblasts (MLF) and mouse lung epithelial cells (MLE-15). (B) 148bp product 
amplified by human PAR, primers in human foetal lung fibroblasts (HFL-1), the 
human lung alveolar epithelial cell line: A549, the human lung bronchial epithelial 
cell line: BEAS-2B, and primary human lung alveolar epithelial cells.
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3.2A.5. Effect of thrombin and the PARi agonist peptide TFLLR-NH2 on CCL2 
protein release from lung epithelial cells (A549)
In order to establish whether PARi activation on lung epithelial cells 
influenced CCL2 protein release, CCL2 protein levels were measured in supernatants 
of cultured monolayers of A549 cells exposed to either thrombin, the PARi agonist 
peptide TFLLR-NH2, or the partial-reverse control peptide FTLLR-NH2, by ELISA. 
A time-course study demonstrated that a 6 h incubation with lOnM thrombin was 
optimal in producing the maximal fold increase in CCL2 (3.7 ± 0.2; p<0.01) of any of 
the time-points examined relative to unstimulated cells (Figure 3.2A.5, Panel A). In 
a dose response study, thrombin induced a concentration-dependent increase in 
supernatant CCL2 protein levels with lOnM thrombin producing a 5.8 ± 0.1 fold 
increase after 6  hours (p<0.01) (Figure 3.2A.5, Panel B). TFLLR-NH2 (2 0 0 pM) 
induced a similar 6.3 ± 0.2 fold increase, whereas the FTLLR-NH2 control peptide 
(200|liM) had no effect (Figure 3.2A.5, Panel C). (Further data supporting the trend 
for increased CCL2 protein release following exposure of A549 to thrombin and 
TFLLR-NH2 are shown in Appendix A3).
3.2A.6. Effect of thrombin and the PARi agonist peptide TFLLR-NHi on CCL2 
mRNA levels in lung epithelial cells
In order to investigate whether changes observed in CCL2 at the protein level 
in response to PARi activation were mirrored by changes in CCL2 mRNA levels, 
mouse (MLE-15) and human epithelial cells (A549 and BEAS-2B) were exposed to 
TFLLR-NH2 (200pM) and thrombin (lOnM) over a 12 hour time-course. RNA was 
extracted from cell monolayers with TRIzol reagent, DNAse treated, reverse- 
transcribed, diluted, and then subjected to real-time PCR with specific murine or 
human CCL2 and IBS primers (please see Materials and Methods: 2.3.3 for a 
detailed description of this methodology and its work-up).
Exposure to thrombin and TFLLR-NH2 was associated with maximal 
increases in CCL2 mRNA levels in A549 cells by 4.1 ± 1.1 and 5.1 ± 0.9 fold; and in 
BEAS-2B cells by 20.0 ± 2.0 and 34.2 ± 8.4 fold respectively (all p<0.01) (Figure 
3.2A.6, Panels A and B).
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Figure 3.2A.5: Thrombin and the PARj agonist peptide TFLLR-NH2 promote 
the release of CCL2 from A549 lung epithelial cells. (A) Time course o f CCL2 
released by A549 in response to lOnM thrombin. Data represent mean ± SEM of 4 
replicates. **p<0 . 0 1  post-hoc pairw ise comparison with control medium at the same 
time-point (Two W ay ANOVA with Student-Newman Keuls post-hoc tests). (B) 
Dose response o f throm bin in inducing CCL2 release from A549 at 6  hours. Data 
represent mean ± SEM of 4 replicates *p<0.01, **p<0.05, comparison of CCL2 
levels at each tim e-point with those exposed to control medium alone (One Way 
ANOVA with Student-Newman Keuls post-hoc tests.). (C) Effect o f 200pM 
TFLLR-NH 2  and FTLLR-NH 2  on CCL2 release. Data represent mean ± SEM of 4 
replicates. *p<0.05 com parison with control medium (One Way ANOVA with 
Dunn’s post hoc tests).
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Figure 3.2A.6: The PAR, agonist peptide TFLLR-NHj and thrombin increase 
CCL2 mRNA levels in human and murine lung epithelial cells
Figures show mRNA levels (as determined by real Time RT-PCR) of CCL2, 
normalised to mRNA levels of 18S within each sample, in response to 200pM 
TFLLR-NH2 and/or lOnM thrombin and relative to control medium at each time- 
point. (A) A549 cells, (B) BEAS-2B cells, (C) MLE-15 cells. Data represent mean 
± SEM of 3-4 replicates for each timepoint. *p<0.05, **p<0.01 compared with 
time-point matched control (thrombin) tp<0 05, ttp<0.01 compared with time- 
point matched control (TFLLR-NHj) (Student’s t tests).
133
Role o f  PARrdependent secondary mediators in lung fibrosis
In order to confirm  the specific nature of the PARi agonist peptide TFLLR- 
NH 2  in influencing CCL2 mRNA levels, the effect of the partial reverse peptide 
FTLLR-NH 2  on mRNA levels was exam ined in parallel cultures. In these experiments 
(please see Figure 3.2A.7) similar increases in mRNA levels in response to TFLLR- 
NH 2  were observed as those displayed in figures 3.2A.6. Conversely, the FTLLR- 
NH 2  peptide had no effect on CCL2 mRNA levels in either cell line.
Confirmation o f a similar effect o f the FAR] agonist peptide TFLLR-NH2 was 
also obtained in murine distal lung epithelial cells (MLE-15). In MLE-15 mouse distal 
lung epithelial cells, TFLLR-NH 2  induced a 2.6 ± 0.4 fold (p<0.05) increase in CCL2 
mRNA levels relative to values obtained for cells exposed to control media at the 
same time-point (6h) (Figure 3.2A.6 , Panel C).
3.2A.7. Effect of Factor Xa on CCL2 mRNA levels in lung epithelial cells
Factor Xa has also been shown to be capable o f activating PARi (Riewald et al. 
2001) or PAR 2  (Bono et al. 2000) depending on cell type; and epithelial cells have 
been reported to release inflamm atory mediators following activation of PARi or 
PAR 2  in vitro  (Asokananthan et al. 2002). Therefore the ability o f Factor Xa to 
influence mRNA levels o f CCL2 in A549 cells was examined. For these experiments 
a concentration of 25 nM of factor X a was used as higher doses are unlikely to be 
physiologically relevant. As shown in Figure 3.2A.8, exposure to 25nM factor Xa 
was associated with a non significant trend for a 2.1 ± 0.2 fold increase in CCL2 
mRNA levels (ns: p=0.07). This suggests that factor Xa may be unable to increase 
CCL2 expression in lung epithelial cells. In further support o f this, and in contrast to 
thrombin and TFLLR-NH 2 , factor X a was also later found to have no influence on 
CCL2 protein release from  prim ary human alveolar epithelial cells (please see Figure 
3.2A.13).
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Figure 3.2A.7: Reversal of the first two amino acids of TFLLR-NHj 
completely abrogates its effect on CCL2 mRNA levels in human lung epithelial 
cells
Figures show relative mRNA levels (as determined by Real Time RT-PCR) of 
CCL2, normalised to mRNA levels of 18S within each sample, 1.5 h after exposure 
to control medium, 200pM TFLLR-NH2 or 200pM FTLLR-NH2. (A) A549, (B) 
BEAS-2B. Data represent the mean ± SEM of 6  replicates. *p<0.05 comparison 
with control (One Way ANOVA with Dunn’s post-hoc tests).
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Figure 3.2A.8: Factor Xa has no effect on CCL2 mRNA levels in A549 cells
Figure shows mRNA levels (as determined by Real Time RT-PCR) of CCL2, 
normalised to mRNA levels of 18S within each sample, in response to 25nM Factor 
Xa and relative to control medium at each timepoint. p<0.07 comparison of FXa- 
induced mRNA levels with time-point matched control (Student’s t test)
3.2A.8. Effect of the specific PARi antagonist RWJ-58259 on thrombin-indued 
CCL2 mRNA levels in lung epithelial cells
In order to investigate the necessity of PARi for thrombin-induced increases in 
CCL2 expression, the effect of the specific PARi antagonist RWJ-58259 on CCL2 
mRNA levels, in response to thrombin, was examined. This antagonist has been 
shown to have an IC50 of 0.4|liM for inhibition of thrombin-induced human platelet 
aggregation (Damiano et al. 2003). Notably however, in this setting the antagonist 
was utilised to inhibit a far more rapid PARi response than PARi-dependent CCL2
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expression. Similar, although slightly higher, concentrations were chosen for 
experiments described in this thesis in order to maximize the chances of observing an 
effect. The antagonist was pre-incubated with cells for 20 minutes prior to their 
stimulation with thrombin. In A549 cells, concentrations of 2 and 6 p,M RWJ-58259 
significantly inhibited thrombin-induced CCL2 mRNA levels, whilst there was a trend 
for inhibition with 4pM RWJ-58259, although this just failed to reach statistical 
significance (p=0.06). All concentrations of antagonist significantly inhibited the 
response in BEAS-2B cells (Figure 3.2A.9). 6 |iM RWJ-58259 completely abrogated 
thrombin-induced increases in CCL2 mRNA levels in A549 cells (p<0.05); and 
blocked thrombin-induced increases in CCL2 mRNA levels in BEAS-2B cells by 
63.72 ± 3.50% (p<0.01). (Further data supporting inhibition of thrombin-induced 
CCL2 mRNA levels by RWJ-58259 are shown in Appendix A4).
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Figure 3.2A.9: The selective PARj antagonist RWJ-58259 inhibits thrombin- 
induced CCL2 mRNA levels in lung epithelial cells
Figures show effect of RWJ-58259 on the percentage maximum increase in CCL2 
mRNA levels in response to lOnM thrombin. (A) A549, (B) BEAS-2B. Data 
represent the mean ± SEM of 4 replicates. *p<0.05; **p<0.01 comparison with 
maximal thrombin-induced mRNA levels in the absence of RWJ-58259 (One Way 
ANOVA with Student-Newman Keuls post-hoc tests). Note that RWJ-58259 did 
not affect baseline CCL2 mRNA levels.
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3.2A.9. Effect of the PAR4  agonist peptide AYPGKF on CCL2 mRNA levels in 
lung epithelial cells
Throm bin can activate PA R i, PAR 3 , and PAR 4 , although PAR 3  does not signal 
directly (reviewed in (Vergnolle 2000)). Epithelial cells have been reported to release 
pro-inflammatory m ediators following activation o f PARi, PAR 2 , and PAR 4  
(Asokananthan et al. 2002), although another report in the literature demonstrates that 
PAR 4  is undetectable on A549 epithelial cells (Grishina et al. 2005). Throm bin’s 
major cellular receptor is PAR i; and 10-100 fold higher concentrations o f thrombin 
are required to activate PAR 4  than PARi because o f throm bin’s far lower affinity for 
PAR 4  (O'Brien e ta l. 2001).
Experiments outlined in this thesis show that thrombin increases CCL2 mRNA 
levels (Figure 3.2A.6 ). It was possible that part o f the effect o f thrombin might have 
been mediated by the activation o f PAR 4 . To determine whether PAR 4  activation 
influences CCL2 mRNA levels in epithelial cells, A549 cells were exposed to the 
specific PAR 4  agonist peptide AYPG KF (200pM ), which activates PAR 4  in rat 
(Hollenberg et al. 2004) and hum an cells (Henriksen & Hanks 2002). As shown in 
Figure 3.2A.10, Panel A, CCL2 mRNA levels, as measured by real-time RT-PCR, 
were unaltered in A549 cells in response to this peptide.
Real-tim e RT-PCR was then utilised to examine whether PAR 4  was expressed 
by A549 cells, and if  it was, to assess its abundance relative to PARi. PAR 4  specific 
primers were optim ised using cDNA from HFL-1 fibroblasts, and were found to have 
com parable am plification efficiency as PARi specific primers. Thus it was possible to 
use these primers sim ultaneously on paired aliquots of cDNA to evaluate the relative 
abundance o f PARi and PAR 4 . In H FL -I, PAR 4  mRNA was detectable but was 1411 
times less abundant than PARi (p<0.01; experiment based on 3 replicates of 
unstim ulated HFL-1 cells). In A549 cells however, PAR 4  was undetectable in a 45 
cycle PCR reaction. Products o f the expected size following PCR of HFL-1 and A549 
cDNA were obtained (Figure 3.2A.10, Panel B) confirming specificity o f the primers. 
These data suggest that A549 cells do not express PAR 4  under the culture conditions 
em ployed in this thesis.
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Figure 3.2A.10: The PAR4  agonist peptide AYPGKF does not influence CCL2 
mRNA levels; and PAR4  is not expressed by A549 cells
(A) mRNA levels (as determined by Real Time RT-PCR) of CCL2, normalised to 
18S within each sample, in response to 200pM AYPGKF and relative to control 
medium at each timepoint. Data represent the mean ± SEM of 4 replicates. (B) 
PAR; and PAR4  products amplified by Real-time RT-PCR of total lung RNA from 
unstimulated HFL-1 or A549 cells. PAR, primers amplify a 148bp product. PAR4  
primers amplify a 119bp product.
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3.2A.10. Effect of Pertussis Toxin and Protein Kinase C inhibition on PARi- 
dependent increases in CCL2 mRNA in lung epithelial cells
PAR, signals by coupling to oc,, Oq, a , 2/i3, and pyG-protein subunits. Different 
responses to PAR, activation in distinct cell types are achieved by differential 
coupling to these subunits. To evaluate whether PAR,-dependent increases in CCL2 
expression were dependent on coupling to GoCi, A549 cells were pre-incubated with 
pertussis toxin for 3 hours before they were stimulated with TFLLR-NH2 (2 0 0 (xM). 
Pertussis toxin functions to ribosylate GOi/o subunits, which effectively blocks 
communication of the receptor with GcXi/o-dependent downstream signalling pathways. 
Pertussis had no inhibitory effect on the increase in CCL2 mRNA or protein levels 
observed in response to TFLLR-NH2 (Figure 3.2A.11).
Signalling downstream of receptor coupling to GOq is classically mediated via 
protein kinase C (reviewed in (Macfarlane et al. 2001)). Protein kinase C has been 
implicated as important in promoting the expression of CCL2 in endothelial cells in 
response to a number of stimuli (Okada et al. 1998),(Wang et al. 1995),(Ni et al. 
2003),(Takahara et al. 1996). Therefore to establish whether PAR,-dependent 
increases in CCL2 expression in epithelial cells were dependent on protein kinase C 
and therefore consistent with receptor coupling to GOq, the specific protein kinase C 
inhibitor Ro-318425 was used. Pre-incubation of A549 cells with the protein kinase C 
inhibitor Ro-318425 prior to exposure to TFLLR-NH2 (200pM), was associated with 
inhibition of TFLLR-induced CCL2 mRNA and protein levels in a dose-dependent 
manner (Figure 3.2A.12). lOpM Ro-318425 blocked TFLLR-induced CCL2 mRNA 
levels and protein levels by 110.47 ± 2.65% and 76.6 ±3.1%  respectively (both
p<0 .0 1 ).
These data are consistent with PAR,-mediated CCL2 expression being 
independent of receptor coupling to Go,, but dependent on protein kinase C, and 
potentially downstream of receptor coupling to GoCq. (Further experiments confirming 
similar effects of pertussis toxin and Ro-314825 are shown in Appendix A5).
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Figure 3.2A.11. Expression of CCL2 in response to TFLLR-NH2 is Pertussis- 
insensitive.
(A) Effect of pertussis toxin on the percentage maximum increase in CCL2 mRNA 
levels in response to 200pM TFLLR-NH2. Data represent the mean ± SEM of 6  
replicates. (B) Effect of Pertussis toxin on TFLLR-induced CCL2 protein release into 
culture supernatants, as measured by ELISA. Data represent mean ± SEM of 6  
replicates, ns: not significant, comparison of TFLLR-induced CCL2 release in the 
presence of pertussis to that without pertussis toxin. (Student’s t test). Note that 
pertussis toxin did not affect baseline CCL2 mRNA or protein levels.
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Figure 3.2A.12: TFLLR-induced CCL2 mRNA and protein levels are protein 
kinase C-dependent.
Figure shows the effect of the PKC inhibitor Ro-318425 on the percentage 
maximum increase in CCL2 mRNA (A), and supernatant protein (B) levels in 
response to 200pM TFLLR-NH2. Data represent the mean ± SEM of 4 replicates. 
**p<0.01 comparison with maximal TFLLR-induced CCL2 mRNA or protein 
levels in the absence of Ro-318425 (One Way ANOVA with Student-Newman- 
Keuls post-hoc tests). Note that Ro-318425 did not affect baseline CCL2 mRNA or 
protein levels.
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3.2A.11. Effect of PARi agonists on CCL2 protein release from primary human 
alveolar epithelial cells.
To establish whether PARi activation influenced CCL2 protein release from 
primary human alveolar epithelial cells, cultured monolayers were incubated for 6 h 
with either thrombin (lOnM), Factor Xa (25nM), or TFLLR-NH2 (200pM), and CCL2 
levels measured in the supernatant by ELISA. Figure 3.2A. 13 shows that thrombin 
increased CCL2 protein levels by 16.0 ± 4.0% (p<0.05), whereas TFLLR-NH2 
increased CCL2 protein levels by 18.6 ± 2.9% (p<0.05). Factor Xa did not 
significantly increase CCL2 protein release above the level of that from cells 
incubated with control media alone. (Further data from two separate experiments, 
utilising cells obtained from two separate donors, and showing increased CCL2 
release from primary alveolar epithelial cells in response to thrombin and TFLLR- 
NH2, are presented in Appendix A6 ).
3.2A.12. Quantitation of relative abundance of PARi expression by A549 and 
BEAS-2B cell lines, and by human primary alveolar epithelial cells.
From the previous results, it is interesting to note that the magnitude of PARi- 
mediated response, in terms of the fold increase in CCL2 mRNA levels following 
exposure to thrombin or TFLLR-NH2, was greater in BEAS-2B than in A549 cells. In 
addition, there was a greater relative increase in CCL2 protein release, following 
exposure to thrombin or TFLLR-NH2, in A549 than in primary human epithelial cells. 
To evaluate whether the magnitude of these responses correlated with the amount of 
PAR] expressed on cells of these types, the relative abundance of PAR, mRNA in 
unstimulated cells in culture was compared using quantitative real-time RT-PCR 
(Figure 3.2A.14). PAR, mRNA levels were normalised to IBS mRNA levels within 
each sample, allowing comparison of relative PARi mRNA abundance across 
different cell types. Relative to A549 cells, BEAS-2B expressed approximately 50% 
more PAR] mRNA (p<0.05); and primary human alveolar epithelial cells expressed 
approximately 75% less mRNA PAR] (p<0.01). Thus the magnitude of responses in 
epithelial cells appear to correlate with the abundance of cellular PAR].
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Figure 3.2A.13: Thrombin and the PARj agonist peptide TFLLR-NHj 
promote CCL2 release from human primary lung alveolar epithelial cells.
Supernatant CCL2 protein, as measured by ELISA, 6  hours after exposure of 
primary alveolar epithelial cells to control medium, thrombin (lOnM), Factor Xa 
(25nM), or TFLLR-NH2 (200|iM). Data represent mean ± SFM of 9-10 replicates, 
ns : not significant, *p<0.05 comparison with CCL2 levels for the media control 
group. (One Way ANOVA with Student-Newman-Keuls post-hoc tests).
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Figure 3.2A.14: Relative expression of PARj (as measured by real-time RT- 
PCR) by human lung epithelial cells
Data represent normalised mRNA levels in each cell type relative to those in A549 
cells, and are the mean ± SEM of 3 replicates. **p<0.01, *p<0.05 comparison with 
PARj mRNA levels in A549 cells (One Way ANOVA with Student-Newman- 
Keuls post-hoc tests).
3.2A.13. Influence of conditioned media of epithelial cells exposed to PARi 
agonists on mononuclear cell chemotaxis
CCL2 is a mononuclear cell chemoattractant. A series of experiments was 
therefore performed to examine whether conditioned media of lung epithelial cells 
exposed to PARi agonists infuenced mononuclear cell (THP-1) chemotaxis in 
transwell migration assays. Figure 3.2A.15 shows that in the assays employed.
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recombinant human CCL2 significantly increased mononuclear cell (THP-1) 
chemotaxis, and that this effect could be specifically blocked with anti-human CCL2 
antibodies.
The ability of conditioned media, generated by exposing monolayers of A549 
cells to thrombin, TFLLR-NH2, and FTLLR-NH2, to similarly influence THP-1 
chemotaxis was then assessed. Unfortunately, these experiments produced 
inconsistent results when repeated in terms of trends and magnitudes of chemotactic 
responses. Figure 3.2A.16 shows two separate experiments showing that conditioned 
media generated by exposure of epithelial cells to either thrombin (lOnM) or factor 
Xa (25nM) had no significant effect on mononuclear cell chemotaxis. Figure 3.2A.17 
shows three experiments, one of which suggests conditioned media generated by 
exposure of epithelial cells to TFLLR-NH2 promoted mononuclear cell chemotaxis 
above that obtained utlising the control peptide FTLLR-NH2. However this was not a 
reproducible finding. Furthermore, there was an apparent trend (not significant) for 
both TFLLR-NH2 and FTLLR-NH2 peptides to promote chemotaxis by themselves to 
an equivalent extent. This effect was apparrently independent of CCL2, as evidenced 
by the lack of its inhibition by anti-CCL2 antibodies (Figure 3.2A.18).
Therefore, during the course of this thesis it was unfortunately not possible to 
establish whether CCL2 generated by lung epithelial cells following PARi activation 
was functional. This would be an important area of further work. However time- 
pressures precluded further work-up of the methodology for these experiments during 
the course of this thesis.
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Figure 3.2A.15:
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Figure 3.2A. 15: CCL2 promotes chemotaxis of THP-1 mononuclear cells.
Figure shows the number of THP-1 mononuclear cells (visualised by microscopy 
per high powered field (HPF)) that have migrated through a porous filter towards 
the chemoattractants described on the x axis. Recombinant human CCL2 (lOng/ml) 
induced chemotaxis, and this effect was attenuated by pre-incubation with an anti- 
CCL2 antibody. Data represent the mean of 5 replicates within each group. 
ttp<0.01 relative to F12K control medium and F12K control medium plus 
antibody. **p<0.01 relative to CCL2 in the absence of antibody (One Way ANOVA 
with Student-Newman-Keuls post-hoc tests).
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Figure 3.2A.16:
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Figure 3.2A.16: Supernatants from epithelial cells exposed to thrombin or 
factor Xa do not significantly influence THP-1 migration: (A and B) Figures 
show 2  separate similar experiments comparing the ability of supernatants of 
A549 cells, exposed to either thrombin (lOnM), Factor Xa (25nM) or control 
medium for 6  hours, to influence migration of THP-1 cells. Data represent the 
mean of 5  replicates in each group, ns: no significant difference between groups 
(One Way ANOVA)
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Figure 3.2A.17:
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Figure 3.2A. 17: Supernatants from epithelial cells exposed to TFLLR-NHj 
(200pM) do not reproducibly influence THP-1 migration: (A-C) Figures show 
3 separate similar experiments comparing the ability of supernatants of A549 
cells, exposed to control medium, TFLLR-NH2 (200|iM) or FTLLR-NH2 (200pM) 
to influence migration of THP-1 cells. Data represent the mean of 5 replicates in 
each group, ns: no significant difference between groups, ns: no significant 
difference between groups, **p<0 .0 1  relative to control conditioned medium and 
FTLLR-NH2 (One Way ANOVA with Student-Newman-Keuls post-hoc tests).
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Figure 3.2A.18:
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Figure 3.2A.18: Effect of conditioned media, TFLLR-NH  ^ and FTLLR-NHj 
peptides on THP-1 migration. Figure shows the effect of conditioned media 
(CM), TFLLR-NH2 and FTLLR-NH2, each with and without anti-CCL2 antibody 
(Ipg/ml), on THP-1 migration, (ns: no statistical differences, One Way ANOVA).
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3.2A. 14. Summary
• PAR] expression increases in the injured murine lung, where it localises to a 
number of cell types including epithelial cells. PAR] is also expressed by lung 
epithelial cells in vitro.
• PAR] and CCL2 immunostaining both localise to bronchial and alveolar 
epithelial cells in adjacent areas of the injured murine lung.
• Exposure of cultured lung epithelial cells to thrombin and TFLLR-NH2 
increases CCL2 mRNA and protein expression.
• CCL2 mRNA levels are not significantly affected by exposure to Factor Xa.
• Thrombin-induced CCL2 mRNA levels are inhibited by the specific PAR] 
antagonist RWJ-58259.
• CCL2 mRNA levels are not significantly affected by exposure to the PAR4 
activating peptide AYPGKF; and A549 epithelial cells do not express PAR4 .
• TFLLR-induced CCL2 mRNA and protein expression is attenuated by protein 
kinase C inhibition but insensitive to pertussis toxin.
• The relative abundance of PAR] mRNA in different epithelial cell types 
correlates with the magnitude of increased CCL2 protein/mRNA following 
exposure to PAR] agonists.
• Conditioned media generated by exposure of monolayers of lung epithelial 
cells to PAR] agonists does not reproducibly influence mononuclear cell 
chemotaxis in transwell migration assays.
• Taken together these data suggest that epithelial cells may provide a cellular 
source of CCL2 expression and release following PAR] activation in the 
injured lung.
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3.2B The effect of PARi activation on lung CTGF expression
3.2B.1. Introduction
Elevated tissue levels of CTGF correlate strongly with fibrosis in the 
bleomycin model of lung injury and in patients with fibrotic diseases of the lung 
(Allen et al. 1999),(Pan et al. 2001), and other organs (reviewed in (Moussad & 
Brigstock 2000)). CTGF is constitutively expressed by endothelial cells, myocytes 
and fibroblasts, but has also been shown to be expressed by epithelial cells (Pan et al. 
2001) in the context of lung injury. Following earlier demonstration in this thesis that 
epithelial cells express PAR, in the injured lung, and that epithelial CCL2 expression 
increased following PAR; activation in vitro, experiments were performed to examine 
whether PAR; activation also influences CTGF expression by lung epithelial cells.
3.2B.2. Effect of thrombin on CTGF protein expression in lung epithelial cells.
To examine the effect of thrombin on CTGF protein expression in lung 
epithelial cells, A549 were exposed to either thrombin (25mM) or control media for 4 
hours, and the cell layer was lysed in 8 M Urea. The concentration and duration of 
exposure of thrombin were chosen because previous work by Dr Rachel Chambers 
(Chambers et al. 2000) had previously shown that thrombin increases CTGF protein 
levels in HFL-1 fibroblasts under similar conditions. The technique of lysing cells in 
8 M Urea was employed because it was found to produce a far greater protein yield 
from cell monolayers of epithelial cells than previous attempts using RIPA buffer. 
CTGF protein was demonstrated in protein extracts of the cell layer by western 
blotting. Previous attempts at western blotting using RIPA buffer were never 
associated with any detectable immunoreactive bands in lysates of A549 cells. 
Western blotting using a polyclonal CTGF antibody showed that the intensity of a 
38kDa immunoreactive band was obviously increased in cells exposed to thrombin 
(Figure 3.2B.1, Panel A, and Appendix A7 for a repeat blot). CTGF protein was also 
examined by immunocytofluorescence following a similar duration of thrombin 
exposure using chamber slides (Figure 3.2B.1, Panel B). Immunocytofluorescence 
was similarly increased following exposure to thrombin. These results show that 
thrombin increases CTGF protein in lung epithelial cells.
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F igure 3 .2B .1 :
(A)
MEDIA C O N T R O L  25nM  THROM BIN
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43 kDa p-ACTIN
Figure 3.2B.1: Thrombin increases CTGF production in lung epithelial cells 
(A549). (A) W estern blot o f cell lysates dem onstrating that CTG F protein increases 
after exposure to throm bin (25nM ) for 4 hours. Equal protein loading o f samples 
was confirm ed by equal p-actin im m unoreactivity when the sam e blot was probed 
with an anti-^-actin  antibody follow ing stripping. (B-D) Im m unocytofluorescence 
dem onstrating increased CTG F im m unoreactivity (yellow) on num erous cells after 
4 hours incubation with throm bin (25nM ) (C) com pared to m edia control (B). No 
im m unostaining was seen when a non-im m une polyclonal IgG was substituted for 
the prim ary anti-CTG F antibody (D). nucleii are stained red.
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3.2B.3. Effect of the thrombin and the PARi agonist peptide TFLLR-NH2 on 
CTGF mRNA levels in lung epithelial cells
In order to determine whether changes in CTGF at the protein level were 
mirrored by changes in CTGF at the mRNA level in lung epithelial cells exposed to 
PARi agonists, murine (MLE-15) and human (A549 and BEAS-2B) lung epithelial 
cells were exposed to TFLLR-NH2 (200pM) and thrombin (lOnM). CTGF and 18S 
mRNA levels were measured over a 12 hour time-course by real-time RT-PCR.
Exposure to thrombin and TFLLR-NH2 was associated with maximal 
increases in CTGF mRNA levels in A549 cells by 5.4 ± 0.7 and 5.1 ± 0.5 fold 
(Figure 3.2B.2, Panel A, both p<0.01), and in BEAS-2B cells by 12.1 ± 0.5and 10.0 
± 1.6 fold respectively (Figure 3.2B.2, Panel B, both p<0.01). (Further data 
supporting this trend is shown in Appendix A8 ). In order to confirm the specific 
nature o f the PARi agonist peptide TFLLR-NH2 in influencing mRNA levels, the 
effect o f the partial reverse peptide FTLLR-NH2 on mRNA levels was examined in 
parallel. In these experiments (please see Figure 3.2B.3) similar increases in mRNA 
levels in response to TFLLR-NH2 were seen as those displayed in figures 3.2B.2 
Conversely, the FTLLR-NH2 had no effect on CTGF mRNA levels.
Confirmation o f a similar effect o f the PARi agonist peptide TFLLR-NH2 was 
also obtained in murine distal lung epithelial cells (MLE-15). TFLLR-NH2 induced 
4.1 ± 0.9 fold maximal increase in CTGF mRNA levels (p<0.05) relative to mRNA  
levels in cells exposed to control media at the same time-point (1.5h) (Figure 3.2B.2, 
Panel C).
3.2B.4. Effect of Factor Xa on CTGF mRNA levels in lung epithelial cells
Factor Xa did not significantly affect CCL2 mRNA or protein levels in lung 
epithelial cells. In contrast, figure 3.2B.4 shows that factor Xa (25nM) did 
significantly increase CTGF mRNA levels, but only by 1.9 ± 0.1 fold (p<0.01) in 
A549 lung epithelial cells. This response was of a much smaller magnitude relative to 
control media than that observed with either thrombin or TFLLR-NH2 (Figure 3.2B.2, 
Panel A).
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Figure 3 .2B .2 : (A)
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Figure 3.2B.2: The PARj agonist peptide TFLLR-NH2 and thrombin increase 
CTGF mRNA levels in human and murine lung epithelial cells
Figures show mRNA levels (as determ ined by real Tim e RT-PCR) o f CTGF, 
norm alised to m RNA levels o f 18S within each sample, in response to 200pM  
TFLLR-N H 2 and/or lOnM throm bin and relative to control medium at each time- 
point. (A) A549 cells, (B) BEAS-2B cells, (C) M LE-15 cells. Data represent mean 
± SEM of 3-4 replicates for each tim epoint. *p<0.05, **p<0.01 compared with 
tim e-point m atched control (throm bin) tp< 0-05 , t tp < 0 . 0 1  compared with time- 
point m atched control (TFLLR-N H 2 ) (S tudent’s t tests).
156
Role o f  PARi-dependent secondary mediators in lung fibrosis
Figure 3.2B.3:
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Figure 3.2B.3: Reversal of the first two amino acids of TFLLR-NHj completely 
abrogates its stimulatory effect on CTGF mRNA levels in human lung 
epithelial cells
Figures show relative mRNA levels (as determined by Real Time RT-PCR) of 
CTGF, normalised to mRNA levels of 18S within each sample, 1.5h after exposure 
to control medium, 200pM TFLLR-NH2 or 2 0 0 pM FTLLR-NH2. (A) A549, (B) 
BEAS-2B. Data represent the mean ± SEM of 6  replicates. **p<0.01 comparison 
with control. (One Way ANOVA with Dunn’s post-hoc tests).
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Figure 3.2B.4: Factor Xa exerts a modest effect on CTGF mRNA levels In 
A549 epithelial cells
Figure shows mRNA levels (as determined by Real Time RT-PCR) of CTGF, 
normalised to mRNA levels of 18S within each sample, in response to 25nM Factor 
Xa and relative to control medium at each time-point. *p<0.05 comparison of FXa- 
induced mRNA levels with time-point matched control (Student’s t test)
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3.2B.5. Effect of the specific PARi antagonist RWJ-58259 on thrombin-indued 
CTGF mRNA levels in lung epithelial cells
In order to investigate the necessity of PARi for thrombin-induced increases in 
CTGF mRNA levels, the effect of the specific PARi antagonist RWJ-58259 on CTGF 
mRNA levels, in response thrombin, was examined. RWJ-58259, at concentrations of 
2, 4, and 6 pM, blocked increases of CTGF mRNA in response to lOnM thrombin in 
lung epithelial cells (Figure 3.2B.5) At 6 pM, RWJ-58259 blocked thrombin-induced 
increases in CTGF mRNA by by 74.44 ± 2.78 in A549 cells; and by 65.48 ± 2.68 in 
BEAS-2B cells (both p<0.01). (Further data supporting the inhibition of thrombin- 
induced CTGF mRNA levels are shown in Appendix A9).
3.2B.6 Effect of Pertussis Toxin and Protein Kinase C inhibition on PARi- 
dependent increases in CTGF mRNA in lung epithelial cells
PARi-dependent increases in CCL2 were found to be mediated by pathways 
which are pertussis-insenstitive, but dependent on protein kinase C (please see Figs. 
3.2A.11 and 3.2A.12) To evaluate whether PARi-dependent increases in CTGF 
mRNA might involve similar pathways, the effects of pertussis toxin and the protein 
kinase C inhibitor Ro-31-8425 were examined. Pertussis toxin or Ro-31-8425 were 
preincubated with A549 cells in vitro, before these cells were stimulated with TFLLR- 
NH2 (200pM).
Pertussis had no effect on TFLLR-induced CTGF mRNA levels (Figure 
3.2B.6, Panel A). The protein kinase C inhibitor Ro-318425 inhibited TFLLR- 
induced CTGF mRNA levels in a dose-dependent manner (Figure 3.2B.6, Panel B). 
At lOjiM, Ro-318425 blocked TFLLR-induced CTGF mRNA levels by 67.19 ± 
1.30% (p<0.01). (Further data supporting this effect is shown in Appendix AlO).
These data suggest that PARi-dependent CTGF mRNA expression occurs by a 
pathway that is independent of receptor coupling to Gotj, but dependent on protein 
kinase C, potentially via receptor coupling to GOq.
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Figure 3.2B.5:
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Figure 3.2B.5: The selective PARj antagonist RWJ-58259 inhibits thrombin- 
induced CTGF mRNA levels in lung epithelial cells
Figures show effect of RWJ-58259 on the percentage maximum increase in CTGF 
mRNA levels in response to lOnM thrombin. (A) A549, (B) BEAS-2B. Data 
represent the mean ± SEM of 4 replicates. **p<0.01 comparison with maximal 
thrombin-induced mRNA levels in the absence of RWJ-58259. (One Way ANOVA 
with Student-Newman-Keuls post-hoc tests). Note that RWJ-58259 did not affect 
baseline CTGF mRNA levels.
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Figure 3.2B.6:
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Figure 3.2B.6: Upregulation of CTGF mRNA levels in lung epithelial cells (A549) in 
response to PARj activation is pertussis-insenstive but protein-kinase C- 
dependent
(A) Figure shows the effect of Pertussis Toxin on the percentage maximum increase in
CTGF mRNA levels in response to 200pM TFLLR-NH2. Data represent the mean 
± SEM of 6  replicates, ns : not significant, comparison of TFLLR-induced mRNA 
levels with pertussis with TFLLR-induced mRNA levels without pertussis 
(Student’s t test).
(B) Figure shows effect of the PKC inhibitor Ro-318425 on the percentage maximum
increase in CTGF mRNA levels in response to 200pM TFLLR-NH2. Data 
represent the mean ± SEM of 4 replicates. *p<0.05, **p<0.01 comparison with 
maximal TFLLR-induced mRNA levels in the absence of Ro-318425. (One Way 
ANOVA with Student-Newman-Keuls post-hoc tests).
Note that Ro-31-8425 and Pertussis toxin did not affect baseline CTGF mRNA levels
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3.2B.7. Summary
• Thrombin increases CTGF protein expression by lung epithelial cells in vitro.
•  Exposure of cultured lung epithelial cells to thrombin and TFLLR-NH2 
increases intracellular CTGF mRNA levels. Responses to thrombin are 
inhibited by the specific PARi antagonist RWJ-58259. Responses to TFLLR- 
NH2 are attenuated by protein kinase C inhibition but are insensitive to 
pertussis toxin.
• CTGF mRNA levels are significantly but only modestly increased by exposure 
to Factor Xa.
• Taken together these data suggest that lung epithelial cells may provide a 
cellular source of CTGF expression and release following PARi activation.
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3.3 The effect of PARi activation on lung epithelial cell TGF- 
P expression
3.3.1. Introduction
Lung epithelial cells are a major source of TGF-|3 following lung injury in 
human fibroproliferative lung disease (Kapanci et al. 1995) and the bleomycin model 
(Azuma et al. 2005a); and TGF-pi is widely considered to play a major pro-fibrotic 
role in the development of fibrosis in these settings (Khalil & Greenberg 
1991),(Khalil et al. 1996),(Khalil et al. 1989). Thrombin has previously been shown to 
increase expression and/or release of TGF-p from vascular smooth muscle cells 
(Bachhuber et al. 1997), and kidney mesangial and epithelial cells (Yamabe et al. 
1997),(Tsunoda et al. 2001),(Shirato et al. 2003). The results outlined in this thesis 
thus far demonstrate that PARi activation on lung epithelial cells increases the 
expression of other mediators implicated in lung fibrosis, namely CCL2 and CTGF. 
The aim of this chapter was to evaluate the effect of thrombin and other PARi 
agonists on epithelial cell release and expression of TGF-p.
3.3.2. Optimisation of the Mink Lung Epithelial Cell Bioassay for measuring 
total TGF-P levels
TGF-p in cell culture supernatants was measured using a mink lung epithelial 
cell bioassay. This assay was originally set up by Abe et al (Abe et al. 1994), and 
utilizes the ability of TGF-P to specifically induce PAI-1 expression. Mink lung 
epithelial cells were originally stably transfected with an expression construct 
containing a truncated PAI-1 promoter fused to the firefly luciferase reporter gene. 
Exposure of these cells to TGF-p results in a dose-dependent increase in luciferase 
activity in cell lysates. Importantly, this promoter fragment was shown to be only 
minimally influenced by other known inducers of PAI-1 expression such as bFGF, 
PDGF-BB, rIL -la, and EGF. Hence the assay is highly specific for TGF-p.
Following cellular synthesis, TGF-p is released as the biologically inactive 
latent-TGF-p, which comprises a complex of a latency-associated peptide (LAP) and 
a 25kDa mature TGF-p dimer. TGF-p activity can potentially be controlled at a
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number of levels, such as protein expression and release, sequestration in the 
extracellular matrix and activation. Since this thesis focused on the ability of PARi 
activation to promote expression and release of pro-fibrotic mediators, the effect of 
PAR I on TGF-p activation was not addressed. The mink lung epithelial cell bioassay 
actually measures TGF-P activity. Therefore, in order to measure levels of total TGF- 
p, culture supernatants were spun free of cells and then heated for 10 min at 80°C. 
This process causes dissociation of the LAP from mature TGF-P dimer, thereby 
activating the pool of latent TGF-p.
To ensure that PAR] activators present in cultured supernatants did not 
interfere with the MLEC assay, TGF-p i standard curves were additionally performed 
in the presence of 25nM thrombin and 200pM TFLLR-NH2 and compared with the 
TGF-P 1 standard curve obtained without these additives. Thrombin and TFLLR-NH2 
had no effect on the measurement of TGF-P 1 standards, and hence this assay is not 
affected by their presence in culture supernatants (Figure 3.3.1, Panel A). To confirm 
that the measurable luminescence induced by supernatants of epithelial cells exposed 
to thrombin was ascribable to TGF-p activity, the pan-specific TGF-p antibody ID 11 
(RnD systems) was employed. Pre-incubation of samples for 20min at 37°C with 
lOOpg/ml ID 11 completely blocked thrombin-induced luminescence (Figure 3.3.1, 
Panel B).
3.3.3. Effect of Thrombin and Factor Xa on total TGF-P release from lung 
epithelial cells
In A549 epithelial cells, thrombin and factor Xa increased supernatant total 
TGF-P in a concentration- and time-dependent manner (Figures 3.3.2 and 3.3.3). 
(Further experiments validating these responses are shown in Appendix A l l  and 
Appendix A12. In Appendix A13, two separate experiments are described showing 
that factor Xa and TFLLR-NH2, but not thrombin, increased supernatant total TGF-P 
in primary human alveolar epithelial cells.)
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Figure 3.3.1: Validation of the mink lung epithelial cell bioassay for 
measuring TGF-p activity in supernatants of human epithelial cells 
exposed to PARj activators. (A) Standard curves of porcine TGF-p, in 
DMEM media alone, and in DMEM with added thrombin (25nM) and TFLLR- 
NH2 (200|xM): Measurable TGF-p activity (luminescence) is unaffected by the 
presence of thrombin or TFLLR-NHj. (B) Measurable TGF-p activity in 
response to thrombin (25nM and 50nM) is abrogated by the pan-specific TGF-p 
antibody IDll  (lOOpg/ml).
165
Role o f PARi-dependent secondary mediators in lung fibrosis
Figure 3.3.2:
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Figure 3.3.2: Thrombin increases total TGF-P release into lung epithelial cell 
(A549) culture supernatants. (A) Thrombin dose response on supernatant total 
TGF-P levels. Data represent the mean ± SEM of 3-4 replicates. **p<0.01 relative 
to control (One Way ANOVA with Student-Newman-Keuls post-hoc tests). (B) 
Time course of total TGF-p levels in response to media control or lOnM thrombin. 
Data represent the mean ± SEM of 3-4 replicates. **p<0.01 comparison with 
control medium at the same time-point (Two Way ANOVA with Student-Newman- 
Keuls post-hoc tests). All data were extrapolated from a parallel TGF-p standard 
curve included for each experiment.
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Figure 3.3.3:
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Figure 3.3.3: Factor Xa increases total TGF-p release into lung epithelial cell 
(A549) culture supernatants. (A) Factor Xa dose response on supernatant total 
TGF-p levels. Data represent the mean ± SEM of 3-4 replicates. **p<0.01 relative 
to control (One Way ANOVA with Student-Newman-Keuls post-hoc tests). (B) 
Time course of total TGF-p levels in response to media control or 25nM factor Xa. 
Data represent the mean ± SEM of 3-4 replicates. *p<0.05, **p<0.01 comparison 
with control medium at the same time-point (Two Way ANOVA with Student- 
Newman-Keuls post-hoc tests). All data were extrapolated from a parallel TGF-p 
standard curve included for each experiment.
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3.3.4. Effect of the PARi agonist peptide TFLLR-NH2 on total TGF-P release 
from lung epithelial cells
Different concentrations of both TFLLR-NH2 and FTLLR-NH2 were assessed 
in parallel for their effect on the release of total TGF-p from A549 over an 18h period 
(Figure 3.3.4) This time was chosen as it at the point of maximal increase in 
supernatant total TGF-p in response to thrombin (Figure 3.3.2). Surprisingly, both 
peptides increased supernatant total TGF-P levels. The increases in TGF-p above 
baseline (control media) in response to exposure to 200pM TFLLR-NH2 and FTLLR- 
NH2 were 2.1 ±0.1 fold, and 1.9 ± 0.2 fold (both p<0.05). There was no significant 
difference in the amount of total TGF-p released in response to these peptides overall 
(Two Way ANOVA), or at any of the individual concentrations examined. Thus in 
contrast to its inability to increase CCL2 and CTGF gene expression, in this setting 
the FTLLR-NH2 peptide increased the release of total TGF-p from lung epithelial 
cells. (Further experiments confirming the agonist effect of FTLLR-NH2 on total 
TGF-P release are shown in Appendix A14).
To further investigate whether TFLLR-NH2 exerted its effect on epithelial cell 
release of TGF-P via activation of PARi, experiments were performed with the PARi 
antagonist RWJ-58259. Epithelial cell monolayers were pre-incubated for 20 minutes 
with antagonist prior to exposure to TFLLR-NH2. The increase in total TGF-p release 
from A549 following exposure to TFLLR-NH2 (200pM) was not inhibited by pre­
incubation with doses of up to lOpM of RWJ-58259. In fact, at 5|iM RWJ-58259 
actually caused a small but significant increase in the magnitude of TFLLR-NH2- 
induced total TGF-p protein release relative to control (Figure 3.3.5).
Thus from these data, although it would appear that both thrombin and factor 
Xa are capable of causing the release of total TGF-p from lung epithelial cells (A549), 
there is insufficient evidence to conclude that PARi activation per se is involved. It is 
possible that coagulation proteinases release TGF-p by proteolytic cleavage from the 
pericellular matrix; and this has been shown to be the case with mesenchymal cells by 
Taipale et al (Taipale et al. 1992). In addition it appears that TGF-p release from 
A549 cells may occur non-specifically in response to small peptides, since TFLLR- 
NH2 and FTLLR-NH2 appear to have near equivalent effects. Importantly this may be 
a phenomenon peculiar to epithelial TGF-p release since FTLLR-NH2 has no such
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effect on CCL2 protein release (Figure 3.2A.5, Panel C) or on CCL2 or CTGF 
mRNA levels (Figure 3.2A.7 and Figure 3.2B.3)
Figure 3.3.4:
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Figure 3.3.4: Effect of the PARj agonist peptide TFLLR-NHj and the reverse 
control peptide FTLLR-NHj on supernatant total TGF-p levels. Comparison of 
effect of TFLLR- and FTLLR-associated total TGF-p release at increasing 
concentrations of peptide. Figure shows total TGF-P in supernatant for each peptide 
and concentration. Data represent mean ± SEM of 5 replicates, ns : not significant, 
overall difference between TFLLR-NHg and FTLLR-NH2; tp<0.05 compared with 
media control (Two Way ANOVA with Student-Newman-Keuls post-hoc tests).
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Figure 3.3.5:
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Figure 3.3.5: The selective PARj antagonist RWJ-58259 does not influence 
TFLLR-induced total TGF-P protein release from lung epithelial cells (A549).
Figure shows the effect of increasing concentrations of RWJ-58259 on total TGF-P 
release induced in response to 200|xM TFLLR-NHj. Data represent mean ± SEM of 
4 replicates, ns comparison of TFLLR-induced TGF-P release in the presence of 
RWJ-58259 with TFLLR-induced TGF-P release in the absence of RWJ-58259. t  
p<0.05 compared to TFLLR-NH2 without RWJ-58259 (One Way ANOVA with 
Student-Newman-Keuls post-hoc tests). Note that RWJ-58259 did not affect media 
control supernatant TGF-P levels.
3.3.5. Effect of thrombin and the PARi agonist peptide TFLLR-NH2 on TGF-Pi 
mRNA levels in lung epithelial cells
In order to investigate whether PARi agonists influenced TGF-p 1 gene 
expression, mouse (MLE-15) and human (A549 and BEAS-2B) lung epithelial cells 
were exposed to TFLLR-NH2 (200pM) and thrombin (lOnM). TGF-Pi and 18S 
mRNA levels were assessed over a 12 hour time-course by real-time RT-PCR. 
(Figure 3.3.6, Panel A).
Exposure to thrombin and TFLLR-NH2 was associated with maximal 
increases in TGF-p 1 mRNA levels in A549 cells by only 1.6 ± 0.2 and 1.4 ± 0.1 fold
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(p<0.05) (Figure 3.3.6 Panel A); and no increases at all in BEAS-2B (Figure 3.3.6 
Panel B) or MLE-15 cells (Figure 3.3.6, Panel C). (Further data supporting the 
minimal effect on TGF-pi mRNA levels in A549 is shown in Appendix A15).
In order to confirm the specific nature of the small but significant response 
observed with the PARi agonist peptide TFLLR-NH2 on TGF-Pi mRNA levels in 
A549 cells, the effect of the partial reverse peptide FTLLR-NH2 was examined in 
parallel. In this experiment (please see figure 3.3.7) a similar increase in mRNA 
levels in response to TFLLR-NH2 was seen as that displayed in Figure 3.3.6 Panel A 
but the FTLLR-NH2 peptide had no effect.
3.3.6. Effect of Factor Xa on TGFpi mRNA levels in lung epithelial cells
Exposure of A549 lung epithelial cells to factor Xa had no effect on CCL2 
mRNA levels but promoted a small but significant increase in CTGF mRNA levels. 
Factor Xa caused a dose and time-dependent increase in release of total TGF-p protein 
levels. To examine whether factor Xa influenced TGF-p 1 gene expression in A549, 
these cells were exposed to factor Xa (25nM) for up to 12h, and TGF-p 1 mRNA 
levels measured by real-time RT-PCR. In fact, factor Xa was found to have no 
significant effect on TGF-p 1 mRNA levels (Figure 3.3.8).
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Figure 3.3.6: (A)
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Figure 3.3.6: The PARj agonist peptide TFLLR-NH2  and thrombin have a 
minor effect on TGF-pj mRNA levels in human and murine lung epithelial 
cells.
Figures show mRNA levels (as determined by real Time RT-PCR) of TGF-pj, 
normalised to mRNA levels of 18S within each sample, in response to 200pM  
TFLLR-NH 2 and/or lOnM thrombin and relative to control medium at each time- 
point. (A) A549 cells, (B) BEAS-2B cells, (C) MLE-15 cells. Data represent mean 
± SEM of 3-4 replicates for each timepoint. *p<0.05 compared with time-point 
matched control (thrombin) fp<0.05 compared with time-point matched control 
(TFLLR-NH 2 ) (Student’s t tests).
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Figure 3.3.7:
® 1.2
2
X  0 .4  
0)
CO l.
(D
Control TFLLR FTLLR
Figure 3.3.7: Reversal of the first two amino acids of TFLLR-NHj abrogates 
its minor effect on TGF-Pj mRNA levels in human lung epithelial cells (A549)
Figures show relative mRNA levels (as determined by Real Time RT-PCR) of 
TGF-pi, normalised to mRNA levels of 18S within each sample, 1.5h after 
exposure to control medium, 200|iM TFLLR-NH2 or 200|iM FTLLR-NH2. Data 
represent the mean ± SEM of 6  replicates. **p<0.01 comparison with control. (One 
Way ANOVA with Student-Newman-Keuls post-hoc tests).
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Figure 3.3.8:
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Figure 3.3.8: Factor Xa has no effect on TGF-pj mRNA levels in A549 cells
Figures show mRNA levels (as determined by Real Time RT-PCR) of TGE-pj, 
normalised to mRNA levels of 18S within each sample, in response to 25nM Factor 
Xa and relative to control medium at each timepoint. ns comparison of FXa- 
induced mRNA levels with time-point matched control (Student’s t test)
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3.3.7. Summary
• Thrombin induces a concentration and time-dependent release of total TGF-p 
from cultured lung epithelial cells.
• Factor Xa induces a concentration and time-dependent release of total TGF- 
P from cultured lung epithelial cells.
• Both the TFLLR-NH2 and the FTLLR-NH2 partial-reverse control peptide 
increase release of total TGF-p from lung epithelial cells.
• The PARi antagonist does not inhibit release of total TGF-p induced by 
TFLLR-NH2.
• Thrombin and TFLLR-NH2 induce a small but significant increase in TGF-P 1 
mRNA levels in A549 but not MLE-15 or BEAS-2B lung epithelial cells.
• The FTLLR-NH2 peptide does not affect TGF-P 1 mRNA levels in A549 cells.
• Factor Xa has no effect on TGF-p 1 mRNA levels in A549 cells.
• Taken together these data show that thrombin and factor Xa promote release 
of total TGF-p from cultured monolayers of epithelial cells, but have very 
little effect on TGF-p 1 mRNA expression. There is not sufficient evidence to 
conclude that this effect on TGF-p release occurs via a PAR 1-dependent 
mechanism.
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3.4. Effect of PARi deficiency on lung parenchymal 
architecture
3.4.1. Introduction
The main phenotypic feature that has thus far been ascribed to PARi  ^ mice in 
the literature is a defect in endothelial vascular development which is associated with 
a 50% intraembryonic lethality (Griffin et al. 2001). Nonetheless, the data desribed in 
the first results chapter of this thesis show that PARi  ^ mice fail to upregulate CCL2, 
CTGF, and TGF-Pi expression in the context of bleomycin-induced lung injury. 
These mediators can all play important roles in the regulation of extracellular matrix 
protein deposition and turnover. Thus it was conceivable that chronic deficiency of 
these mediators might be associated with insufficient extracellular matrix protein 
deposition and the development of emphysema. In a similar vein, Bonniaud et al 
previously showed that mice deficient in SMAD3, a pivotal signalling intermediate of 
the TGF-p pathway, developed spontaneous emphysema (Bonniaud et al. 2004).
In this chapter, lung architecture was examined in aged mice to ascertain if 
PARi deficiency was associated with the development of emphysema or other 
structural lung abnormality.
3.4.2. Effect of prolonged PARi deficiency on lung architecture
In order to evaluate whether PARi deficiency has any effect on the structure of 
the lung parenchyma over time, PARi  ^ and WT mice were allowed to age for 2 years. 
Relative to young mice (6 - 8  weeks), a degree of airspace enlargement and 
perivascular inflammatory infiltrates were evident in sections of these lungs (Figure 
3.4.1) However, these changes appeared equivalent for PARf^’ (Panels E-H) and WT 
mice (Panels A-D), suggesting that PARi-deficiency does not in itself accelerate the 
development of emphysema.
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Figure 3.4.1 (please see overleaf): PARi deficiency is not associated with any obvious 
structural lung abnormality in mice with increasing age.
Images (x 40 original magnification) of lung sections from elderly mice of between 20 and 26 
months of age, stained with haematoxylin and eosin. Each picture depicts representative lung 
parenchyma of an individual mouse. (A-D: WT mice; E-G: FARf '^ mice). ASE = airspace 
enlargement. PI = pulmonary infiltrates.
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3.4.3. Summary
PARi deficiency does not predispose to accelerated development of 
emphysema or other structural abnormality in mice with increasing age.
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4. DISCUSSION
4.1 Overview
Excessive local procoagulant activity typifies fibroproliferative disorders of 
the lung. Coagulation proteinases such as thrombin are likely to play a major role in 
the pathogenesis of fibroproliferative lung disorders by the generation of potent pro- 
inflammatory and pro-fibrotic mediators from a number of cell types following 
activation of PARi. The dysfunctional interaction between epithelial cells and 
fibroblasts is increasingly recognised as an important process driving fibrogenesis in 
these conditions. This thesis therefore examined the hypothesis that PAR] activation 
promotes lung injury and fibrosis via the release o f a number o f specific secondary 
mediators; with the pulmonary epithelium representing an important cellular source 
of these mediators.
This thesis reports a number of novel observations. First, PARi-deficient mice 
are protected from bleomycin-induced lung inflammation and fibrosis. Second, this 
protection is associated with reduced lung mRNA and/or protein levels of CCL2, 
CTGF, and TGF-pi. Third, PARi expression is increased in the injured murine lung; 
and one of the sites at which this increased expression is most evident is the lung 
epithelium. Finally, activation of PARi on mouse and human lung epithelial cells in 
vitro promotes the expression of CCL2 and CTGF, but not TGF-pi.
Taken together the studies performed in this thesis support the notion that 
activation of PARi in the injured lung may play an important role in the pathogenesis 
of fibroproliferative lung disorders by inducing local generation of pro-inflammatory 
and fibrotic mediators from lung epithelial cells. The following sections will discuss 
the results of these studies and their implications in detail.
4.2 Effect of PARi deficiency on bleomycin-induced lung 
inflammation
Lung injury induced by intratracheal bleomycin is associated with widespread 
epithelial cell injury via the local generation of free radicals and reactive oxygen
180
Role o f PARi-dependent secondary mediators in lung fibrosis
species. Consequent expression of pro-inflammatory cytokines such as TNF-a, IL-1, 
and IL- 6  by resident lung cells is likely to be important in the initiation of the cellular 
inflammatory response. This may occur as a direct result of cell stress or as a result of 
activation of a number of Toll-like receptors on the surface of these cells. Some Toll 
like receptors, for example Toll-like Receptor 2 have been shown to be directly 
activated by bleomycin (Razonable et al. 2005), while others may be activated by 
reactive oxygen species, proteins released from dead or dying cells, and breakdown 
products of extracellular matrix (reviewed in (Chaudhuii et al. 2005)).
Epithelial/endothelial barrier integrity is compromised by epithelial cell loss 
and results in vascular leak, which is manifest by increased protein content in 
bronchoalveolar lavage. Vascular leak facilitates exposure of circulating coagulation 
proteinase zymogens to tissue factor which is upregulated on a number of resident 
lung cells in both intravascular and extravascular compartments in the injured lung. 
This initiates the coagulation cascade which culminates in the generation of thrombin, 
and subsequently fibrin deposition in the pulmonary interstitium. As mentioned 
previously, thrombin and fibrin are each able to modulate inflammation. Fibrin may 
promote inflammation by serving as an important matrix for the recruitment of 
inflammatory cells and by influencing the release of pro-inflammatory mediators from 
resident cells. Thrombin may promote inflammation by activating its major cellular 
receptor PARi on endothelial cells to promote adhesion and transmigration of 
circulating leucocytes, and generate potent pro-inflammatory mediators from resident 
lung cells.
Importantly, the attenuated responses demonstrated in PARi  ^ mice in this 
thesis are unlikely to be due to a difference in the immediate injury caused by 
bleomycin between the two mouse genotypes, since BALF LDH activity at 24 hours 
was increased to a similar extent in WT and PARi  ^ mice. BALF LDH activity is a 
useful indicator of lung damage (Drent et al. 1996), as it reflects cytoplasmic LDH 
released into the extracellular space from damaged or dead cells. At 24 hours, cell 
injury is likely to be caused by bleomycin-associated free radicals and reactive 
oxygen species, but may also potentially be aggravated by inflammation initiated by 
local cell injury and stress. It is not therefore surprising that the injury and 
inflammation is equivalent in the two genotypes at this early stage as it precedes the 
time-point at which significant generation of thrombin would be expected to exert any 
influence on inflammatory processes via the activation of PARi. Nevertheless this is
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an important control in assessing the effect of PARi on inflammation and fibrosis in 
vivo. The similar response to bleomycin in the two genotypes confirms that bleomycin 
produces the same initial experimental injury in PARi  ^ and WT mice, and that 
attenuation of inflammation and fibrosis in PARi  ^ mice is not attributable to altered 
sensitivity or response to it.
In order to examine specifically the role of PARi on inflammatory processes, 
assessments were made of lung weight, BALF lavage protein content and BALF 
leukocyte numbers on day 6 : a time-point at which thrombin has previously shown to 
be maximal in the bleomycin model (Tani et al. 1997),(Howell et al. 2001). Lung 
weight was expected to increase following bleomycin due to inflammatory cell 
infiltration, alveolar flooding, and interstitial oedema. Increases in lung weight were 
observed for both WT and PARi  ^ mice, but the increase in PARi  ^ was around half 
that in WT mice.
BALF leukocyte numbers were assessed as an index of lung inflammation.
There was a substantial increase in BALF leukocyte number in WT but not in PAR
mice. In a previous comparable pilot experiment performed by Dr David Howell there
was a similar trend for an attenuation in the increase of BALF leukocytes in PAR
mice. In this study, whilst the absolute numbers of leukocytes in response to 
bleomycin were different in the two genotypes, the relative proportions of 
polymorphonuclear leukocytes, lymphocytes, and monocyte/macrophages was 
unaltered. Differential counting of leukocyte subsets was therefore not performed for 
the purposes of the current thesis. Whilst such a reduction in BALF cell number 
clearly supports reduced parenchymal inflammation, it remains possible that BALF 
cell number may be be influenced, in part, by inflammation occurring in the airways 
as well as in the parenchyma. To further validate that changes observed in BALF cell 
number are representative of cellular infiltration of the lung parenchyma, quantitative 
assessment of inflammatory cell number in histological lung sections or in dispase 
digestions of lungs (by fluorescence activated cell sorting (FACS) could be 
undertaken).
There was a substantial increase in BALF protein content in both genotypes. 
However this response was blunted in PARi  ^ mice consistent with reduced vascular 
leak and a lesser degree of compromise of epithelial/endothelial barrier integrity in the 
absence of PARi. Taken together the attenuations in increases in lung weight, BALF
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protein content, and BALF leukocyte number in bleomycin-instilled PARf^' mice, 
demonstrate a reduced inflammatory response in the absence of PARi.
There are a number of potential mechanisms by which PARi may contribute to 
the inflammatory response. Activation of this receptor by either thrombin or 
immediate upstream coagulation proteinases on a variety of cell types from both intra- 
and extra-vascular compartments has been shown in in vitro studies to induce the 
production and release of a host of pro-inflammatory mediators, including amongst 
others IL-lp, IL- 6  and IL- 8  (Naldini et al. 1998),(Johnson et al. 1998),(Ueno et al. 
1996),(Asokananthan et al. 2002). Activation of PARi by thrombin also induces the 
expression of endothelial cell surface adhesion molecules, such as E- and P-selectin 
and intercellular adhesion molecule-1 (ICAM-1) (Sugama et al. 1992),(Shankar et al. 
1994) in vitro. In terms of influencing BALF protein levels, both thrombin and PARi 
peptide agonists have been shown to increase vascular permeability by both direct and 
nitric oxide-dependent effects on endothelial cells (reviewed in (Siflinger-Bimboim & 
Johnson 2003)), and via the release of histamine from mast cells (Cirino et al. 1996). 
Potential effects of PARi activation previously described in the literature are also 
described in depth in Introduction 1.4.1. Cellular effects of PARi activation. 
Importantly, the necessity for PARi in mediating inflammatory responses in vivo was 
further confirmed in experiments where thrombin-induced increases in pulmonary 
microvascular permeability were shown to be abrogated in isolated lung preparations 
obtained from PARi  ^ mice (Vogel et al. 2000).
To begin to delineate the potential mechanism by which PARi  ^ mice were 
protected from bleomycin-induced lung inflammation, measurements were made of 
the pulmonary levels of two PARi inducible mediators CCL2 and IL-6 . CCL2 is a 
potent chemoattractant for mononuclear cells, and tissue levels correlate closely with 
infiltration of mononuclear cells in a host of human inflammatory conditions. IL- 6  
promotes leukocytosis and differentiation of B and T lymphocytes, and macrophages 
(reviewed in (Naka et al. 2002)). It also stimulates the acute phase response after 
tissue injury (Castell et al. 1988). This functions to limit the growth of any infective 
organisms, to remove harmful molecules, and to activate the repair processes to return 
organs to normal function. Both CCL2 and IL- 6  have been implicated in the 
inflammatory response to bleomycin (Smith et al. 1995),(Smith et al. 1998). IL- 6  
levels were found to be increased to the same extent in response to bleomycin injury
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in both mouse genotypes, suggesting that the upregulation of this cytokine occurs via 
a PARi-independent pathway in this model, and further that the protective response 
observed in PARi  ^ mice cannot be explained by an attenuated IL- 6  response. These 
findings for IL- 6  levels are further in agreement with a recent study in a mouse model 
of sepsis, where deficiency of PARi or PARi alone had the same effect on IL- 6  
expression following endotoxic insult as observed for WT mice. However, when 
PARi deficiency was combined with hirudin, thus additionally blocking signalling 
through PARi and PAR4, IL- 6  levels were reduced relative to those in WT mice, 
suggesting that multiple PARs may be responsible for the regulation of this pro- 
inflammatory mediator in model of sepsis (Pawlinski et al. 2004), and possibly other 
models.
In contrast to IL-6 , CCL2 levels were significantly reduced in bleomycin 
instilled PARf^ rnice compared with correspondingly injured WT mice in this study. 
In terms of the functional significance of this observation, anti-CCL2 antibodies have 
been shown to reduce leukocyte accumulation following bleomycin-induced lung 
injury (Smith et al. 1995), suggesting that this chemokine plays an important role in 
the inflammatory response to bleomycin. Although multiple PARs may mediate the 
cross-talk between coagulation and inflanunation in certain disease settings, findings 
from this study suggest that PARi plays a critical role in such cross-talk in this injury 
model.
It was initially postulated that the relative abundance of Thi-type and Th2-type 
cytokines might reveal evidence of a difference in Thi/Th2 cytokine profiles between 
PARi  ^ and WT mice. Thus the Thi and Th2-type cytokines: TNF-a and IL-10 levels 
in lung homogenates were measured.
TNF-a is a cytokine associated with Thi responses, and exerts pro- 
inflammatory effects via triggering local expression of cytokines and chemokines via 
NF-kB and AP I-dependent pathways (reviewed in (Varfolomeev & Ashkenazi 
2004)). TNF-a levels are increased in response to lung injury in the bleomycin model 
(Piguet et al. 1989),(Ortiz et al. 1998),(Gurujeyalakshmi et al. 2000),(Cavarra et al. 
2004). A pro-inflammatory role for TNF-a is suggested by the observation that 
overexpression of TNF-a under the control of a SPC promoter in vivo is associated 
with chronic inflammation (Fujita et al. 2003), and anti-TNF-a antibodies reduce 
bleomycin-induced alveolitis (Piguet et al. 1989). However it seems that TNF-a may
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be able to both promote and inhibit fibrosis. TNF-a promotes proliferation of 
fibroblasts in vitro (Sugarman et al. 1985), and anti-TNF-a antibodies inhibit 
bleomycin-induced lung fibrosis (Piguet et al. 1989). Conversely, TNF-a is able to 
inhibit TGF-p-induced CTGF expression and collagen synthesis by fibroblasts in vitro 
(Abraham et al. 2000), whilst TNF-a overexpression protects against murine 
experimental lung fibrosis (Fujita et al. 2003). Interestingly, work by Oikonomou et al 
(Oikonomou et al. 2006) suggests that the presence of TNF as a soluble form 
following bleomycin lung injury is a prerequisite to the development of fibrosis. TNF 
normally exists as both transmembrane and soluble forms, each of which is 
functionally active. TNF is originally produced as a 26 kDa transmembrane molecule, 
which must be cleaved by TNF-a converting enzyme (TACE) to release the soluble 
17 kDa TNF-a. Transgenic mice expressing only the transmembrane form of TNF-a 
are protected from bleomycin-induced lung fibrosis, but co-administration of 
aerosolized recombinant soluble TNF-a with bleomycin in these mice leads to 
pulmonary fibrosis. In the present study, given the observation that there was a 
significant increase in lung TNF-a levels in response to bleomycin in WT but not in 
PARi  ^ mice, it is tempting to speculate a pro-inflanunatory and pro-fibrotic role for 
TNF-a following PARi activation, although it is unfortunately not possible to 
determine whether changes in TNF-a following bleomycin in either genotype reflect 
changes in transmembrane or soluble fractions because TNF-a was measured in 
homogenates of whole lung.
IL-10 is thought to inhibit pulmonary inflammation in response to bleomycin, 
since IL-10-deficient mice have a higher density of inflammatory cells in the 
pulmonary interstitium and BALF, but no difference in the degree of fibrosis 
compared to WT (Kradin et al. 2004). Given that PARi activation is able to promote 
IL-10 production in human peripheral blood mononuclear cells (Naldini et al. 2003), 
it was initially hypothesised IL-10 levels would be reduced in PARi  ^ mice deficiency. 
In fact, levels of IL-10 were similar constitutively in both genotypes, and were 
increased by a similar amount in both genotypes following bleomycin. Thus the 
protective response observed in PARi  ^ mice appears to be independent of IL-10. It is 
possible that PARi activation does not induce production of IL-10 on murine lung 
cells as it does on human peripheral blood mononuclear cells. On a technical note, the 
measurable IL-10 in lung homogenates was very low; in fact slightly below the
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sensitivity range for the ELISA, and it is possible, then, that real differences were 
missed for this reason.
4.3 Effect of PARi deficiency on bleomycin-induced lung 
fîbrosis
In addition to the observation that PARi  ^ mice were protected from 
bleomycin-induced inflammation, a further major finding of this thesis was that 
PARi  ^ mice were also protected from bleomycin-induced fibrosis. Assessment of the 
fibrotic response at day 14 revealed that total lung collagen accumulation was 
attenuated by about 60% in PARi  ^ mice instilled with bleomycin compared with 
correspondingly injured WT mice. PARi  ^ mice also exhibited an attenuation in the 
increase in lung weight and their lung architecture was visibly less disrupted by 
fibrotic tissue on histological examination. The observed reduction in bleomycin- 
induced CCL2 levels in PARi  ^ mice described in this thesis may further be relevant 
to the reduced lung collagen accumulation in these mice. In addition to influencing 
inflammatory cell recruitment, there is accumulating evidence that CCL2 may 
influence the development of fibrosis. For example, CCL2 induces TGF-pi and 
procollagen gene expression in fibroblasts in vitro (Gharaee-Kermani et al. 1996), 
downregulates alveolar epithelial cell production of the anti-fibrotic prostanoid PGE2 
in vitro (Moore et al. 2003), and acts as a chemoattractant for collagen-synthesising 
fibrocytes in vivo (Moore et al. 2005). However, the most compelling evidence for 
the biological relevance of CCL2 in promoting fibrosis was provided by studies in 
which mice lacking the CC chemokine receptor CCR2 (the major CCL2 receptor) 
have been shown to be protected from bleomycin and fluorescein isothiocyanate 
(FrrC)-induced pulmonary fibrosis (Gharaee-Kermani et al. 2003),(Moore et al. 
2001). Of note, the reduction in lung collagen accumulation observed in CCR2- 
deficient mice appeared to occur without significant attenuation of the preceding 
inflammatory response. Moreover, studies employing anti-CCL2 gene therapy 
administered at early and late phases of the bleomycin response confirms that this 
chemokine plays an important role during the chronic fibrotic phase (Inoshima et al.
2004). In addition, given that a Th2 cytokine profile is associated with fibrosis, it is 
tempting to speculate that a further possible mechanism by which CCL2 could
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potentially promote fibrosis is by shifting the Thi/Th2 cytokine balance in favour of a 
Th] profile. Evidence to support the plausibility of CCL2 in promoting such a shift 
comes from studies by Karpus et al, in which CCL2 was shown to promote the 
differentiation of naïve T cells to a Thz phenotype in vitro (Karpus et al. 1997), and 
from studies by Gu L et at, in which CCL2  ^ mice on a Balb/c background were 
unable to mount the Th2 response to Leishmania major typical of Balb/c mice (Gu et 
al. 2 0 0 0 ).
The expression of two other PARi-inducible pro-fibrotic mediators, TGF-pi 
and CTGF, was examined in PARi  ^ mice relative to WT mice. TGF-Pi and CTGF 
immunoreactivity was significantly reduced in bleomycin-instilled PARi  ^ mice 
relative to bleomycin-instilled WT mice. Immunoreactivity in these studies reflects 
both positive staining from resident lung cells, as well as from locally activated cells, 
and recruited inflammatory cells. However, a difference in immunoreactivity between 
lungs of bleomycin-treated WT and PARi  ^ mice was apparent for both the 
interstitium and the alveolar wall, independently of whether there was evidence of 
increased cell number or matrix accumulation. This suggests that there may be a 
difference in local upregulation of CTGF and TGF-pi between the two mouse 
genotypes. Corresponding changes at the mRNA level for CTGF further support this 
notion, although additional studies (e.g. in situ hybridisation) might be useful to 
validate the observation, particularly in the case of TGF-p.
The changes in inununoreactivity were also preceded by a significant 
reduction in CTGF mRNA levels on day 7. This observation is in agreement with a 
previous report that direct thrombin inhibition attenuates bleomycin-induced lung 
collagen accumulation and CTGF mRNA levels (Howell et al. 2001) and further 
suggests an important role for thrombin as a major PAR] activator in this model. In 
contrast, although TGFpi protein expression in the injured lung was reduced by over 
half in bleomycin-instilled PAR]  ^ mice compared with correspondingly injured WT 
mice at day 14, there was no detectable change in TGFpi mRNA expression at 7 or 14 
days. Although not a universal finding, this lack of an effect at the mRNA level has 
previously been reported by others. For example, Kaminski et al were unable to detect 
increases in TGF-P i, -P2 and -P3 mRNA in this model, even though the signature gene 
expression profile associated with increased TGF-Pi signaling was clearly evident 
(Kaminski et al. 2000).
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The observation that PARi deficiency is associated with reduced TGF-pi 
immunoreactivity in response to bleomycin injury is particularly of interest given the 
compelling evidence that TGF-p is a major pro-fibrotic mediator in this model (Khalil 
et al. 1989), as well as in patients with fibrotic lung disease (Khalil et al. 1991),(Khalil 
et al. 1996), and suggests that this may represent an important pathway by which 
PARi activation contributes to the fibrotic phase in this model. It is important to point 
out that PARi is also associated with reduced immunoreactivity for CTGF and TGF- 
Pi in saline control mice. Thus it is possible that PARi activation also influences 
levels of these growth factors in the normal uninjured lung, although in this study 
there was no evidence of any structural differences within the lung parenchyma of 
uninjured aged PARi  ^ relative to WT mice.
It is likely that the differences in TGF-p i and CTGF immunostaining between 
WT and PARi  ^ mice are due to PARi activation only increasing expression of these 
proteins in WT mice. Nevertheless, there may be additional or alternative reasons for 
these differences in immunostaining. Firstly, these growth factors could bind to a 
relatively more abundant extracellular matrix in WT mice. In addition to inducing 
procollagen expression (Chambers et al. 1998), PARi activation also increases 
production of proteoglycans (Cizmeci-Smith & Carey 1997) and fibronectin 
(Armstrong et al. 1996). Active TGF-Pi can bind directly to proteoglycans, fibrillin, 
fibronectin and type IV collagen (Taipale et al. 1992), although the majority of 
matrix-associated TGF-pi is in the latent form localized to this site via binding of 
LTBP to the matrix (Taipale et al. 1994). CTGF also readily localizes to the 
extracellular matrix (Kireeva et al. 1997) via its ability to bind to heparan sulphate 
proteoglycans (Gao & Brigstock 2003). It is possible then that a difference in the 
extent of CTGF and TGF-pi localization to the extracellular matrix between the two 
genotypes contributes to the differences in immunostaining observed. Secondly, 
whilst there is good evidence that PARi activation on a number of cell types 
influences the production of pro-fibrotic mediators, it is not possible to rule out the 
possibility that protection from bleomycin-induced fibrosis in PARi  ^ mice results, at 
least in part, from an attenuated early inflammatory response in this model, although 
there is now increasing evidence that inflammation is in fact not an essential precursor 
or requirement for fibrogenesis (Huaux et al. 1998),(Munger et al. 1999),(Adamson et 
al. 1988).
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4.4 Effect of PARi deficiency on fibrin formation
Importantly, assessment of the extent of fibrin deposited at day 6 , which 
corresponds temporally with maximal thrombin generation following bleomycin 
administration (Tani et al. 1997),(Howell et al. 2001), revealed apparently similar 
increases for both genotypes suggesting that these attenuated responses were not due 
to differences in fibrin formation between the two mouse genotypes. In addition, it 
strongly supports the notion that the observed differences in inflammatory and fibrotic 
responses are due to coagulation proteinases such as thrombin activating PARi rather 
than promoting coagulation. Hence whilst fibrin has the potential to influence 
inflammation by promoting the release of pro-inflammatory mediators and serving as 
a provisional matrix on which inflammatory cells can adhere, these effects may not be 
relevant to the difference in inflammatory response observed between PARi  ^ and WT 
mice.
In addition to modulating inflammation, fibrin has also been implicated in 
promoting fibrosis in vivo. In support of the hypothesis that fibrin may contribute to 
the progression of fibrosis, experimental strategies that would be expected to favour 
fibrin clearance, such as deletion of the PAI-1 gene (Hattori et al. 2000) or 
overexpression of uPA (Sisson et al. 1999), have been associated with an attenuation 
in fibrosis following bleomycin instillation. However, it has recently become 
apparent that such experimental manipulation of the plasminogen system may exert 
antifibrotic effects by increasing local levels of the anti-fibrotic mediator hepatocyte 
growth factor (HGF), rather than reducing fibrin deposition (Hattori et al. 2004). In 
addition, since fibrinogen knockout mice are not protected from bleomycin-induced 
lung fibrosis (Hattori et al. 2000),(Ploplis et al. 2000) there is not insufficient 
evidence to conclude that fibrin exerts a direct pro-fibrotic influence in vivo. In the 
present study, the similar extent of fibrin deposition in both WT and PARi  ^ mice on 
day 6  is consistent with fibrin not being relevant to the attenuated fibrotic response in 
PARi  ^ mice.
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4.5 PARi expression is increased in response to lung injury
PARi immunostaining was markedly increased in wild-type mice in response 
to bleomycin injury, and this was most apparent on epithelial cells and macrophages, 
although abundant spindle shaped fibroblast-like cells also stained prominently for 
PAR] in fibrotic foci. In our laboratory increased PARi mRNA levels following 
bleomycin injury have also been demonstrated in homogenates of rat lung by northern 
blotting (Dr David Howell PhD thesis 2003) and in homogenates of mouse lung by 
real-time RT-PCR (personal communication and unpublished data. Dr Chris J Scotton, 
Centre for Respiratory Research UCL,). In support of injury-dependent local 
upregulation of PARi expression, real-time RT-PCR in the current study 
demonstrated around a 5-fold increase in PARi mRNA in lavaged cells, which were 
predominantly macrophages, 14 days after bleomycin. However it is of course 
possible that this reflects a change in the relative proportions of PARi-expressing 
inflammatory cells rather than increased PARi expression per se. In order to confirm 
that the increased PARi immunostaining on injured lung epithelial cells was 
attributable to increased gene expression, in-situ hydridisation studies would be useful. 
Alternatively, laser capture microdissection could be employed to isolate epithelial 
cells for real-time RT-PCR from uninjured and injured lung.
There are a number of potential mechanisms by which PARi expression may 
be elevated in the injured lung. Expression of this receptor is modulated by a variety 
of mediators and stimuli relevant to tissue injury. PARi expression has been shown to 
be increased in response to thrombin in endothelial cells (Ellis et al. 1999), to TGF-pi 
in vascular smooth muscle cells (Schini-Kerth et al. 1997), and to IL-ip, TNF-a and 
TGF-p 1 in skeletal muscle (Mbebi et al. 2001). Furthermore, monocyte differentiation 
has been shown to correlate with increased PARi expression in vitro (Naldini et al. 
1998). Importantly, activation of PARi by thrombin induces fibroblast to 
myofibroblast differentiation (Bogatkevich et al. 2001) and PARi expression by these 
cells has also been shown to be increased in vitro and in vivo (D'Andrea et al. 2001).
Experiments in this thesis strongly suggest that PARi expression increases in 
the injured lung. It is plausible that such increased PARi expression is important in 
the exaggerated production of PARi-dependent mediators following lung injury.
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Whether this is indeed the case, and the precise mechanisms by which PARi 
expression is regulated are important questions to address in further work.
4.6 Effect of lung epithelial cell PARi activation on CCL2 
and CTGF expression
FAR] activation in the injured lung is likely to influence inflammation and 
fibrosis by a number of mechanisms which involve a range of different cell types and 
secondary mediators. Since protection in PARi-deficient mice is associated with 
reduced lung levels of CCL2, CTGF, and TGF-pi, it follows that these PARi- 
dependent mediators may promote inflammation and/or fibrosis following PARi 
activation in the injured lung.
In light of the prominent PARi immunostaining on epithelial cells in the 
injured murine lung and the growing body of evidence implicating epithelial cells as 
being an important source of inflammatory and fibrotic mediators, the effect of PARi 
activation on production of the secondary mediators CCL2, CTGF, and TGF-pi by 
lung epithelial cells was examined. In this thesis, an attempt was made to 
comprehensively evaluate the effect of PARi activation on generation of the described 
secondary mediators from lung epithelial cells in vitro. Possible in vivo experiments to 
support the results of these in vitro studies are outlined in a later section: 4.10 
Further work.
In the first instance, real-time RT-PCR was employed to assess whether the 
lung epithelial cells used for in vitro experiments express PARi under the culture 
conditions in which the experiments were planned. Mouse lung fibroblasts and human 
foetal lung fibroblasts were used as positive controls as they are known to express 
PARi and be responsive to PARi activation from previous studies performed at the 
Centre for Respiratory Research (Chambers et al. 1998),(Chambers et al. 2000). In 
this study, all lung epithelial cell lines examined (MLE-15, A549, BEAS-2B) and 
primary human lung alveolar epithelial cells were found to express PARi in vitro.
Both A549 and primary alveolar epithelial cells produce CCL2 constitutively 
as has been described previously (Pechkovsky et al. 2005). Thrombin and the PARi 
agonist peptide TFLLR-NH2 significantly increased CCL2 protein release from both
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A549 and primary human lung alveolar epithelial cells, although the relative increase 
in CCL2 protein release over baseline was lower in primary cells. Taken together with 
the observation that both PARi and CCL2 immunostaining localise to epithelial cells 
in adjacent areas of injured lung, this strongly suggests that lung epithelial cells may 
be a biologically relevant potential source of CCL2 following PARi activation in vivo.
It is possible that the reduced magnitude of PARi response in primary cells is 
attributable to a lower expression of PARi relative to A549 (figure 3.2A.14). 
However these primary cells may be more representative of alveolar epithelial cells in 
uninjured lung. Given the observation that epithelial PARi immunostaining increases 
in response to lung injury, it is tempting to speculate that hyperplastic alveolar 
epithelial cells in situ in fibroproliferative lung diseases reflect injured and/or 
activated cells and similarly express more PARi, and consequently exhibit PARi- 
dependent responses of a greater magnitude. In support of this notion, the injury 
related factors IL-lp, TNF-a and TGF-Pi have previously been shown to increase 
PARi expression on myotubes, which then also display a marked increase in the 
calcium signal obtained in response to thrombin (Mbebi et al. 2001).
In vitro experiments in this thesis also validate lung epithelial cells as a 
potential source of CTGF following PARi activation. Thrombin increased CTGF 
protein production in A549 cells as demonstrated by western blotting and 
immunocytofluorescence studies. Interestingly, in initial attempts at western blotting 
of A549 epithelial cell lysates, CTGF was not detected in a cell layer lysed with RIPA 
buffer or in the culture supernatant. However, it was detected using western blotting 
when the cell layer and matrix were lysed in 8 M Urea. This is consistent with CTGF 
being tightly (covalently) associated with the pericellular matrix following secretion, 
and not released in substantial amounts into the cell culture supernatant. Of additional 
interest was the observation from immunocytofluorescence studies that CTGF only 
appeared to be associated with a subpopulation of cells following their exposure to 
thrombin. Distinct subpopluations of A459 cells in culture have been described 
previously (Croce et al. 1999), and it is possible that different subpopulations express 
differing amounts of various proteins, including CTGF. Alternatively it is possible 
that only cells which are in a certain phase of the cell cycle express CTGF. Consistent 
with this notion, a previous study has shown that type II alveolar epithelial cells which 
appeared to be proliferating were immunoreactive for CTGF in IPF lung sections (Pan 
et al. 2001). Finally it is possible that this observation could be explained by a
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processing artefact whereby pericellular matrix-associated CTGF is lost from the 
vicinity o f a proportion o f the cells stained, although the propensity for CTGF to 
tightly associate with pericellular matrix components suggests this is less likely.
Real-time RT-PCR studies showed that expression at the mRNA level of 
CCL2 and CTGF in response to PARi agonists was closely mirrored at the protein 
level. Exposure o f human and mouse epithelial cells to thrombin or TFLLR-NH2  
promoted significant increases in CCL2 and CTGF mRNA levels. The smaller 
increases in CCL2 and CTGF mRNA levels in response to TFLLR-NH2 in mouse 
than in human lung epithelial cells is interesting. Given that the magnitude of certain 
cellular responses in human epithelial cells correlated with relative PARi expression 
(please see fig 3.2A.14), it is possible that a reduced response in mouse epithelial 
cells is attributable to reduced PARi expression compared to human lung epithelial 
cells in vitro. Alternatively, the small magnitude of response in murine cells to the 
human TFLLR-NH2 PARi agonist peptide could be explained by a species difference. 
Whilst TFLLR-NH2 has been shown to activate PARi on murine cells (Fang et al. 
2003), its amino acid sequence is closer to the human SFLLR than to the mouse 
SFFLR tethered ligand sequence. Hence it is possible that it is therefore less effective 
at activating murine PARi. Alternatively differences in response in MLE-15 cells 
might relate to the culture conditions and supplements in which they are maintained. 
In order to retain their type II alveolar epithelial phenotype, MLE-15 cells are cultured 
in a medium (HITES) supplemented with a number o f hormones and growth factors. 
Although these cells were quiesced in a serum- and supplement-free medium for 24 
hours before exposure to TFLLR-NH2 , a number of the supplements previously in the 
culture medium up until that point have been shown to influence expression o f a 
variety o f genes including CCL2 and CTGF. Supplements possibly relevant in this 
regard are glucocorticoids (Natori et al. 1997),(Matsuda et al. 2005),(Rageh et al. 
2001), insulin (Mamounas et al. 1991), albumin and transferrin (Wang et al. 1997), 
and estradiol (Xie et al. 2002). It is possible then that these supplements interfered 
with the regulation o f CCL2 and CTGF by PARi.
The difference in the magnitude o f the response obtained for A549 and BEAS- 
2B is interesting. As alluded to previously, it is possible that a greater increase in 
CCL2 and CTGF mRNA levels in BEAS-2B cells might be related to the high 
expression levels of PAR] (figure 3.2A.14) in these cells compared with A549 cells.
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The potential of airway epithelial cells to produce pro-inflammatory and pro-fibrotic 
mediators in vitro is also worthy of note. These observations are consistent with the 
notion that these cell types may represent a source of pro-inflammatory and pro- 
fibrotic mediators, in addition to hyperplastic type II alveolar epithelial cells, in 
fibroproliferative lung disorders.
Factor Xa is able to activate PARi (Riewald et al. 2001) as well as PAR2 
(Bono et al. 2000) depending on cell type and co-factor expression. However, in 
contrast to thrombin. Factor Xa did not significantly influence CCL2 mRNA levels in 
A549 cells, and increased CTGF mRNA levels by less than half that observed in 
response to thrombin. This may reflect functional selectivity of PARi, whereby 
different receptor agonists are coupled to distinct intracellular signalling pathways and 
subsequently mediate different cellular responses following PAR cleavage (Riewald 
& Ruf 2005),(McLaughlin et al. 2005b). Alternatively, it is possible that this reflects a 
lower affinity of factor Xa than thrombin for PARi. Higher concentrations of factor 
Xa than the 25nM used in this thesis are probably not physiologically relevant in vivo, 
since the plasma concentration of the zymogen factor X is around 170nM (Halkier.T 
1991), and the amount of factor Xa in BALF of injured rat lung has been reported to 
be in the region of 1.4nM (Chan et al. 2006). Coversely, slightly higher concentrations 
of thrombin than FXa may be physiologically relevant in vivo. The circulating 
concentration of prothrombin is around lOOOnM, but a physiologically relevant 
concentration (in the lung) of thrombin is probably around 10nM-25nM, based on the 
observation of BALF concentrations of around 6 nM in healthy volunteers, and 13nM 
in systemic sclerosis patients (Hemandez-Rodriguez et al. 1995). In addition, factor 
Xa by itself has been shown to have a lower affinity for PARi than when present as a 
complex associated with tissue factor and factor Vila (Riewald et al. 2001). Thus it is 
possible that factor Xa is less biologically important than thrombin in the generation 
of PARi-dependent mediators described in this thesis.
In order to determine whether thrombin’s influence on CCL2 and CTGF 
mRNA levels was via PARi, the specific PARi antagonist RWJ-58259 was utilized. 
This is a small indole-based compound which specifically inhibits the tethered ligand 
of PARi binding to the second extracellular loop, and thus inhibits receptor activation. 
RWJ-58259 inhibited PARi responses when used at concentrations between 2 and 
6 |iM. Other investigators have used similar concentrations and found the I C 5 0  of
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RW J-58259 to be in the jiM range (Damiano et al. 2003),(Andrade-Gordon et al. 
2001). Thrombin-induced CCL2 mRNA levels were totally abrogated in A549 cells, 
and were substantially attenuated in BEAS-2B cells. Similarly thrombin-induced 
CTGF mRNA levels were substantially attenuated in A549 and BEAS-2B cells. The 
reduced inhibitory effect o f the antagonist on responses in BEAS-2B cells is 
interesting and may have several explanations. First, it is possible that thrombin 
additionally influences CCL2 and CTGF mRNA via other receptors in these cells. 
These could include other PARs or the so-called non-proteolytically activated 
receptor (n-PAR). This hypothetical receptor is presumed to be mediate cellular 
effects of thrombin that are independent o f proteolysis (Jenkins et al. 1995). In order 
to address this possibility, the effect o f proteolytic inhibitors on abrogating the effect 
o f thrombin on CCL2 and CTGF mRNA levels in BEAS-2B cells would be a useful 
further experiment. Second, it is possible that cleaved PARi is able to transactivate 
PAR 2  in these cells, as has been demonstrated in endothelial cells (O'Brien et al.
2000). As RW J-58259 blocks the interaction o f the tethered ligand to the second 
extracellular loop of the PARi receptor, it would not prevent PAR 2  transactivation. 
However, the substantial attenuation o f thrombin-induced CCL2 and CTGF mRNA 
levels in A549 and BEAS-2B cells with RW J-58259 suggests that thrombin is acting 
largely, if  not wholly, via PARi in these cells. Nevertheless, two useful further 
experiments would be to assess: i) whether a higher concentration o f RWJ-58259 
completely abrogated these responses, and ii) the effect of the PAR 2  agonist SLIGRL 
on CCL2 and CTGF mRNA levels.
In addition to being able to activate PARi, thrombin can activate PAR 3  and 
PAR4 , although PAR] has not been shown to signal directly. However, the AYPGKF 
peptide, which activates PAR 4  on human platelets, was found to have no influence on 
CCL2 mRNA levels in A549 cells. In addition real-time RT-PCR demonstrated that 
PAR4  mRNA was not expressed by these cells. This is in agreement with previous 
work by Grishina et al showing PAR 4  to be absent on A549 cells (Grishina et al.
2005), although contrasts with work by Asokananthan et at, which showed PAR 4  to 
be present (Asokananthan et al. 2002). Taken together the data obtained in 
experiments from the current thesis show that thrombin-induced CCL2 and CTGF 
expression in lung epithelial cells is PARi-dependent and PAR 4 -independent.
Increases in CCL2 mRNA and protein levels in response to TFLLR-NH 2  were 
unaffected by pertussis toxin but attenuated in a concentration-dependent manner by
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the protein kinase C inhibitor Ro-31-8425. Hence these responses are pertussis- 
independent but protein-kinase C dependent. Of note, it is possible that following 
PARi activation, CCL2 protein release is regulated by a pathway which is, in part, 
protein kinase C-independent. In support of this notion, in response to TFLLR-NH2 
and an equivalent concentration of Ro-31-8425, CCL2 protein release was inhibited to 
a lesser extent than CCL2 mRNA levels.
CTGF mRNA levels were similarly unaffected by pertussis toxin, but inhibited 
in a dose-dependent manner by Ro-31-8425, consistent with CTGF also being 
expressed in response to PARi activation via a protein kinase C-dependent pathway. 
Interestingly, the extent of inhibition of TFLLR-induced CTGF mRNA levels by Ro- 
31-8425 was less than that of TFLLR-induced CCL2 levels. This suggests that PARi- 
induced CTGF expression could be additionally mediated by other non protein-kinase 
C pathways and possibly also downstream of coupling to other G-protein subunits. It 
is tempting to speculate a role for a Gai 2/13-dependent pathway since one of its 
putative downstream mediators Rho A has been shown to be essential for 
upregulation of CTGF expression by 5HT, lypophosphatidic acid (LPA) and TGF-Pi 
in mesangial cells (Hahn et al. 2000), and simvastatin in fibroblasts (Eberlein et al.
2001). Moreover overexpression of constitutively active Rho A induces CTGF 
expression in fibroblasts (Ott et al. 2003).
Taken together these data are consistent with PARi activation promoting 
epithelial CCL2 and CTGF expression, at least in part, via coupling to GoCq. Further 
studies would clearly be needed to confirm this, and delineate the precise signalling 
pathways involved, although this would have been beyond the scope of this thesis. 
Further studies would also be useful to establish whether CCL2 or CTGF expressed in 
lung epithelial cells possesses any biological functional activity. Unfortunately, results 
of experiments examining whether CCL2, derived form epithelial cells following 
PARi activation, possessed biological functional activity were inconsistent. Therefore 
it is not possible to conclude whether or not CCL2 derived in this way possesses 
biological functional activity. In the first instance, future studies could be directed 
toward further optimisation of monouclear cell chemotaxis assays in order to establish 
whether epithelial cell-derived CCL2 promotes mononuclear cell chemotaxis. 
Alternatively, similar assays could be designed to examine whether epithelial-derived
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CCL2 promotes chemotaxis of fibrocytes, or downregulates production of PGE2 by 
other alveolar epithelial cells.
4.7 Effect of PARi activation on lung epithelial cells on TGF- 
P expression and release
To investigate whether PAR] activation influences TGF-p release from lung 
epithelial cells, A549 were exposed to thrombin and factor Xa. Both these proteinases 
increased the release of total TGF-p into the cell culture supernatant in a 
concentration and time-dependent manner. There was a large increase in the amount 
of total TGF-P in culture supernatants at concentrations of lOOnM of thrombin 
compared with 10, 25, and 50nM, which were equally efficacious in their ability to 
influence TGF-p release. The distinct effect at this high dose could a consequence 
thrombin being toxic to cells, promoting cell necrosis and/or apoptosis. Both 
mechanical cell damage (Howat et al. 2002) and apoptosis (Hodge et al. 2002) have 
previously been shown to increase TGF-p release from lung epithelial cells. Whilst 
cell toxicity was not obviously apparent from visual inspection of cell monolayers by 
light microscopy in the current study, assessment of supernatant LDH levels would be 
a useful further experiment to investigate this possibility.
The PARi agonist peptide TFLLR-NH2 also increased supernatant total TGF-p 
levels. 200pM TFLLR-NH2 increased total TGF-P release by around two-fold. 
However a similar nearly two-fold increase was also obtained with the partial reverse 
control peptide FTLLR-NH2 . The effect of TFLLR-NH2 was not significantly 
different from that of FTLLR-NH2 overall or at any dose examined. In contrast the 
FTLLR-NH2 peptide did not display such an agonist effect in terms of influencing 
CCL2 and CTGF mRNA levels, or CCL2 protein levels. Hence this is consistent with 
TFLLR-NH2 and FTLLR-NH2 influencing TGF-P release from epithelial cells via a 
PARi-independent mechanism. Possible mechanisms of this TGF-p release could be 
in response to these peptides activating an alternative cellular receptor other than 
PARi, or as a non-specific response to exposure to small peptides. The observation 
that it was not possible to antagonize TFLLR-induced TGF-p release with
197
Role o f  PARi-dependent secondary mediators in lung fibrosis
concentrations of PAR] antagonist up to lOpM further led to the conclusion that 
TFLLR-NH2 was not acting via PARi in this setting.
In light of the above findings with regard to the TFLLR-NH2 peptide, it is 
likely that the influence of thrombin and factor Xa on TGF-p release are also 
independent of PAR] activation, although assessment of whether these responses 
failed to be attenuated by the PARi antagonist would clearly be required to validate 
this. It is possible that the effects of these proteinases occur via proteolytic cleavage 
and release of TGF-p from the pericellular matrix, but such a proteolytic effect would 
obviously not explain the release of TGF-p in response to TFLLR-NH2 and FTLLR- 
NH2. Such a proteolytic effect has been previously demonstrated in cultured 
mesenchymal cells in response to plasmin and thrombin (Taipale et al. 1992). In these 
studies these proteinases caused a decrease of matrix-associated TGF-p with a 
concurrent increase TGF-P in the supernatant. However for thrombin, this effect was 
not readily apparent with thrombin concentrations below 5units/ml (around 125nM), 
which is much higher than the concentration used in the experiments performed 
during this thesis. In view of insufficient evidence to conclude that thrombin/ factor 
Xa and TFLLR-induced TGF-p protein release was PARi mediated, the mechanism 
of TGF-p release from lung epithelial cells in vitro was not pursued further in 
experiments of this thesis.
Real-time RT-PCR experiments were performed to establish whether PAR] 
activation influenced TGF-p 1 mRNA levels in lung epithelial cells. There was a small 
significant increase in TGF-p 1 mRNA levels in response to thrombin and TFLLR- 
NH2 in A549 cells, but not in other cell types examined. The biological significance 
of this small -1.5 fold increase is debatable. The observation that in contrast to CTGF, 
TGF-P 1 mRNA levels were not found to be differentially increased at day 7 in PARi  ^
mice further supports the notion that PARi activation does not significantly influence 
TGF-P 1 at the transcriptional level.
Release of supernatant TGF-p in response to thrombin is unlikely to be 
dependent on TGF-P 1 expression, since cellular mRNA levels are not substantially 
affected by thrombin. It would, in theory, be possible for thrombin to increase TGF-P 
expression and release by an effect on translation but not transcription. In order to 
determine whether thrombin-induced TGF-P release is independent of TGF-P
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expression, experimental approaches using actinomycin-D, cyclohexidine, and 
brefeldin-A would be useful. Actinomycin-D: an inhibitor of transcription, and 
cycloheximide: an inhibitor of protein synthesis, could be used to investigate whether 
the response is dependent on TGF-p transcription and de novo TGF-P protein 
production. Brefeldin A, an inhibitor of protein transport and exocytosis could be used 
to investigate whether thrombin-induced TGF-P release was via a mechanism 
involving exocytosis of pre formed TGF-P stored within from intracellular storage 
vesicles.
TGF-P bioactivity is regulated on a number of levels including transcription, 
translation, storage and release, localization, and activation. It is conceivable that 
PARi could promote TGF-p activation. This latter possibility was not specifically 
addressed in the experiments outlined in this thesis, although interestingly, during the 
course of experiments performed in this thesis, PARi activation has been shown to 
induce expression of the latent TGF-p activator thrombospondin-1 in endothelial cells 
(McLaughlin et al. 2005a), and to promote TGF-P activation in lung epithelial cells 
via a ttvpô integrin-dependent mechanism (Jenkins et al. 2006). However, the in vivo 
experiments of this thesis demonstrated a reduction in total TGF-pi inununostaining 
in PARi  ^ mice. Possible explanations for this are reduced specific extracellular 
matrix components to which TGF-pi can bind in PARi  ^ mice, or that PARi activation 
may increase TGF-p i expression/release in resident lung cells other than epithelial 
cells. Alternatively, PARi activation may indirectly increase lung epithelial cell TGF- 
P expression/release by a mechanism dependent on the expression of other mediators.
4.8 Characterization of lung parenchymal architecture in 
PARi mice
The results oulined in this thesis demonstrate that PARi  ^ mice are protected 
from bleomycin-induced lung inflammation and fibrosis. Other published reports have 
shown that PARi  ^ mice are also protected from experimentally induced arthritis 
(Yang et al. 2005), glomerulonephritis (Cunningham et al. 2000), bladder injury 
(Saban et al. 2007) and cerebral infarction (Junge et al. 2003). These reports strongly 
support the importance of PARi in orchestrating injury responses. Despite this, PARi-
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deficiency in mice does not appear to adversely affect normal physiology in adult 
mice, and no specific phenotypic features have been thus far ascribed to adult PARf^' 
mice in the literature, although importantly PARf^’ mice do have a defect in - 
endothelial vascular development which is associated with a 50% intraembryonic 
lethality (Griffin et al. 2001). In addition, gene expression profiling studies have 
demonstrated that less than 0.5% of genes are differentially regulated in uninjured 
lungs of PARi  ^ and WT mice (personal conununication and unpublished data. Dr 
Chris J Scotton, Centre for Respiratory Research). Nevertheless, given that the results 
of this thesis demonstrated a reduction in lung levels of CCL2, CTGF, and TGF-pi at 
baseline and/or in response to bleomycin in PARf^' mice, and that these mediators 
have all been associated with deposition of extracellular matrix proteins, it was 
conceivable that their chronic deficiency might be associated with compromised 
extracellular matrix protein deposition and the development of emphysema over time. 
In a similar vein, Bonniaud et al previously showed that mice deficient in SMAD3, a 
pivotal signalling intermediate of TGF-P, developed spontaneous emphysema 
(Bonniaud et al. 2004).
On visual inspection of histological sections of WT and PARf^' mice, there 
was no difference between genotypes. A degree of airspace enlargement and scattered 
peribronchiolar inflammatory infiltrates were present in both genotypes, and most 
likely reflect usual age-related changes. Hence this data suggests that targeting this 
receptor would not adversely influence matrix turnover in areas of uninjured lung. 
This data could be further validated by assessing whether PARf^' mice are more prone 
than WT mice to the development of emphysema following exposure to tobacco 
smoke.
4.9 Summary and Clinical Implications
The data presented in this thesis demonstrate that PAR, '  mice exhibit 
attenuated inflammatory and fibrotic responses to bleomycin-induced lung injury. 
This protection is associated with reduced lung levels of CCL2, CTGF, and TGF-Pi. 
The effect is apparrently independent of the generation of fibrin, and these results 
support the notion that PAR i-dependent generation of these mediators may contribute 
to inflammation and fibrosis following lung injury. Moreover epithelial cells express
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PARi in the injured murine lung, and activation of PARi in vitro on both murine and 
human lung epithelial cells induces the expression of CCL2 and CTGF, but not TGF- 
Pi. These results therefore support the stated hypothesis of this work, namely that 
PAR, activation promotes lung injury and fibrosis via the release of a number of 
specific secondary mediators; with the pulmonary epithelium representing an 
important cellular source of these mediators.
Following epithelial injury, hyperplastic type II alveolar epithelial cells have 
the potential to differentiate into type I cells, and then spread. Such re-epithelialisation, 
is part of a normal healing response. Alternatively, hyperplastic type II alveolar 
epithelial cells can also persist in an activated phenotype and serve as a source of 
pathological pro-inflammatory and pro-fibrotic mediators. It is tempting to speculate 
that PAR, activation on such cells by locally generated coagulation proteinases might 
relatively favour the persistence of an activated phenotype with the potential for 
exaggerated production of secondary mediators, and abnormal interactions with 
underlying mesenchymal cells. This would relatively favour the development of 
fibrosis rather than re-epithelialisation and healing. This hypothetical sequence of 
events is illustrated in figure 4.1.
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Figure 4.1: Contribution of Alveolar Epithelial Injury and Coagulation to Lung Fibrosis.
Diffuse multifocal injury results in lo ss  of type I AEG, and activation/ hyperplasia of type II AEG. Type 
II cells then either proliferate and differentiate into type I AEG a s  part of a normal healing response, 
or  persist in a  pathological activated phenotype, with increased expression of PAR^. Vascular leak 
permits the generation of thrombin, s ince circulating coagulation factor zym ogens are exposed  to 
upregulated tissu e  factor expression  on resident lung cells. Thrombin activates PAR^ on epithelial 
cells to produce pro-inflammatory and profibrotic secondary mediators, which in turn drive fibroblast 
activation and collagen synthesis.
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This work has important implications for human fibroproliferative lung 
disorders. Evidence for the importance of coagulation in the pathogenesis of 
fibroproliferative lung disorders is growing. The anticoagulant activated protein C has
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been shown to improve survival in sepsis (Dhainaut et al. 2003), the most common 
risk factor for the development of acute lung injury/ ARDS. Moreover in 2005, 
anticoagulation was demonstrated to produce a substantial survival benefit over 
control (63% vs 35% 3y survival) in a small phase III placebo-controlled randomised 
clinical trial (Kubo et al. 2005) of IFF patients.
Epithelial cells represent an important site at which PARi activation can 
promote inflammation and fibrosis within the lung. Therefore a therapeutic approach 
involving inhaled agents to block FAR] activation or its specific associated signalling 
pathways may potentially be useful in fibroproliferative lung disorders. Inhalation of a 
FAR] blocking agent could be beneficial over administration by oral or parenteral 
routes by delivering the drug more directly to lung epithelial cells. It would certainly 
be more convenient than a drug given by the parenteral route, and would not be 
subject to the first-pass metabolism that is often a problem for orally administered 
drugs. Importantly, a FARi blocking strategy is additionally likely to be associated 
with less bleeding complications than a strategy to globally inhibit coagulation, such 
as by warfarin, since FAR] blockade would more specifically interfere with cellular 
rather than procoagulant effects of coagulation proteinases. FAR] antagonists are now 
increasingly credible therapeutic agents. In April 2006, Schering-Plough announced 
fast track designation for a FAR] antagonist (SCH 530348), which was already in 
phase II clinical drug development, for assessment in its ability to reduce 
cardiovascular morbidity and mortality in patients with acute coronary syndromes. In 
the not too distant future, such FAR] blocking strategies may yet prove to be a much 
needed therapeutic approach for a number of devastating fibroproliferative lung 
disorders which are currently untreatable.
4.10 Further work
To extend the findings of this work, the following specific experiments would 
be useful. Some would require the generation of transgenic mice and were therefore 
beyond the scope of this thesis.
1. Assessment of the difference in inflammation and fibrosis between FAR]  ^ and 
WT mice at 21 days following bleomycin. It is possible that attenuated fibrosis
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at 14 days results, at least in part, from an attenuated early inflammatory 
response. A similar, or greater, attenuation at the later 21 day time-point would 
further support that PARi deficiency is associated with attenuation of fibrosis, 
since this time-point is temporally more distant from the early bleomycin- 
induced inflammation.
2. Evaulation of whether a PARi antagonist confers protection from bleomycin- 
induced inflammation and/or fibrosis in WT mice. Administration of the 
antagonist during different stages following bleomycin may shed light on the 
importance of PARi activation specifically to early inflammatory and to later 
fibrotic events. Unfortunately at the time of this thesis, lack of compound 
availability prevented this from being possible
3. Characterization of mechanisms by which PARi expression is regulated in 
lung epithelial cells. Exposure of lung epithelial cells in vitro to mediators 
such as IL-lb, TNF-a and TGF-pi (which have been shown to influence PARi 
expression in other cell-types), and subsequent assessment of PARi mRNA 
levels may reveal whether these factors influence PARi expression.
4. Evaluation of whether overexpression of PARi under the influence of an 
epithelial specific promoter (e.g. SPC) in WT mice is associated with 
increased bleomycin-induced injury and fibrosis. A similar approach could be 
undertaken to determine the effect of epithelial re-expression of PARi in 
PA R ,'' mice.
5. Evaluation of whether re-expression of CCL2 or CTGF which are deficient in 
PARi  ^ mice, restores susceptibility of PARi  ^ mice to bleomycin-induced 
fibrosis. These genes could be specifically re-expressed on epithelial cells 
using an approach such as that described above, or in a less specific manner 
within the lung. This approach would further support the in vivo relevance of 
CCL2 and CTGF as important PARi secondary mediators in this model.
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6. APPENDIX
A .l: Protection from  bleomycin-induced inflammation and fibrosis in PARi 
mice (KO): pilot data from  D r David Howell
A.1.1. BALF inflammatory cells 7 days post saline/ bleomycin:
W T saline 
(n=10)
W T bleo 
(n=12)
KG saline 
(n=8)
KG bleo 
(n=13)
Mean cell no. 
(x 10  ^± SEM):
13.2 ±2.5 77.4 ± 116.6
p<0.05 vs WT 
saline
10.2 ± 15.1 34.2 ± 77.5
p=ns vs KG 
saline
p<0.05 vs WT 
bleo
A.1.2. BALF protein 7 days post saline/ bleomycin:
W T saline 
(n=10)
WT bleo 
(n = ll)
KG saline 
(n=8)
KG bleo 
(n=13)
Mean BALF 52.3 ± 17.4 818.9 ± 163.1 14.6 ± 9.5 384.3 ± 96.7
protein (mg/ml 
± SEM):
p<0.05 vs WT 
saline
p<0.05 vs KG 
saline
p<0.05 vs WT 
bleo
A.1.3. BALF collagen (as measured by HPLC) 14 days post saline/ bleomycin:
W T saline 
(n=15)
W T bleo 
(n=14)
KG saline 
(n=14)
KG bleo 
(n=13)
Mean collagen 
(mg/lung ± 
SEM):
1.42 ±0.05 2.38 ± 0.07
p<0.01 vs WT 
saline
1.47 ±0.09 1.82 ±0.12
p=ns vs KG 
saline
p<0.05 vs WT 
bleo
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A2: Confirmatory experiment showing attenuation in lung weight increase 
following bleomycin in PARi mice (non-lavaged lungs)
Lung weight in non-lavaged lungs 6 days post saline/ bleomycin:
WT saline 
(n=9)
WT bleo 
(n= ll)
KO saline 
(n=9)
KO bleo 
(n=9)
Mean lung 
weight (mg ± 
SEM)
157.3 ± 7 .7 271.5 ± 16.1
p<0.01 vs WT 
saline
143.7 ± 4.7 218.6 ± 17.8
p<0.01 vs KO 
saline
p<0.01 vs WT 
bleo
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A 3: Confirm atory experiments showing throm bin and TFLLR-NH 2  increase 
release of CCL2 protein from  A549 cells
A.3.1. Effect of thrombin (lOnM) on CCL2 protein release into culture supernatants 
of A549 cells:
Control medium (n=4) throm bin (n=4)
S upernatan t CCL2 after 82.2 ± 2.8 165.4 ± 1.5
48h (pM ± SEM)
p<0.01 vs control
A.3.2. Effect of TFLLR-NH2 (200|xM) and FTLLR-NH2 (200pM) on CCL2 protein 
release into culture supernatants of A549 cells:
Control medium 
(n=4)
TFLLR (n=4) FTLLR (n=4)
Supernatan t 
CCL2 afte r 6h 
(pM  ± SEM)
20.9 ± 0.3 77.4 ± 0.9
p<0.01 vs control 
p<0.01 vs FTLLR
19.8 ±0.6
A.3.3. Effect of thrombin (lOnM), Factor Xa (25nM), TFLLR-NH2 (200pM) and 
FTLLR-NH2 (200|xM) on CCL2 protein release into culture supernatants of A549 
cells:
Control
medium
(n=6)
throm bin
(n=6)
factor Xa 
(n=6)
TFLLR
(n=6)
FTLLR
(n=6)
S uperna tan t 
CCL2 afte r 
6h (pM  ± 
SEM )
23.5 ± 1.2 62.8 ± 2.0
p<0.01 vs 
control
39.6 ± 2.0
p<0.01 vs 
control
84.5 ± 0.9
p<0.01 vs 
control
p<0.01 vs 
FTLLR
28.2 ± 0.6
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A.4: Confirm atory experiments showing PARi antagonist inhibits thrombin- 
induced increases in CCL2 mRNA levels in A549 and BEAS-2B cells
A.4.1. Effect of RWJ-58259 on thrombin-induced increases in CCL2 mRNA in A549 
cells:
[RWJ-58259]
(itM)
0
(n=4)
2
(n=4)
4
(n=4)
6
(n=4)
% (± SEM) of 
maximum 
throm bin- 
induced CCL2 
mRNA levels
100 ± 10.8 8.4 ± 3.2 14.0 ±1.7 13.3 ±1.2
p<0.01 vs 
media control / 
drug vehicle
p<0.01 vs 
media control / 
drug vehicl
p<0.01 vs 
media control / 
drug vehicle
A.4.2. Effect of RWJ-58259 on thrombin-induced increases in CCL2 mRNA in 
BEAS-2B cells:
[RWJ-58259]
([iM)
0
(n=4)
2
(n=4)
4
(n=4)
6
(n=4)
% (± SEM) of 100 ± 11.6 69.3 ± 5.5 67.8 ± 9.8 39.5 ± 6.7
maximum 
throm bin- 
induced CCL2 
mRNA levels
p<0.01 vs 
media control / 
drug vehicle
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A.5: F u rther experiments showing throm bin- or TFLLR-NH 2 -induced increases 
in CCL2 mRNA levels in A549 cells are unaffected by pertussis toxin, but 
inhibited by the PKC inhibitor Ro-318425
A.5.1. Effect of pertussis toxin on TFLLR-NH 2 -induced increases in CCL2 mRNA in 
A549 ceils:
[Pertussis toxin] (ng/ml) 0 100
(n=4) (n=4)
% (± SEM) of maximum 100 ± 18.6 85.5 ± 4 .4
TFLLR-induced CCL2
mRNA levels
p=ns vs media control /
drug vehicle
A.5.2. Effect of pertussis toxin on thrombin-induced increases in CCL2 mRNA in 
A549 cells:
[Pertussis toxin] (ng/ml) 0
(n=4)
100
(n=4)
% (± SEM) of maximum 
throm bin-induced CCL2 
mRNA levels
100 ± 34.5 73.8 ± 15.9
p=ns vs media control / 
drug vehicle
A.5.3. Effect of Ro-318425 on TFLLR-NH 2 -induced increases in CCL2 mRNA in 
A549 ceils:
[Ro-318425] (pM) 0 1
(n=3) (n=3)
% (± SEM) of maximum 100 ± 10.4 21.4 ± 3 .9
TFLLR-induced CCL2 
mRNA levels
p<0.01 vs media control / 
drug vehicle
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A.6: Confirm atory experiments showing throm bin and TFLLR-NH 2  increase 
release of CCL2 protein from prim ary hum an alveolar epithelial cells
A.6.1. Effect of thrombin (lOnM), TFLLR-NH2 (ZOOpM) and FTLLR-NH2 (200pM) 
on CCL2 protein release into culture supernatants of primary alveolar epithelial cells 
{donor 2):
Control 
m edium (n=6)
throm bin
(n=6)
TFLLR
(n=6)
FTLLR
(n=6)
Supernatant 
CCL2 after 6h 
(pM ± SEM)
88.1 ±9.2 121.6 ±3.5
p<0.05 vs 
control
111.8±7.8
p<0.05 vs 
control
99.6 ± 5.8
p=ns vs 
control
A.6.2. Effect of thrombin (lOnM), factor Xa (25nM), and TFLLR-NH2 (200|iM) on 
CCL2 protein release into culture supernatants of primary alveolar epithelial cells 
{donor 3):
Control 
medium (n=6)
throm bin
(n=6)
factor Xa 
(n=6)
TFLLR
(n=6)
Supernatant 
CCL2 after 6h 
(pM ± SEM)
1063.6 ±7.2 1138.9±21.6
p<0.05 vs 
control
1199.9 ±36.9
p<0.05 vs 
control
1242.1 ±5.6
p<0.05 vs 
control
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A.7: Additional experiment showing throm bin increases CTGF protein in 
epithelial cells (by western blot)
Figure shows immunreactive 38kDa band obtained after western blotting of lysates of 
A549 epithelial cells with anti-CTGF polyclonal antibody. Cells were exposed to 
25nM thrombin for 4 hours. Coomassie staining of gel ran in parallel confirms 
approximate equal protein loading between samples.
control throm bin
m
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A.8: Confirm atory experim ent showing TFLLR-NH 2  increases CTGF mRNA 
levels in A549 cells
1.5h
Time-point 
3h 6h 12h
Normalised 
CTGF mRNA 
levels relative to 
time-point 
matched media 
control (±
SEM)
4.37 ± 0.65 4.10 ±0.20 1.12 ±0.09 0.86 ±0.12
Normalised 
CTGF mRNA 
of media 
control (± 
SEM)
1.01 ±0.18 1.00 ±0.10 1.00 ±0.06 1.00 ±0.08
p<0.01 p<0.01 p=ns p=ns
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A.9: Confirm atory experiments showing PARi antagonist inhibits thrombin- 
induced increases in CTGF mRNA levels in A549 and BEAS-2B cells
A.9.1. Effect of RWJ-58259 on thrombin-induced increases in CTGF mRNA levels in 
A549 cells:
[RWJ-58259]
(pM)
0
(n=4)
2
(n=4)
4
(n=4)
6
(n=4)
% (± SEM) of 100 ± 10.9 59.9 ± 12.2 51.1 ±9.9 27.2 ± 7.9
maximum
throm bin-
induced CTGF
mRNA levels
p<0.05 vs p<0.05 vs p<0.01 vs
media control / media control / media control /
drug vehicle drug vehicle drug vehicle
A.9.2. Effect of RWJ-58259 on thrombin-induced increases in CTGF mRNA levels in 
BEAS-2B cells:
[RWJ-58259]
(pM)
0
(n=4)
2
(n=4)
4
(n=4)
6
(n=4)
% (± SEM) of
maximum
throm bin-
induced
CTGF mRNA
levels
100 ± 0.83 81.0 ±7.0 88.4 ± 2.9 71.5 ±4.4
p<0.05 vs 
media control / 
drug vehicle
p<0.01 vs 
media control / 
drug vehicle
p<0.01 vs 
media control / 
drug vehicle
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A. 10: Confirm atory experiments showing thrombin- or TFLLR-NHz-induced 
increases in CTGF mRNA levels in A549 cells are unaffected by pertussis toxin, 
but inhibited by the PKC inhibitor Ro-318425
A.10.1. Effect of pertussis toxin on TFLLR-NHi-induced increases in CTGF mRNA 
levels in A549 cells:
[Pertussis toxin] (ng/ml) 0
(n=4)
100
(n=4)
% (± SEM) of maximum 100 ± 18.2 67.2 ± 11.3
TFLLR-induced CTGF
mRNA levels
p=ns vs media control /
drug vehicle
A.10.2. Effect of pertussis toxin on thrombin-induced increases in CTGF mRNA 
levels in A549 cells:
[Pertussis toxin] (ng/ml) 0
(n=4)
100
(n=4)
% (± SEM) of maximum 
throm bin-induced CTGF 
mRNA levels
100 ±20.4 92.6 ± 9.4
p=ns vs media control / 
drug vehicle
A.10.3. Effect of Ro-318425 on TFLLR-NH2-induced increases in CTGF mRNA 
levels in A549 cells:
[Ro-318425] (pM) 0 1
(n=3) (n=3)
% (± SEM) of maximum 
TFLLR-induced CTGF 
mRNA levels
100 ±8.4 66.0 ± 0.4
p<0.05 vs media control / 
drug vehicle
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A l l :  Three separate experiments confirm that throm bin increases the release of 
total TGF-P from lung epithelial cells
A .l 1.1. Thrombin dose response on total supernatant TGF-p levels in mink lung 
epithelial cell cultures (18h):
[Thrombin] (nM)
control 0.1 1 10 25 50 100
(n=4) (n=4) (n=4) (n=4) (n=4) (n=4) (n=4)
Supernatant 1.88 ± 1.81 ± 1.90 ± 2.47 ± 2.58 ± 3.26 ± 4.11 ±
total TGFp 0.11 0.08 0.06 0.10 0.08 0.08 0.29
(ng/ml ±
SEM)
p<0.01
vs
media
control
p<0.01 p<0.01 p<0.01
A .l 1.2. Thrombin dose response on total supernatant TGF-p of A549 cell cultures 
(18h):
(Note that pre-incubation of samples with IDl l  pan-TGF-p antibody (lOOpg/ml) 
reduces measurable TGF-P to zero, confirming specificity of assay for TGF-p).
[Thrombin] (nM)
control 0.1 1 10 25 50 100 100
(n=4) (n=4) (n=4) (n=4) (n=4) (n=4) (n=4) +
ID ll
Supernatant 
total TGFP 
(ng/ml ± 
SEM)
1.28 ±  1.87 ±  1.96 ±  2.17 ±  2 .10  ±  2.23 ±  2.33 ± 0 .00
0 .07  0 .08 0 .18 0 .09 0.12 0 .08 0.13
p<0.01
vs
media
control
p<0.05 p<0.01 p<0.01 p<0.01 p<0.01
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A. 11.3. Thrombin time-course on total supernatant TGF-P of A549 cell cultures 
(lOnM thrombin):
3h
(n=4)
6h
(n=4)
Time-point 
9h 12h
(n=4) (n=4)
18h
(n=4)
24h
(n=4)
48h
(n=4)
Supernatant Control 0.05 0.06 0.11 0.13 ± 0.36 ± 0.49 ± 1.84 ±
total TGFP media ± ± ± 0.01 0.05 0.04 0.13
(ng/ml ± 0.00 0.01 0.00
SEM)
Throm bin 0.07 0.16 0.25 0.30 ± 0.45 ± 0.72 ± 2.06 ±
± ± ± 0.05 0.02 0.06 0.03
0.02 0.01 0.11
p=ns vs p<0.01 p=ns vs p<0.05 p=ns vs p<0.05 p=ns vs
time- vs time- time- vs time- time- vs time- time-
point point point point point point point
matched matched matched matched matched matched matched
control control control control control control control
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A.12: Five separate experiments confirming that factor Xa increases the release 
of total TGF-p from lung epithelial cells
A.12.1. Effect of 25nM Factor Xa on total supernatant TGF-p of A549 cells (18h):
Control medium 25nM FXa
(n=6) (n=6)
Supernatant total TGFP 0.26 ± 0.05 0.68 ±0.18
(n^m l ± SEM)
p<0.01 vs control
A.12.2. Effect of 25nM Factor Xa on total supernatant TGF-P of A549 cells (18h):
Control medium 25nM FXa
(n=6) (n=6)
Supernatant total TGFP 0.21 ±0.02 0.50 ± 0.06
(ng/ml ± SEM)
p<0.01 vs control
A.12.3. Effect of 25nM Factor Xa on total supernatant TGF-P of A549 cells (18h 
measured by ELISA):
Control medium 25nM FXa
(n=9) (n=9)
Supernatant total TGFp 0.11 ±0.08 0.38 ±0.01
(ng/ml ± SEM)
p<0.01 vs control
A.12.4. Effect of lOnM and 25nM Factor Xa on total supernatant TGF-p of A549 
cells:
Control medium lOnM FXa 25nM FXa
(n=6) (n=6) (n=6)
Supernatant total 0.14 ±0.02 0.29 ± 0.02 0.47 ± 0.03
TGFP (ng/ml ±
SEM)
p<0.01 vs control p<0.01 vs control
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A. 12.5. Factor Xa time-course on total supernatant TGF-p of A549 cells (25nM FXa):
3h 6h
Time-point 
12h 18h 24h 48h
(n=3) (n=3) (n=3) (n=3) (n=3) (n=3)
Supernatant Control 0 .0 4  ± 0 .0 5  ± 0 .0 7  ± 0 .2 1  ± 0 .3 0  ± 0 .1 8  ±
total TGFP media 0 .0 0 0 .0 2 0 .0 1 0 .0 1 0.02 0 .0 0
(ng/ml ± 
SEM) Factor Xa 0 .1 4  ± 0 .1 8  ± 0 .2 8  ± 0 .7 7  ± 1 .0 4  ± 0 .9 5  ±
(25nM) 0 .0 3 0 .0 1 0 .0 4 0 .0 4 0 .0 7 0 .1 0
p<0.05 vs 
time-point 
matched 
control
P<0.01 vs 
time-point 
matched 
control
pcO.Ol vs 
time-point 
matched 
control
p<0.01 vs 
time-point 
matched 
control
p<0.01 vs 
time-point 
matched 
control
p<0.01 vs 
time-point 
matched 
control
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A.13: Two separate experiments confirm that factor Xa and TFLLR-NH 2 , but 
not throm bin exert a small stim ulatory effect on total TGF-P release from 
prim ary hum an lung alveolar epithelial cells
A.13.1. Effect of thrombin, factor Xa, and TFLLR-NH2 on total supernatant TGF-p of 
primary alveolar epithelial cells after 18 h {donor /):
Control 
medium (n=6)
lOnM
throm bin
(n=6)
25nM Fxa 
(n=6)
200pM 
TFLLR (n=6)
Supernatant 
total TGFP 
(ng/ml ± SEM)
2.51 ±0.14 2.90 ±0.13 2.89 ±0.10 2.99 ±0.11
p=0.06 vs 
control
p<0.05 vs 
control
p<0.01 vs 
control
A. 13.2. Effect of thrombin, factor Xa, and TFLLR-NH2 on total supernatant TGF-p of 
primary alveolar epithelial cells after 18 h {donor 3):
Control 
medium (n=6)
lOnM
throm bin
(n=6)
25nM Fxa 
(n=6)
200pM 
TFLLR (n=6)
Supernatant 
total TGFP 
(relative 
luminescence 
units ± SEM)
8900.2 ± 379.8 9935.4 ± 344.4
p=0.07 vs 
control
10060 ± 252.6
p<0.05 vs 
control
10831.5 ± 
417.9
p<0.01 vs 
control
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A. 14: Two further experiments showing that TFLLR-NH 2  and FTLLR-NH 2  both 
increase release of total TGF-p from lung epithelial cells
A. 14.1. Effect of TFLLR-NH2 and FTLLR-NH2 on total supernatant TGF-p of A549: 
Control medium TFLLR-NH 2  FTLLR-NH 2
(n=5) (n=7) (n=7)
Supernatant total 
TGFp (relative 
luminescence units 
±SEM )
0.35 ± 0.05 1.29 ±0.08 
p<0.01 vs control
0.84 ± 0.05 
p<0.01 vs control
A.14.2. Effect of TFLLR-NH2 and FTLLR-NH2 on total supernatant TGF-P of A549:
Control medium TFLLR-NH 2 FTLLR-NH 2
(n=5) (n=7) (n=7)
Supernatant total 
TGFP (relative 
luminescence units 
±SEM )
0.20 ± 0.04 0.91 ±0.06 
p<0.01 vs control
0.68 ± 0.05 
p<0.01 vs control
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A.15: F u rth er experim ent showing TFLLR-NH 2  has little effect on TGF-pi 
mRNA levels in A549 cells
1.5h
Time-point 
3h €h 12h
Normalised 
TGF-pi mRNA 
control relative 
to time-point 
matched 
control (±
SEM)
1.22 ±0.09 1.15 ±0.06 1.13 ±0.04 1.41 ±0.12
Normalised 
TGF-pi mRNA 
of control (± 
SEM)
1.01 ±0.08 1.00 ±0.03 1.00 ±0.04 1.01 ±0.08
p=0.14 p=0.06 p=0.05 p<0.05
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